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Abstract  
In this thesis, the capability of the electrohydrodynamic atomization (EHDA) 
process for preparing drug delivery carriers consisting of biodegradable polymeric 
particles with different sizes and shapes was explored. The first part of the thesis 
describes a detailed investigation of how the size, morphology and shape of the 
particles generated can be controlled through the operating parameters; specifically 
the flow rate, applied voltage and the properties of the solutions. Diameter and shape 
of the particles were greatly influenced by viscosity and applied voltage. The mean 
size of the particles changed from 340 nm to 4.4 µm as the viscosity increased from 
2.5 mPa s to 11 mPa s. Also, using more concentrated polymer solution (30 wt%) 
and higher applied voltage (above 14 kV) were found to be ideal for promoting chain 
entanglement and shape transition from spherical to oblong to a more needle-like 
shape. Estradiol-loaded micro and nanoparticles were produced with mean sizes 
ranging from 100 nm to 4.5 µm with an encapsulation efficiency ranging between 
65% to 75%. The in vitro drug release profiles of the particles started with an initial 
short burst phase and followed by a longer period characterised by a lower release 
rate. Two strategies were developed to tailor these profiles. First, ultrasound was 
explored as a non-invasive method to stimulate “on demand” drug release from 
carrier particles. Systematic investigations were carried out to determine the effect of 
various ultrasound exposure parameters on the release rate in particular output 
power, duty cycle and exposure time. These three exposure parameters were seen to 
have a significant enhancing effect upon the drug release rate (up to 14%). The 
second strategy explored was coating the surface of the particles with chitosan and 
gelatin. This enabled control and reduction of the prominence ‘burst release’ phase 
without affecting other parts of the release profile. Coating the particle surface with 
1 wt% chitosan solution considerably reduces the initial release by 62%, 60% and 
42% for PLGA 2 wt%, 5 wt% and 10 wt%, respectivly in the first 72 hours This 
work demonstrates a powerful method of generating micro and nano drug-loaded 
polymeric particles, with modified release behaviour and with control over the initial 
release. 
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Chapter 1 
  
Introduction and Background 
 
1.1 Background 
The first microencapsulation procedure was published by Bungenburg de Jong and 
Kaas1 in 1931 which deals with the preparation of gelatin microspheres 
[Bungenburg de Jong and Kaas 1931]. In the late 1940s and 1950s, Green et al. of 
National Cash register Co., Dayton, Ohio, developed a microencapsulated dye for 
the manufacture of carbonless copying paper which eventually lead to several 
patents and made microencapsulation more common [US Pat. 2712507, US Patent 
2800457]. Since then, and particularly since the mid 1970s, microencapsulation has 
become more and more popular in the pharmaceutical industry as well as for many 
other products and processes in daily use. Encapsulated products now available 
include liquid crystals, adhesives, perfumes and fragrances, cosmetics, insecticides, 
algaecides, fertilizers, washing powders, animal feed stocks, tissue mimicking 
materials , medicinal products, insulation materials, etc [Arshady 1990, Schmidt and 
Roessling 2006]. Such particles normally have diameters between 50 nm and 1 mm 
with a solid, liquid, or gaseous core. The wall material can be made from polymers, 
surfactants, glasses, oxide ceramics, mixed oxides or even metals [Bertling et al. 
2004, Gaponik et al. 2004]. The main motivating factors for encapsulation are as 
follows: taste and odor masking, separation of incompatible components, protection 
from immediate environment, modification of impact strength, alteration of colloidal 
and surface properties, prolonged action or sustained release, targeted release, 
improved biocompatibility [Arshady 1989]. 
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In medical and pharmaceutical applications, there is rapidly growing interest in the 
use of particles as drug delivery systems and in the synthesis of artificial cell 
structures [Bertling et al. 2004, Botchwey et al. 2004]. Both micro and nano 
particles are used therapeutically. For example, particles loaded with an entrapped 
therapeutic agent can transport the substance through blood vessels and release their 
load at a target site [Panyam and Labhasetwar 2003]. The preparation of effective 
drug delivery systems, however, still represents a significant on-going challenge in 
medicine [Mathiowitz et al. 1997]. The goal in designing an ideal drug carrier is to 
obtain sustained and controlled release which can decrease the fluctuation and 
variation of drug dosage and keep drug concentration constant over the designated 
treatment period to maximise the effectiveness of the therapeutic agent [Luan et al. 
2006, Yang et al. 2001]. In particular, the aims in designing a drug delivery system 
are to minimize drug degradation and loss, to prevent harmful side-effects and to 
maximise drug bioavailability and the percentage of the drug accumulated in the 
required zone. Therefore, various preparation techniques have been studied with a 
view to generating drug carriers or vehicles which can be tailored to achieve these 
aims [Freitas et al. 2005, Yang et al. 2001]. 
 
Techniques used to produce micro- and nano-particles of different sizes for 
biological uses, include single and double emulsification, phase separation, spray 
drying, coacervation, and electrohydrodynamic atomization (EHDA) [Mitragotri and 
Lahann 2009]. Several of these methods suffer from the fact that protein 
denaturation and unsteadiness during encapsulation and release process may occur. 
For example, the double emulsion method involves exposing the active 
pharmaceutical ingredients to organic solvents, high shear stresses, and aqueous-
organic interfaces. Spray drying requires high temperatures and is thus not suitable 
for highly thermally sensitive materials. Furthermore, particle size cannot be easily 
controlled using this technique. In the coacervation method, residual solvents and 
coacervating agents can cause frequent damage to the coacervation. Of these 
techniques, EHDA has recently attracted the attention of many researchers for 
generating drug delivery vehicles. It is an attractive process based on the formation, 
control and breaking up of jet under the influence of a high electrical field. The 
process involved in this technique is referred to by a number of different terms in the 
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literature. In this thesis, ‘EHDA’ processing or ‘electrospraying’ will be used. In this 
method a single needle or a co-axial series of needles can be used. In the latter, two 
different liquids or suspensions are pumped through two concentrically aligned 
needles, which are subjected to an applied voltage. The co-flowing liquids are 
capable of experiencing various modes of atomization. Among these modes, the 
‘cone jet’ mode is normally the most desirable mode. In this mode, the liquid(s) 
issuing from the capillary are in the form of a regular, axisymmetric cone with a thin 
jet at its apex. The jet can break-up eventually which results in near monodisperse 
compound particles with the outer material surrounding or encapsulating the inner 
one. This phenomenon has particular importance for encapsulation of targeted drug 
delivery and material processing [Loscertales et al. 2002]. The EHDA method has 
many advantageous over conventional methods, which are discussed below: 
 
• It is a method capable of producing fine and near monodisperse particles. 
Monodisperse particles have the advantage of possessing more regular and 
predictable drug release profiles. 
 
• Particles are produced at ambient temperature and pressure, and without the 
need for additives other than normal polymer solvents, thus overcoming the 
problems associated with defunctionalisation of drugs under harsh processing 
conditions. 
 
• It is a technique that can be scaled up easily for mass production with 
multiple electrospraying needles being used in parallel or if it is miniaturised into a 
portable device for in situ particle fabrication [Deng et al. 2006 and Regele et al. 
2002]. 
 
• This method is very flexible and different surfactants can be added to adjust 
the encapsulation efficiency (EE) and to control the release profile. 
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• It is a cost-effective and convenient method which provides a means of 
directly encapsulating a drug inside a polymeric carrier of pre-determined size in a 
single step, unlike many existing methods which require two or more steps to 
achieve an encapsulated product. 
 
• The EHDA process can be halted at anytime simply to check the quality of the 
produced particles. Whereas, single and double emulsification methods are multi-
steps methods, therefore, all steps of the fabrication should be completed in order to 
be able to check quality of the production. The option of terminating the process at 
anytime to check the quality and characteristic of the fabricated particles is often 
very desirable. 
 
• The electrosprayed solution could be a mixed solution, an emulsion, even a 
solid particle dispersion. Also, during the fabrication process different polymers can 
be employed. 
 
The above-mentioned advantages make EHDA an attractive method for the 
production of drug delivery vehicles. 
 
Biodegradability is another key feature of drug delivery devices [Burton et al. 2000]. 
The elimination of an inactive material by a natural process is preferred over surgical 
removal of a drug delivery system, which may leave non-degradable foreign debris 
in the body for an indefinite period of time. Biodegradable polymeric materials are 
the most promising materials that can be used for encapsulating drugs in developing 
drug delivery systems (DDS) for sustained and controlled release of drugs. These 
DDS are used to provide a predetermined amount of drug at an appropriate time and 
at a targeted site over the duration of several minutes to several years [Kawaguchi 
2000, Pareta and Edirisinghe 2006]. There are several types of biodegradable 
polymers but only relatively few have been approved by the US Food and Drug 
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Administration [Sinha and Trehan 2003]. Amongst them are polycaprolactone 
(PCL), poly (L-lactic acid) and poly (DL-lactic acid) (PLA), poly(glycolic acid) 
(PGA), and their copolymers such as poly(DL-lactic-co-glycolic acid) (PLGA). 
PLGA is a good candidate as a biodegradable and biocompatible polymer. It 
degrades via hydrolysis in the body and produces the monomers, lactic acid and 
glycolic acid. These two monomers are by-products of different metabolic pathways 
in various bio-processes under normal physiological conditions. PLGA has been 
used to fabricate micro- and nano-scale particles for controlled release systems 
[Okada and Toguchi 1995]. PCL also degrades via hydrolysis at its ester linkages 
under physiological conditions in the human body [Armani and Liu 2000].  
 
The drug release characteristics of polymeric carriers encapsulating various 
hydrophobic drugs have been studied [Avgoustakis 2004]. However, there have been 
relatively few attempts to modulate and manipulate the drug release profile. There 
are two features of a polymeric drug delivery system which require particular 
attention. First, eliminating or controlling the initial undesirable ‘burst release’ 
phase. This is the rapid release of drug during the first 24 hours after administration, 
which typically accounts for 20 to 80% loss of the total encapsulated drug. Second, 
the ability to modify the release profile in situ, e.g. in order to achieve pulsatile 
release. One method for achieving this type of profile is control drug release through 
external stimuli, for example exposure to light, electrical or magnetic fields or 
ultrasound. 
 
Ultrasound has many applications in medicine. Its most common one is in diagnostic 
imaging [Moore and Promes 2004]. However, there are other more recent 
applications relating to drug delivery and stimulating drug release processes 
[Mitragotri et al. 1995]. In ultrasonically stimulated systems, ultrasonic waves 
increase the degradation of the polymeric carrier so stimulating the drug release. For 
instance, in a study by Miyazaki et al., it was found that using ultrasound in an 
insulin loaded ethylenevinyl alcohol copolymer system, caused a sharp drop in blood 
glucose levels right after ultrasonic waves were administered [Miyazaki et al. 1988]. 
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Drug delivery systems are an intricate system from the vehicles where the drugs are 
entrapped to the way the drug is released into its physiological environment. 
Developing such a system requires certain objectives to be able to produce a product 
that can delivery controllable release of drugs, which are mentioned in the next 
section. 
1.2 Objectives of the research 
 
Figure 1.1 Objectives of the research presented in this thesis 
 
The flow chart in Fig. 1.1 sets out the key objectives of this study. The detail of each 
objective is discussed below. 
 
1.2.1 Production of PLGA particles using single-needle and co-axial EHDA 
setup 
The first main objective of this work was to demonstrate whether single-needle and 
co-axial electrohydrodynamic processing could successfully produce polymeric 
nanometre and micrometre scale particles via a single step process which provides 
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control over particle size, size distribution and shape under ambient conditions. To 
meet this objective, several studies were necessary which were arranged into 
different stages as follows: 
 
1.2.1.1 EHDA mode mapping and size distribution study 
The first aim was to investigate the fundamentals of single-needle EHDA processing 
for the preparation of polymeric carriers. It was determined how the size and size 
distribution of the particles generated can be systematically controlled through the 
range of operating parameters: polymer solution flow rate, applied voltage and the 
inherent properties of the solution such as viscosity and electrical conductivity 
during particle generation. It was shown how changes in these parameters affect the 
mode of jetting and the desirable stable ‘cone-jet’ mode window. In this part of 
investigation, the biodegradable polymer polycaprolactone was used and a particle 
range of 300 nm – 4.5 µm in diameter were prepared. After these extensive studies 
the ideal set of processing parameters for obtaining PCL particles with different size 
ranges were determined. 
 
1.2.1.2 Fabrication of PLGA particles with different shapes 
The second aim was to find a simple method for generating PLGA and PCL 
biodegradable particles with both different sizes and shapes based on EHDA 
processing. Most work on drug-delivery carriers has focused on spherical particles 
because size has been considered to be the most significant, if not the only parameter 
of interest. In addition, non-spherical particles have often proved difficult to 
fabricate. However, there is increasing evidence that particle shape may play a 
significant role in the effectiveness of drug delivery and other biomedical 
interventions, for example shape-related phagocytosis by macrophages [Champion 
and Mitragotri 2006] and the rate of cellular internalisation of particles based on 
their shape [Gratton et al. 2007]. Thus, further understanding the shape related 
phenomena is essential for enhancing future prospects. This requires examination of 
the potential of non-spherical particles as suitable carriers for drug delivery and in 
order to do this, more convenient preparation methods are essential. A second aspect 
of this part of the research was to demonstrate that the length and width of the non 
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spherical particles and hence the aspect ratio can be controlled to reduce the particle 
shape from the micro to the nano scale. 
 
1.2.1.3 Production of drug loaded PLGA particles using co-axial EHDA setup 
Production of particles and capsules with a narrow size distribution is of tremendous 
interest in biomedical engineering [Zhu et al. 2000, Kissel et al. 1995, Vonarbourg et 
al. 2009]. In particular, research into the encapsulation of various therapeutic 
materials by efficient methods is important for the preparation of advanced particles 
with different cores, targeting behaviour, and release profiles [Luan et al. 2006]. 
Since the single needle EHDA process has been shown to be a promising technique 
for fabricating drug delivery carriers with a given size and size distribution, the next 
objective was to encapsulate a therapeutic material into the PLGA polymeric 
particles via co-axial EHDA processing.  
 
To fulfil these objectives, first, evans blue dye was chosen as a model encapsulated 
material, to show the feasibility of the encapsulation process. In the next step, a real 
drug, estradiol, was used instead of evans blue dye as the encapsulated agent. The 
structure and size of these drug-loaded PLGA particles were also characterised. This 
study confirmed that EHDA co-axial processing has considerable potential as a 
technique for producing drug-loaded particles. 
 
1.2.2 Drug release study and controlling the release profile  
As discussed before, the first main objective was the fabrication of polymeric drug 
loaded carriers via both single and co-axial EHDA processing.  The second main 
objective was an in-depth study of the release profiles for these carriers and the 
effect of different parameters on the release characteristics, which have not been well 
documented in previous EHDA studies. The overall aim was to achieve a regulated 
and controllable drug release profile. 
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1.2.2.1 Ultrasound stimulated release 
The final objective was to tailor and control the drug release profiles. In one set of 
experiments, ultrasound was used to stimulate in vitro drug release. Ultrasound 
responsive drug delivery systems have great potential for applications requiring 
stimulated release in vivo with a high degree of control over spatial and temporal 
location. Systematic investigations were carried out to determine the effect of 
various ultrasound exposure parameters, in particular: output power, duty cycle and 
exposure time, on the release rate of a model drug (estradiol), encapsulated in PLGA 
particles of different sizes prepared using EHDA. 
 
1.2.2.2 Controlled burst release phase 
In another set of experiments, the aim was to control the ‘burst release’ phase of the 
drug release profiles. Burst release is a very fast release phase during the first day of 
release typically accounting for 20 to 80% loss of the total drug which can cause 
many severe toxicity effects. This reduces the effective lifetime of the therapeutic 
system. Therefore, an optimized coating technique was used to tailor the in vitro 
drug release profiles for a system of PLGA particles encapsulating the hydrophobic 
drug, estradiol. It was shown that coating the particles with different materials can 
significantly reduce the initial burst without affecting the subsquent parts of the 
release profile. This part of work demonstrates a powerful method of generating 
drug-loaded polymeric particles, with modified release behaviour with a controlled 
burst release phase. The surface modified particles have great application in 
controlled therapeutic delivery systems with less undesirable side effects and the 
reducing potential loss of drug during the initial lifecycle of the vehicle. 
1.3 The structure of the thesis  
The organisation of this thesis is given in this section. This Chapter 1 provides 
background information about the research project and gives an overview about the 
basics of electrohydrodynamic atomization and other related techniques that are used 
for micro and nano encapsulation. The objectives of the research are stated and the 
organisation of this thesis and scope of the research outlined. 
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Chapter 2 presents a detailed literature survey. Since the aim of the research is to 
prepare micro and nano particles through EHDA to be used as drug delivery 
vehicles, an extensive collection of literature has been surveyed to understand the 
principles of electrohydrodynamic atomization, the procedure and its uses, as well as 
the materials and the methods used for the preparation of polymeric particles. Also, a 
literature survey has been presented on micro and nano particulate drug delivery 
systems and conventional encapsulation methods in comparison with the 
electrohydrodynamic atomization.  
 
Chapter 3 describes the experimental setup, materials used, experiments and 
characterisation procedures carried out, and a detailed description of the 
experimental tools employed. 
 
In Chapter 4, results obtained during the experiment using single needle and co-
axial EHDA processing are discussed in conjunction with existing literature. This 
chapter is split into three sections; in Section 4.1, PCL solutions with different 
concentrations were used to show the feasibility of fabrication of polymeric particles 
via EHDA. Different modes of EHDA processing were studied and classified. The 
effect of different parameters such as; applied voltage, flow rate, viscosity and drug 
loading were studied on size, size distribution, polydispersivity index and 
morphology of the PCL particles. 
 
In Section 4.2; a method to fabricate PLGA and PCL drug carriers with different 
shapes and sizes was established. The effect of different parameters, such as 
collecting distance, on the morphology, size and size distribution of the PLGA 
particles was studied. The next part of the chapter was concerned with the 
fabrication of non-spherical PCL particles using a viscous solution and investigating 
the effect of polymer concentration, applied voltage and flow rate on the shape and 
size of the particles. 
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Section 4.3 discusses how co-axial electrohydrodynamic atomization can be used for 
encapsulating a second material inside the polymeric matrix with a controlled mean 
size and size distribution. The production of evans blue and estradiol loaded PLGA 
particles of various sizes was investigated.  
 
Chapter 5 studies the release profiles of the drug loaded PLGA particles and 
discusses how to tailor and control the release profiles. This chapter has three 
sections. Section 5.1 focuses on the in vitro release study via two techniques, the 
colorimetric and the UV spectroscopy methods. The next parts of the chapter are 
focused on tailoring and controlling the drug release profiles. A detailed description 
is given in Section 5.2 about the ultrasound stimulated drug release from PLGA 
nano and micro particles. An extensive study was conducted to determine the effect 
of various ultrasound parameters such as out-put power, duty cycle and ultrasound 
timing on the release profile and on microstructure and biodegradation of the 
particles. Section 5.3 discusses the charactecterisation and modification of the 
release pattern of estradiol from PLGA micro and nano particles with improved 
initial release characterisation. A coating technique was used to tailor the in vitro 
drug release profiles for a system of PLGA particles encapsulating a hydrophobic 
drug, estradiol. The three most important factors affecting drug release were 
identified as: particle size, type and concentration of the coating agent. 
 
Chapter 6 is divided into two sections. Section 6.1 summarizes the experimental 
results and presents the conclusions of the work. Section 6.2 discusses some 
recommendations for future work, employing EHDA processing and beyond, to 
continue the research presented in this thesis in new directions. Finally, the literature 
referred to throughout the thesis is listed in the References section. 
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Chapter 2  
Literature review  
 
2. 1 Introduction 
The objective underlying the research described in this thesis is to investigate 
electrohydrodynamic atomization as a technique for preparing micro and nano 
particles that can satisfy the requirements for particles that are used primarily in 
medical engineering, targeted drug delivery and controlled released systems. 
 
In order to fulfil this objective, first the relevant literature will be reviewed as 
follows: 
 
• Fundamental concepts of drug delivery systems, routes of drug delivery 
and the mechanism of drug release: the goals of drug delivery systems, 
various routes of drug administration and the mechanisms that control the 
drug release including degradation and erosion of the polymeric carrier are 
presented. Furthermore, a detailed description of various particulate drug 
carriers with different structures will be given. 
 
• Techniques for polymeric particle preparation: different methods for the 
fabrication of drug loaded polymeric carriers such as: emulsion-solvent 
evaporation, coaccervation phase separation and spray drying are discussed 
and they are compared with electrohydrodynamic atomization processing 
which is used in this study. 
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• Electrohydrodynamic atomization processing: previous work on the 
processing methods based on electrohydrodynamic atomization (EHDA) and 
the theory of this processing technique are reviewed. Various modes of 
electrohydrodynamic atomization and all the parameters such as processing 
parameters (applied voltage and flow rate) and liquid properties (surface 
tension, viscosity, electrical conductivity, relative permittivity and density) 
involved in this process is well explained. Also, the application of single 
needle and co-axial electrohydrodynamic atomization method in preparation 
of various drug carriers such as particles, capsules, aerosols, porous 
structures and microbubbles, are reviewed in order to understand how these 
techniques offer opportunities for further research. 
 
• Polymer based drug delivery systems: polymers have been extensively 
used for the preparation of drug delivery carriers.  In this section, a detailed 
examination of synthetic polymers such as poly (lactic acid) (PLA), poly 
(glycolic acid) (PGA), poly (ε-caprolactone) (PCL) and poly (lactic acid-co-
glycolid acid) (PLGA) will be made. 
 
• Controlling the drug release profile: the ultimate aim in a drug delivery 
system is to have a regulated release profile from the drug loaded carrier. In 
this study, two approaches were investigated to fulfil this aim including 
ultrasound stimulated drug release and controlling the burst release phase 
using a coating technique. Ultrasound responsive drug delivery systems have 
great potential for applications requiring stimulated release in vivo with a 
high degree of control over spatial and temporal location. The role of 
ultrasound in biomedical engineering especially in drug delivery and drug 
release will be explained. In the last part of this chapter previous studies on 
the effects of burst release in drug delivery, the mechanism of the initial 
release and the control of this phenomenon were reviewed.  
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2.2 The drug delivery concept and goal of drug delivery systems 
Successful therapy with any agent requires the drug to reach the site of action in 
adequate amounts and over an appropriate length of time. The aim of many 
controlled drug delivery systems is to have a delivery profile that will yield a high 
drug concentration level in the blood over a long period of time. An effective drug 
delivery system must thus: a) allow the drug to be released in the correct place, in the 
correct quantity, and in the correct time window, i.e. demonstrate appropriate 
“bioavailability” and/or b) minimise adverse reactions or side-effects of the drug, 
whilst not introducing any new ones [Gregoriadis 1977]. 
 
In conventional drug delivery systems, such as tablets or injections, the 
concentration level of the therapeutic agent decreases significantly after its 
administration. It is difficult to keep the drug concentration in the blood stream at a 
therapeutic level for extended periods of time, and multiple administrations are 
usually required to obtain the desired therapeutic effect [Cohen et al. 1991]. In these 
systems, high drug concentrations may induce adverse toxic effects, because in such 
systems, delivering the therapeutic agent is only dependent on diffusion or partition 
from the blood stream to the action site. The only real advantage of these systems 
over controlled release systems is their low processing and administration cost. Fig. 
2.1a shows a typical release profile and drug concentration level for a conventional 
drug delivery system. The drug level in the blood rises after each administration of 
the drug and then decreases until the next administration. The concentration of any 
therapeutic agent has two limits in blood; the upper limit (the toxic level of the 
therapeutic agent) and the lower limit (the effective therapeutic level). The key point 
with traditional drug administration is that the drug level of the agent should remain 
between these limits [Park et al. 1998].  
 
In contemporary drug delivery systems which can release drugs over long periods of 
time, the concentration level of the drug in the blood follows the profile shown in 
Fig. 2.1b, remaining constant between the toxic and effective level of the therapeutic 
agent for a specific time [Brannon-Peppas 1997]. For example, in treatment of the 
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imbalance in biological homeostasis, the drug may be released only when it is 
needed (Fig. 2.1c). This type of release profile is typically called “pulsatile release”. 
Highly localised drug release can also be achieved by various targeting strategies 
(Fig. 2.1d). Release is restricted to a target site at a high local concentration for an 
extended time. Therapeutic efficiency in these systems is very high while side effects 
are significantly reduced. 
 
   
          
Figure 2.1 Different types of controlled release systems characteristics. (a) Drug 
delivery based on simple diffusion and partition. (b) Sustained release to prolong the 
therapeutic period. (c) Pulsatile release to tightly maintain homeostasis. (d) On-site 
release to maximize therapeutic efficiency and to minimize side effect [Kim et al. 
2009].  
 
In summary, drug delivery and targeting systems (DDTS) aim to overcome the 
limitations of conventional drug administration methods and thus improve drug 
performance. Ideal DDTS should: 
D 
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• Specifically direct the drug to target cells or target tissue and ensure minimal 
         drug leakage during transit to target, 
• Keep the drug out of non-target organs, cells or tissue, 
• Protect the associated drug from metabolism, 
• Protect the associated drug from clearance, 
• Retain the drug at the target site for the desired period of time, 
• Facilitate transport of the drug into the target tissues and cells, 
• Be biocompatible, biodegradable and non-antigenic 
 
In certain situations, some of these requirements may be inappropriate. For example, 
the drug may work outside the cell, thus cell penetration may not be necessary 
[Brocchini and Duncan 1999].  
 
2.3 Routes of drug delivery using micro and nano particles 
There are many potential routes of administration for drug loaded micro- and nano- 
particles, ranging from parenteral, i.e. intramuscular and subcutaneous, to nasal, 
pulmonary, oral, ophthalmic, transdermal etc. In this section a short description of 
the most popular drug delivery routes is given. 
 
Oral drug delivery: This is the most common method of drug delivery as it is 
convenient and can be controlled by the patient. There are, however, some 
disadvantages associated with this route. For instance, the oral route is very variable, 
so that there is noticeable potential for bio-inequivalence between orally 
administered drugs [Zhang et al. 2002].  
 
Parenteral drug delivery: Parenteral therapy is used if drugs cannot be given by the 
oral route, this could be because of two reasons; first, poor absorption properties of 
the drug, second, propensity to degrade in the gastrointestinal tract. Drugs can be 
delivered by injection to carry the drug to target sites in the body. Routine parenteral 
administration by injection serves to deliver drugs to specific body tissues. The most 
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common ways of administering the drugs are intramuscular (IM), intravenous (IV) 
and subcutaneous (SC) [Sinha and Trehan 2005].  
 
Pulmonary drug delivery: Therapeutic agents that have an effect on the respiratory 
system can be delivered by inhalation [Clark 1995] and delivering therapeutic agents 
to lungs is one of the most significant local therapeutic systems. The physical 
characteristics of the drug carriers are crucial for successful pulmonary drug 
delivery. For instance, the desirable particle size should be in the range of 1–5µm 
[Grossman 1994, Schreier et al. 1993]. Inhalation treatment can often benefit from a 
sustained release of the drug, by the aid of biodegradable polymeric materials 
[Kawashima 1998]. Gradual release from an inhaled drug loaded particle can extend 
the residence of the drug in the airways and can decrease the percentage of the 
therapeutic agents in the bloodstream. Also, this would be more convenient for the 
patient due to the reduction in the dosage frequency [Schreier et al. 1993]. 
 
Transdermal drug delivery: This method typically utilises an adhesive patch 
containing drugs, which passively diffuse through the skin. Although the skin acts as 
a potent barrier against external damage, transdermal delivery systems have been 
developed to overcome this resistance and now many drugs are delivered 
transdermally such as contraceptives, nicotine and estrogen [Singh and Roberts 
1989, Prausnitz et al. 2004].  
 
In all of the above drug delivery routes, polymeric particulate carriers encapsulating 
therapeutic agents are used with various sizes ranging from nano to micro size. 
 
2.4 Particulate drug carriers  
The development of drug delivery carriers is a relatively new area of science, as the 
technology to work at atomic, molecular and supramolecular levels has only become 
widely available in recent years. Particulate drug carriers include different types of 
structures such as micro/nanospheres, micro/nano particles, liposomes, vesicles, 
micelles and dendrimers (Fig. 2.2). Microspheres are small spherical units, 
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composed of various abut natural and synthetic materials with diameters in the 
micrometre range. The therapeutics agents can be dispersed or dissolved in the 
matrix. Nanospheres are spherical nano-scale structures, where active compounds 
can also be firmly adsorbed at their surface, entrapped or dissolved in the matrix. 
Nanocapsules have a polymeric shell and an inner core. In this case, the active 
substances are dissolved in the core [Mainardes et al. 2006]. 
 
 
Figure 2.2 Pharmaceutical carriers [Kaparissides et al. 2006]. 
 
Liposomes consist of a lipid bilayer surrounding an aqueous core. They can be 
produced in sub-micron size, and they can carry drugs in their lipid bilayer or 
aqueous core [Bangham et al. 1965]. Micelles are a collection of amphiphilic 
surfactant molecules that spontaneously aggregate in water into a spherical vesicle. 
The centre of the micelle is hydrophobic and therefore can sequester hydrophobic 
drugs until they are released by some drug delivery mechanism. Usually, micelles 
are formed from small molecules that have a hydrophilic or polar or charged “head” 
group and a hydrophobic “tail”, often composed of the hydrocarbon portion of long 
fatty acids. The molecular size and other geometrical features of the surfactants 
determine the size of the micelle [Nishiyama and Kataoka 2003, Savic et al. 2003]. 
A dendrimer is generally described as a macromolecule, which is characterised by 
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its highly branched 3D structure that provides a high degree of surface functionality 
and versatility. Dendrimers have often been referred to as the “Polymers of the 21st 
century” [Pushkar et al. 2006, Lee et al. 2005]. The unique architectural design of 
dendrimers, high degree of branching, multivalency, globular architecture and well-
defined molecular weight, clearly distinguishes these structures as unique 
nanocarriers in medical applications such as drug delivery, gene transfection, tumor 
therapy, diagnostics, etc. Synthetic approaches lead to a dendritic architecture with 
properties amenable to modiﬁcations of shape, size, polarity, surface properties and 
internal structure [Boas and Heegaard 2004]. 
2.5 Mechanisms of drug release  
Drug release from synthetic degradable polymeric carriers involves a series of steps: 
diffusion, chemical reaction and solvent activation. A convenient classification of 
controlled-release systems is based on the mechanism that controls the drug release 
which requires dissolution of the drugs followed by diffusion through the polymeric 
particle’s structure to reach the release medium. Two types of diffusion-controlled 
systems have been developed; the first is a reservoir device and the second is a 
matrix device [Huang and Brazel 2001]. 
 
In a reservoir device, the drug is physically entrapped inside a polymeric vehicle that 
can then be injected or implanted in the body. The drug diffuses through the polymer 
membrane, which protects and surrounds the drug from the environment (Fig. 2.3a). 
Early forms of these systems involved non-degradable polymers such as silicone 
rubber, which could release low molecular mass lipophilic drugs over extremely 
long time periods [Folkman and Long 1964]. This type of approach led to the 
development of Norplant, small silicone capsules containing contraceptives that are 
slowly released by diffusion through the polymer for 5 years. 
 
The process of diffusion is generally described by a series of equations governed by 
Fick’s first law of diffusion: 
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                                                                            (2.1)      
 
Where J (the flux density) is the amount of drug crossing a certain area (the 
membrane) per unit time and is typically expressed in units such as moles of 
particles per m2 per second. D is the diffusion coefficient of the drug in the 
membrane. This reflects a drug molecule’s ability to diffuse through the polymeric 
matrix and is dependent on factors such as molecular size and charge. ∂c/∂x: 
represents the rate of change in concentration c relative to a distance x in the 
membrane. 
 
In matrix systems, drugs are physically embedded and distributed in a polymeric 
carrier (Fig. 2.3b) through which the drug subsequently diffuses out [Langer and 
Folkman 1976, Langer 1990]. Matrix devices are probably the most common of the 
devices for controlling the release of drugs. This is possibly because they are 
relatively easy to fabricate, compared to reservoir devices, and there is less danger of 
an accidental high dosage that could result from the rupture of the membrane of a 
reservoir device. 
 
The release properties of matrix devices may be dependent upon the solubility of the 
drug in the polymer matrix or, in the case of porous matrixes, the solubility in the 
sink solution within the particle's pore network, and also the tortuosity of the 
network [Huang and Brazel 2001]. 
 
In some other drug delivery systems, the mechanism of the drug release is based on a 
combination of diffusion and degradation processes. In these systems, biodegradable 
(or bioerodible, see below) polymers are used for fabrication of drug carriers. The 
rationale for using bioerodible systems is that the bioerodible devices are eventually 
absorbed by the body and thus need not be removed surgically. 
 
Polymer bioerosion can be defined as the conversion of a material that is insoluble in 
water into one that is water-soluble. In a bioerodible system (Fig. 2.3c), the drug is 
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ideally distributed uniformly throughout a polymer in the same way as in monolithic 
systems. As the polymer surrounding the drug is eroded, the drug escapes. 
 
 
     
 
        
 
 
Figure 2.3 Schematic representation of (a) reservoir diffusion controlled (b) 
monolithic (matrix) diffusion controlled and (c) biodegradable (bioerodible) drug 
delivery devices. 
 
(a) 
(b) 
(c) 
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2.6 Polymer degradation and erosion 
Classification of the biopolymers used in drug delivery systems can be difficult due 
to the inherent diversity of structures. However, it is useful to categorise them 
because it can emphasise common properties within groups of polymers. There are 
many descriptions of degradation and erosion in the literature [Vert et al. 1992]. 
However, the following definitions are used in this thesis: degradation is based on a 
chemical process and specifically refers to bond cleavage and the chain scission 
process during which polymer chains are cleaved to form oligomers and monomers. 
Erosion is basically a physical phenomenon dependent on dissolution and diffusion 
processes leading to depletion of material [Tamada and Langer 1990]. 
 
Polymer degradation: degradation is one of the significant processes leading to 
drug release. Therefore it needs to be studied more extensively. Depending on the 
mode of degradation, polymeric biomaterials can be further classified into 
hydrolytically degradable polymers and enzymatically degradable polymers. 
Enzymatic degradation, mainly occurs in natural biopolymers like proteins (gelatin 
and collagen), polysaccharides and poly (β-hydroxy acids), where appropriate 
enzymes are available [Huang and Brazel 2001]. 
 
Hydrolytic degradation is the main type of degradation especially for synthetic 
polymers. There are various factors that influence this process: the type of chemical 
bond, pH, copolymer composition and water uptake are the most important. Some of 
these factors can have a significant effect on the degradation process. One of the 
most important parameters for monitoring degradation is molecular weight. Besides 
loss of molecular weight, other parameters have been proposed as a measure of 
degradation, including: loss of mechanical strength, complete degradation into 
monomers or monomer release [Huang and Brazel 2001]. 
 
Polymer erosion: polymer erosion can have two different mechanisms, first; surface 
erosion, second; bulk erosion [Gopferich 1996]. Surface eroding polymers lose 
material from the surface only (Fig. 2.4a). They get smaller but keep their original 
geometric shape. In other words, surface erosion occurs when the rate of erosion 
exceeds the rate of water permeation into the bulk of the polymer. This is often 
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considered to be a desirable mechanism of erosion in drug delivery because of the 
kinetics of erosion, and hence the rate of drug release, are highly reproducible and 
predictable. Furthermore, the magnitude of the rate of the erosion may be changed 
by simply changing the surface area of the drug delivery device. The slow rate of 
water permeation into surface eroding devices has the further beneficial effect of 
protecting water labile drugs up to the time of drug release [Gopferich 1996]. 
Examples of surface eroding polymers are the poly (anhydrides) and the poly (ortho 
esters). Both of these classes of biodegradable polymers possess highly labile groups 
that ensure rapid hydrolysis of polymer chains encountering water molecules. Water 
permeation is retarded by designing the polymers with hydrophobic monomer units. 
Alternatively, hydrophobic excipients can be added to stabilise the polymer bulk 
[Lee et al. 2004, Modi et al. 2005]. In ideal surface erosion, the erosion rate is 
directly proportional to external surface area. Surface erosion can lead to zero-order 
drug release (a steady amount of drug is released over time) provided that diffusional 
release is limited and the overall shape remains constant.  
 
 
Figure 2.4 Schematic illustration of the biodegradation of a polymeric drug delivery 
system(a) bulk erosion and (b) surface erosion.  
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For bulk eroding polymers, degradation and erosion are not confined to the surface 
of the device. Therefore, the size of a device may remain constant for a considerable 
portion of time during its application (Fig. 2.4a). In this case, bulk erosion occurs 
when the rate of water permeation into the bulk of the polymer exceeds the rate of 
erosion. As a consequence, polymer molecules in the bulk may be hydrolyzed and 
the kinetics of polymer degradation/erosion are more complex than for surface 
eroding polymers. The majority of biodegradable polymers used in controlled drug 
delivery undergo bulk erosion, including the very important poly (ester) materials 
[Lee et al. 2004]. 
 
For most biodegradable polymers, both surface and bulk erosion mechanisms will 
occur, but the relative extent of the mechanisms varies radically with the chemical 
structure of the polymer backbone. Polymer erosion is much more complicated than 
degradation, because it depends on many other processes, including degradation, 
swelling, the dissolution and diffusion of oligomers and monomers, and 
morphological changes. Even more parameters apply to some special types of 
polymers such as electrically erodible materials [Kwon et al. 1991].  
 
2.7 Techniques of micro and nano polymeric particle preparation 
There are several methods for micro and nano encapsulation of therapeutic agents 
such as the emulsion solvent evaporation/extraction method, spray drying, 
coaccervation phase separation and elctrohydrodynamic atomization. All techniques 
have their own advantages and disadvantages. Using a specific method depends on 
the polymer, the drug, the site of the drug action, and the duration of the therapy 
[Jain et al. 2000, Fukushima et al. 2000, Okada and Toguchi 1995]. Generally, 
several requirements need to be met for successful and effective preparation of 
polymeric particles such as: 
 
• The chemical stability and biological activity of the therapeutic agent should 
be preserved during the whole process. 
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• The encapsulation efficiency and the yield of the process should be high 
enough for mass production. 
• Particles should be in a certain size range and they should be almost 
monodisperse. 
• Particles should have a controlled release profile without high initial burst 
release. 
 
2.7.1 Emulsion-solvent evaporation/extraction methods 
2.7.1.1 Single emulsion method 
This technique is used to load hydrophobic drugs via an oil-in-water (o/w) 
emulsification method. In the first step the polymer is dissolved in a water-
immiscible solvent and subsequently the drug is dissolved into the polymer solution. 
At the end, the resulting solution is emulsified in water using an emulsifier [Jain et al. 
2000, Hombreiro et al. 2000]. Usually, the amount of solvent in the emulsion is 
reduced by increasing the temperature to evaporate the residual solvent [Arshady 
1991]. This technique is only suitable for hydrophobic drugs. The encapsulation 
efficiencies for hydrophilic drugs are very low since drugs may diffuse out or 
partition from the dispersed oil phase into the aqueous phase [Hombreiro et al. 2000, 
Arshady 1991]. 
 
2.7.1.2 Double emulsion method 
Most water-soluble drugs are encapsulated by the water-in-oil-in-water (w/o/w) 
method [Crotts and Park 1998, Okochi and Nakano 2000]. In this technique, the 
polymer is dissolved in an organic solvent and then the aqueous solution of the drug 
is emulsified in to form a water-in-oil (w/o) emulsion. Subsequently, a w/o/w 
emulsion is formed by adding the w/o emulsion into an excess amount of water 
containing an emulsifier under vigorous stirring (Fig. 2.5). The residual solvent is 
removed by evaporation or another extraction method. The advantage of this method 
to the single emulsion technique is its high encapsulation efficiency for hydrophilic 
drugs [Crotts and Park 1998, Okochi and Nakano 2000]. 
	   	   	   Chapter	  2:	  Literature	  Review	  
	  
26	  
 
Figure 2.5 Processing scheme for microsphere preparation by double emulsion 
technique [Chiellini et al. 2008]. 
 
2.7.2 Coacervation phase separation  
The term coacervation is derived from the Latin acervus, meaning aggregation, and 
the prefix ‘co’ to indicate union of colloidal particles. The process of three steps is 
carried out under continuous agitation: first, formation of three immiscible chemical 
phases, second, deposition of the coating, and third, rigidization of the coating 
[Carrasquillo et al. 2001, Mallarde et al. 2003] (Fig. 2.6). 
 
Formation of three immiscible chemical phases: the three phases are a liquid 
vehicle phase, core material phase and coating material phase. The three phases are 
formed by dispersing the core material in a solution of coating polymer, the vehicle 
phase is used as a solvent for the polymer. For the coating material phase, an 
immiscible polymer in liquid state is formed by: (i) changing temperature of polymer 
solution, (ii) addition of salt, (iii) addition of nonsolvent, or (iv) addition of 
incompatible polymer to the polymer solution [Madan 1978]. 
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Deposition of the coating: this involves depositing the liquid polymer coating upon 
the core material. This happens if the polymer adsorbs at the interface formed 
between the core material and liquid vehicle phase, and this adsorption phenomenon 
is a prerequisite to effective coating.  
 
Rigidization of the coating: The continued deposition of the coating material is 
promoted by a reduction in the total free interfacial energy of the system by 
rigidization of the coating. This can be carried out using thermal cross linking or 
desolvation techniques. 
 
 
Figure 2.6 Schematic representation of the coacervation process. (a) Core material 
dispersion in a solution of the shell polymer, (b) separation of coacervate from 
solution, (c) coating of core material by microdroplets of coacervate, (d) coalescence 
of coacervate to form continuous shells around the core particles. 
 
The processing setup for this method is relatively simple. It contains mainly of 
jacketed tanks with changeable speed agitators. The significant disadvantage of this 
method is that the droplets formed stick to each other prior to the completion of the 
process and produce large aggregates. 
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2.7.3 Suspension cross-linking 
Preparation of polymeric particles by suspension cross-linking involves the 
formation of a stable droplet suspension of the polymer solution (or melt) in an 
immiscible liquid, gradual hardening of the droplets by covalent cross-linking and, 
finally, recovery of the resulting cross-linked polymer particles. For the preparation 
of particles, the core material remains completely within the droplets. This means 
that the core material (dispersed or dissolved) should have a substantially higher 
affinity for the droplet phase than the suspension medium. The average size of the 
droplets must be about one order of magnitude larger than that of the core particles 
to ensure complete encapsulation [Arshady 1989]. 
 
2.7.4 Spray drying 
 
Figure 2.7 Processing scheme for microsphere preparation by spray drying 
[Zbicinski et al. 2000].  
 
The spray drying method offers several advantages in comparison with the methods 
described above. It has improved reproducibility and processing conditions are 
relatively mild which helps to control the particle size; but the two main 
disadvantages of this technique are: loss of a large number of particles due to 
products sticking to the wall of the spray-drier, and production of large aggregates 
before the complete removal of the solvent [Murillo et al. 2002, Blanco-Prieto et al. 
2004, Burke et al. 2004]. The schematic process is shown in Fig. 2.7. 
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2.7.5 Electrohydrodynamic atomization  
This is the method used in all of the experiments discussed in this thesis. 
Electrohydrodynamic atomization (EHDA) is an attractive method for generating 
particles suitable for use as drug delivery vehicles [Ding et al. 2005, Pareta and 
Edirisinghe 2006]. As mentioned above, different fabrication methods such as single 
and double emulsification are commonly deployed to fabricate drug-loaded 
polymeric particles [Yang et al. 2001, Zhu et al. 2000, Zhang et al. 2008]. However, 
there are inevitably certain disadvantages associated with these methods. For 
example, conventional emulsification methods result in a broad particle size 
distribution [Kissel et al. 1995]. Also, some non-degradable additives such as 
surfactants or polymers are commonly used as emulsifiers [Freitas et al. 2005] and 
the separation of particles from the solvent can be time-consuming and expensive 
but needs to be carried out to reduce the amount of residual solvent to a safe level. 
Most importantly, the biofunctionality of drugs, especially in the case of 
biomacromolecules can be greatly reduced during processing due to exposure to 
certain condition, e.g., elevated temperatures and high shear stresses [Rasiel et al. 
2002, Kohane et al. 2006]. 
 
Figure 2.8 Schematic representation of the single needle EHDA set up used in this 
work using polycaprolactone (PCL) as a polymeric carrier.  
 
In EHDA, particles are produced at the ambient temperature and pressure, thus 
overcoming the problems associated with defunctionalisation of drugs under extreme 
processing conditions. Also this method is capable of generating particles with a 
	   	   	   Chapter	  2:	  Literature	  Review	  
	  
30	  
narrow size distribution, and a mean diameter which can be varied between hundreds 
of micrometres and tens of nanometres by controlling the processing parameters, e.g. 
flow rate(s), needle diameter(s) and applied voltage [Samarasinghe et al. 2008, Xie 
et al. 2008, Ahmad et al. 2008]. 
 
EHDA is a phenomenon which occurs when a liquid is passed at a controlled flow 
rate through a capillary needle maintained at several kilovolts relative to a ground 
electrode few centimetres away. The schematic representation of a single EHDA 
setup is shown in Fig. 2.8.  
2.8 Principles and theoretical aspects of electrohydrodynamic atomization 
processing 
                 
Figure 2.9 Schematic representation of cone-jet mode, (a) Forces acting on a cone-
jet, (b) An axisymmetric liquid cone with a thin jet at its apex [Hartman et al. 1999]. 
 
The influence of an applied electrical field on a conducting liquid was described in 
1600 when William Gilbert reported that electrostatically charged amber, could 
produce a jet of liquid to be emitted from a droplet [Gilbert 1600]. 
Electrohydrodynamic research was first presented in the technical literature by Lord 
Rayleigh, who also studied the effect of an electric field on liquid drops. He 
concluded that the stability of a drop suspended from a capillary is dependent upon a 
balance of forces such as the electrical stresses due to the presence of an electric 
(b) (a) 
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field and the surface tension forces [Rayleigh 1882]. In particular he observed that 
the deformed liquid can take on a conical shape and a thin jet evolve from the tip of 
a cone. Taylor subsequently explained the conical shape through a mathetmatical 
description of the balance between electrostatic stresses and surface tension [Taylor 
1964]. 
 
This “cone-jet mode” is the most desirable mode for producing fine particles. In the 
cone-jet mode the liquid issues from the capillary in the form of a regular, symmetric 
cone with a thin jet at its apex (Fig. 2.9a), stretching along the capillary axis and 
breaking up into fine droplets. To achieve this, liquid is pumped through a nozzle at 
a low flow rate and a droplet is formed at the tip of this nozzle. An electric field is 
applied which induces a surface charge to the droplet. As a result of the electric 
stress, the droplet is transformed into a conical shape. The liquid acceleration and the 
shape of the liquid cone results from the balance of several forces involved. These 
are: liquid pressure, liquid surface tension, gravity and electric strengths in the liquid 
surface. The conical shape is sometimes referred to as a ‘Taylor cone’ which forms 
when the outward stress due to an applied electric field balances the inward stress 
due to the liquid surface tension. The forces that are involved in the formation of a 
cone jet are illustrated in Fig. 2.9b [Hartman et al. 1999]. The applied electric field 
accelerates the surface charge towards the cone apex. This jet breaks up into a 
number of primary or main droplets and a number of secondary droplets and 
satellites [Jaworek and Krupa 1999a and 1999b]. 
 
Most theoretical studies are devoted to the cone-jet mode. Zeleny (1917) was the 
first to study this mode. Taylor successfully examined the cone profile and angle 
based on the liquid in the cone. By assuming that the jet is much thinner than the 
capillary tube for a liquid with relatively high conductivity, Mora and Loscertales 
(1994) reported scaling laws of droplets sizes and spray current (two ratios below) 
related to the flow rate and liquid properties [Mora and Loscertales 1994, Zeleny 
1917]: 
 
                                                        (2.1) 
                                                     (2.2) 
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where r* is the scaled jet radius, ε0 is the vacuum permittivity, ε is the liquid to 
vacuum permittivity ratio, K is the liquid conductivity, Q is the flow rate, I is the 
spray current, and f(ε) is a dimensionless function of ε and γ, with γ being the 
surface tension of the liquid.  
 
However, the use of scaling laws for the prediction of resultant relics is still 
somewhat controversial, because experimental errors in the reported measurements 
do not allow adequate distinction between different relics [Ganan-Calvo 1997a and 
1997b]. In addition, there is a range of combinations where EHDA is stable for 
different properties of injected liquids. For example, Mei and Chen (2007) showed 
that increased flow rate of the inner liquid results in an increase in capsule size for a 
certain value of inner liquid flow rate [Mei and Chen 2007]. However, over a certain 
range of material combinations and processing parameters, capsule diameter 
decreases with an increase in the magnitude of the following processing parameters: 
voltage, electrical conductivity, and surface tension of the sprayed solution. In 
contrast, an increase in particle diameter can also be obtained by means of increasing 
flow rate, density, and viscosity of the sprayed solution [Zhang et al. 2006]. 
 
2.8.1 Modes of electrohydrodynamic atomization 
The geometrical features of the jet and the various types encountered as a function of 
the operating parameters have been classified previously by Jaworek and Krupa 
(1999a and 1999b). Different parameters such as the physical properties of the liquid 
(e.g. surface tension, density, electrical conductivity and viscosity) and processing 
parameters (e.g. flow rate and electric field strength) have significant influences on 
generating EHDA modes [Paine et al. 2007]. At a low voltage only fragments of the 
pumped solution are jetted, creating various modes such as dripping, microdripping, 
rapid microdripping, unstable cone-jet modes. At higher applied voltages, different 
modes involving a sustained and a continuous jet can be formed; these are stable 
cone-jet, multi-jet, and irregular instable jet modes (Fig. 2.10). In these modes, under 
the action of high voltage, the jet usually breaks up into particles a few millimetres 
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from the needle orifice. The meniscus and the jet can be stable or spin around the 
needle axis or rotate irregularly [Cloupeau and Prunet-Foch, 1994, Hayati et al. 
1987a, Hayati et al. 1987b]. 
 
Figure 2.10 Various modes of electrospraying, (a) dripping mode; (b) rapid dripping 
mode; (c) unstable cone-jet mode; (d) stable cone-jet mode; and (e) multi-jet mode; 
and (f) irregular instabilies mode [Jaworek and Sobczyk 2008].  
2.8.2 Effect of liquid flow rate on cone-jet mode 
The size distribution of particles produced by electrohydrodynamic atomization in 
the cone-jet mode depends on the diameter of the jet, and on the break-up of this jet 
into droplets. Every liquid has a minimum flow rate, below which a stable cone-jet 
mode cannot exist for a given voltage. At this minimum flow rate the jet breaks up 
due to asymmetric instabilities. These instabilities are also called varicose 
instabilities [Hartman et al. 2000]. At higher flow rates, the current through the 
liquid cone increases. With increasing current, the surface charge on the jet increases. 
Above a certain surface charge the jet break-up will also be influenced by lateral or 
azimuthal instabilities of the jet. These instabilities are also called kink instabilities. 
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When the influence of these ‘kink’ instabilities increases, then the size distribution of 
main droplets also become wider [Hartman et al. 2000]. 
 
2.8.3 Effect of applied voltage on the cone-jet mode 
The electric field between the capillary and the ground electrode is an important 
parameter in controlling the process of electrohydrodynamic atomization. This is 
determined mainly by the applied voltage and other factors such as the configuration 
of the ground electrode. Within a well defined voltage range, the meniscus of liquid 
becomes conical and stationary. Below this voltage range, the spray always operates 
in pulsating mode [Ganan-Calvo et al. 1997a and 1997b]. With a given inter-
electrode spacing, different modes of atomization can be observed if the voltage is 
gradually increased from low values to high values. Applied voltage is a key variable 
in establishing the cone-jet mode and the cone-jet mode can prevail within a range of 
applied voltages [Tang and Gomez 1994]. Within this range, droplet size reduces 
with increasing applied voltage. Thus, it is necessary to select the highest possible 
value of applied voltage and the lowest possible value of flow rate (within the stable 
jet range) to achieve the minimum droplet size [Jayasinghe and Edirisinghe 2004]. 
For highly conducting and viscous liquids, the sizes of the droplets produced in the 
cone-jet mode are found to be relatively insensitive to the applied voltage [Ku and 
Kim 2002]. 
 
2.8.4 Liquid properties   
The modes of electrohydrodynamic atomization are also influenced by the liquid 
properties such as surface tension, viscosity, electrical conductivity, relative 
permittivity, and density [Ganan-Calvo et al. 1997a and 1997b, Hartman et al. 1999]. 
Each of these properties is discussed briefly below.  
2.8.4.1 Surface tension 
In order to form a stable cone-jet, the surface tension has to be overcome by the 
electric stresses. The higher the surface tension the greater the electric field strength 
required. According to the experimental results obtained by Smith (1986) the 
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threshold voltage for the stable cone-jet will increase with the liquid surface tension 
[Smith 1986] but if the liquid surface tension is very large, a stable jet may not be 
established because the field required exceeds that for the electric break down in the 
gas surrounding the cone. Tang and Gomez (1995) used gases with higher electrical 
breakdown strength as a surrounding fluid instead of air to obtain the stable cone-jet 
mode for water. 
 
2.8.4.2 Viscosity 
Viscosity is another vital liquid property which plays a significant role in the jet 
break-up process and influences the size of the particles produced [Lopez-Herrera et 
al. 2003]. According to Weber (1931) an increase in viscosity will lead to an 
increase of droplet size in electrohydrodynamic processing [Weber 1931]. 
Jayasinghe and Edirisinghe (2002) studied the effect of viscosity on the size of relics 
produced by electrohydrodynamic processing. They found that an increase in 
viscosity over three orders of magnitude had a dramatic effect on the size of particles 
obtained. 
 
2.8.4.3 Electrical conductivity 
Liquid conductivity is the most important property for electrospraying in the cone-jet 
mode. Sufficient electrical conductivity is necessary for the liquid droplet at the 
capillary exit to be transformed into a conical shape. On the other hand, if the 
electrical conductivity is too high, electrohydrodynamic processing will be 
impossible due to corona discharge occurring before the required applied voltage for 
the stable cone-jet mode is obtained. Liquids with low conductivity (insulators), e.g., 
olive oil, cannot be subjected to electrohydrodynamic atomization, although they can 
be electrosprayed in cone-jet mode by artificially increasing their conductivities with 
additives such as ethanol [Lopez-Herrera et al. 2003]. The value of liquid 
conductivity influences the morphology of the liquid issued in the stable cone-jet 
mode. As conductivity increases, the filament width, length, flow rate for the cone-
jet mode and droplet size all decrease [Ganan-Calvo et al. 1997a and 1997b]. 
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2.8.4.4 Relative permittivity 
Relative permittivity or dielectric constant is a measure of the polarisability of a 
material in an electric field. Polarisation reduces the magnitude of the electric field 
inside the liquid. Relative permittivity along with the vacuum permittivity and 
conductivity determines the electrical relaxation time, te = βεo/Κ. Electrical 
relaxation time is the time required to smooth a perturbation in the electric charge; β 
being the relative permittivity, εo and Κ are the vacuum permittivity and electrical 
conductivity, respectively [Ganan-Calvo et al. 1997a and 1997b].   
 
2.8.4.5 Density 
The density of the liquid plays an important role in determining the jet characteristics 
in the cone-jet mode. When the viscosity and the conductivity of the liquid are large 
enough, the electrical charge is efficiently transmitted across the jet section by 
viscous forces. However, the viscous force depends on the density of the liquid 
[Ganan-Calvo et al. 1997a and 1997b]. Also, the liquid density is of some 
importance due to the influence of gravity on the cone shape. For large capillaries, 
diameters larger than 1mm, gravity influences the shape of the cone strongly 
[Hartman et al. 1998]. 
 
2.8.4.6  Needle size and electrode configuration 
With regard to needle size, there is a difference of opinion among researchers. 
Cloupeau and Prunet-Foch (1990) showed that, for a given liquid, the range of flow 
rates varies with the change of needle size [Cloupeau and Prunet-Foch 1990]. Tang 
and Gomez (1996) found that the droplet size is independent of the needle size. 
However, they showed that the needle size significantly affected the stable cone-jet 
domain of electrospraying. The maximum liquid flow rate needed for the stable 
cone-jet electrospray decreases dramatically as the needle diameter increases. This 
shows that in the voltage-flow rate graph, the stable cone-jet domain of the 
electrospray becomes narrower as the needle size increases [Tang and Gomez 1996]. 
 
Jayasinghe et al. (2002) showed that the droplet trajectories depend on the 
configuration of the ground electrode. For a point like ground electrode, the smaller 
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the radius of the point, the higher the concentration of the droplets produced in the 
spraying pattern. They pioneered the use of a point-like ground electrode. This 
configuration of the ground electrode was the key to their innovation of electrostatic 
atomization printing (EAP) [Jayasinghe et al. 2002]. 
2.9 Co-axial electrohydrodynamic atomization (CEHDA) 
Co-axial electrohydrodynamic atomization (CEHDA) is a further development of 
EHDA. The technique uses electrohydrodynamic forces to generate co-axial jets of 
immiscible liquids or suspensions. A schematic of the basic experimental setup for 
CEHDA is given in Fig. 2.11. Two immiscible liquids or suspensions (T1 Outer 
Liquid, T2 Inner Liquid) are passed through two concentrically arranged capillaries. 
The outer and inner needles are connected to the same electrical potential of several 
kilovolts relative to an earthed ring electrode 
 
 
 
 
 
 
 
 
Figure 2.11 Schematic representation of the CEHDA setup [Loscertales et al. 2002]. 
 
High 
Voltage 
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2.9.1 The mechanism of co-axial electrohydrodynamic atomization 
 
Figure 2.12  Formation of a cone-jet in CEHDA with outer meniscus surrounding 
the inner one, (a) no flow; (b) dripping mode demonstrating immiscibility; and (c) 
Formation of a compound cone-jet in CEHDA. 
 
For a certain range of values of the applied voltages and flow rates, a cone-jet is 
formed at the exit of the needles with an outer meniscus surrounding the inner one. 
A liquid thread is issued from the vertex of each one of the two menisci, giving rise 
to a compound jet of two co-flowing liquids or suspensions (Fig. 2.12) [Loscertales 
et al. 2002]. 
 
2.9.2 The driving liquid concept  
To obtain a structured cone-jet, electrohydrodynamic forces must act on at least one 
liquid, although they may act on both. The liquid upon which electrohydrodynamic 
forces act predominantly to form a cone-jet is called the driving liquid. The driving 
character of one of the liquids can be determined by comparing their electrical 
relaxation times. The electrical relaxation time, te= βεo/Κ is the time required to 
smooth a perturbation in the electric charge. The driving character of one of the 
liquids can be lost in favour of the other if the electrical conductivity of the latter is 
enhanced sufficiently by adding a suitable additive to it [Lopez-Herrera et al. 2003]. 
When charges are located at the outer interface, the tangential electrical stresses 
which point towards the vertex of the conical interface must be efficiently 
transmitted throughout the liquid bulk by viscous diffusion. This requires that the 
viscosity of the outer liquid be high enough to play an important role in the liquid 
(a) (b) (c) 
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motion. Moreover, the use of a less viscous liquid outside would give rise to intense 
re-circulations in the electrified meniscus and these re-circulatory motions are 
incompatible with steady compound jets. However, liquids with lower viscosity can 
be used as drivers when they are used inside, even when a non conducting liquid 
such as olive oil is used outside. This is also one way of electrospraying liquid 
insulators [Loscertales et al. 2002].  
2.10 Applications of single needle and co-axial EHDA methods in preparation of 
various drug carriers 
The versatility of electrohydrodynamic atomization has been demonstrated through 
several published results in the pharmaceutical field. Current challenges in the field 
of drug delivery lie in the development of drug-encapsulation carriers on the 
micrometre or nanometre scale. In this section, various techniques are discussed in 
the context of potential biomedical applications of the different products, specifically 
drug delivery vehicles, which were produced using single needle and co-axial EHDA 
methods.  
 
2.10.1 The application of single needle EHDA processing 
In single needle EHDA processing, a therapeutic agent is incorporated in the 
particles, e.g. dispersed in a polymeric matrix [Ciach 2007]. The processing 
parameters and physical properties of the solutions used play an important role in 
determining the characteristics of the carrier. It has been shown that adjusting the 
processing parameters (i.e. needle size, working distance, flow rate and applied 
voltage) enables carriers to be obtained with different size, shape, and morphology 
for different applications [Xie et al. 2006a and 2006b, Berkland et al. 2004]. The 
first part of the experimental work in this thesis will concentrate on this (Chapter 4); 
with extensive studies on controlling the size of the fabricated particles via the 
processing parameters. In the next section, a detailed description of various 
structures such as particles, aerosols, and porous structures made via single needle 
EHDA will be given. 
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2.10.1.1 Particles 
The fabrication of drug loaded particles with high encapsulation efficiency and a 
well defined and controllable size distribution is one of the most significant 
challenges in current pharmaceutical and medical research [Langer 1998]. Wu et al. 
used an EHDA technique to produce nanoparticles (300−400 nm in diameter) which 
were composed from genetically engineered elastin-like polypeptides (ELPs), a 
biodegradable and bioresponsive polymer. They successfully loaded doxorubicin 
into the particles and the loading of this drug at 20 w/w% did not influence particle 
morphology. The particle diameter, polydispersity (ratio of standard deviation to 
mean size) and morphology, were significantly influenced by solvent concentration, 
spraying voltage, and polymer molecular weight. Release of the drug was influenced 
by the pH and solubility of the ELPs [Wu et al. 2009a]. Xu et al. similarly prepared 
bovine serum albumin (BSA)-loaded tripolyphosphate (TPP) cross-linked chitosan 
particles whose size was found to be strongly influenced by the flow rate [Xu and 
Hanna 2007]. In another study, BSA was loaded into particles by electrospraying an 
emulsion of BSA in a poly(lactide) (PLA) solution and spherical particles in the 
range of 0.8 to 4 µm with smooth surfaces were produced [Xu et al. 2006]. The 
encapsulation efficiency and the yield of the process were between 22 to 80% and 64 
to 80%, respectively. However, the release profile of the drug did not reach a steady 
state within the time of observation due to PLA erosion. 
 
It has been shown that EHDA processing can be used for preparing polymeric 
nanoparticles incorporating both hydrophilic and hydrophobic drugs [Valo et al. 
2009, Pareta et al. 2005], that the biofunctionality of the drug is unaffected and that 
high encapsulation efficiencies can be achieved. For example, Xie et al. fabricated 
particles by EHDA processing for sustained delivery of the anticancer drug 
paclitaxel to treat C6 glioma with an encapsulation efficiency of ~80% [Xie et al. 
2006a]. Similar values were reported for the case of Ampicillin loaded chitosan 
micro/nanoparticles with a size of 520 nm [Arya et al. 2009] and by Ding et al. for 
taxol-loaded polycaprolactone (PCL) particles which exhibited excellent sustained 
release profiles over a month [Ding et al. 2005]. 
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Furthermore, changing the properties of the solvents and solutions used in EHDA 
also provides a means of tailoring the morphology and structure of the particles 
[Farook et al. 2009a]. Berkland et al. showed that specific structural types, such as 
tapered shapes, porous surfaces, and blood cell-shaped particles, could be achieved 
by varying the properties of the polymer solvent used [Berkland et al. 2004]. The 
size of the fabricated particles has also been shown to decrease with increasing 
conductivity of the polymer solution. Furthermore, the morphology of the fabricated 
particles can be significantly altered by using different combinations of polymers 
(e.g. poly (ε-caprolactone) (PCL), poly (lactic acid-co-glycolid acid) (PLGA), poly-
D-lactic acid (PDLA) and poly-L-lactic acid (PLLA)) and solvents [Yao et al. 2008]. 
 
2.10.1.2 Aerosols 
Aerosols are another type of pharmaceutical carrier, which can be produced using 
single needle EHDA. Aerosol-based pulmonary disease therapy emerged in 1990. 
An inhaled drug delivery system should have some critical characteristics. For 
instance, for effective delivery of the aerosol down to the lower airways, the final 
aerodynamic size of the particles should be between 2-5µm, and they should also be 
monodisperse [Ijsebaert et al. 1999]. EHDA processing was shown to meet these 
requirements for the production of aerosols. The resulting droplets were nearly 
monodisperse, and the droplet size could be easily varied by the voltage and flow 
rate. Zimlich et al. (2000) developed a hand-held prototype of pulmonary drug 
delivery nebulizer using EHDA principles. Here 78% of the aerosol with a droplet 
size of 1-6µm were found in the respiratory tract, which was approximately four 
times higher than that achieved using some other commercially tested devices 
[Zimlich et al. 2000]. 
 
2.10.1.3 Porous particles 
Porous structures have attracted much attention because of their specific morphology 
and high surface area to volume ratio. The bioactive agents can be arranged in a 
specific order to make this structure have a unique architecture for biomedical 
applications [Jiang et al. 1999]. Wu and Clark (2007) electrosprayed porous PCL 
particles by jetting into a water bath using various solutions of different PCL 
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concentrations in chloroform solvent. Solvent evaporation and phase separation are 
the two main mechanisms for the formation of pores. They showed that solvents 
with low boiling points make pores with irregular morphologies and large 
dimensions. Moreover, Wu and Clark demonstrated that rapid solvent evaporation 
mechanism has a key role in forming porous particles via EHDA processing [Wu 
and Clark 2007]. 
 
2.10.2 Co-axial EHDA processing and its application 
As mentioned in Section 2.6, the co-axial EHDA processing provides a powerful 
technique for the production of capsules in both the micrometre and nanometre size 
range. It facilitates encapsulation of sensitive core materials, for example, cells, 
enzymes or drugs in a protective shell. A range of polymeric materials including 
polyurethanes, polysiloxanes, polylactides (PLA), polyglycolides (PGA), 
poly(lactide-co-glycolides) (PLGA), are employed as shell materials for capsule/ 
bubble production because of their desirable physical properties, such as elasticity, 
insulating ability, physical strength, toughness, and freedom from leachable 
impurities. Many of these polymers are designed to degrade within the body [Langer 
1998, Brannon-Peppas 1997], in particular polylactide (PLA), polyglycolides (PGA), 
and poly(lactide-co-glycolides) (PLGA). These biodegradable polymeric carriers 
have been extensively investigated as they have shown no adverse tissue reactions 
when carrying bio-active agents and, as above, can be hydrolyzed in the body to 
form products that can be easily eliminated, sparing the need to remove these 
implants by surgery. Another versatile application of co-axial EHDA is the 
production of microbubbles, which have shown great promise in therapeutic 
applications such as targeted drug delivery, diagnostic imaging, thrombolysis, gene 
therapy, and focused ultrasound surgery [Mizushige et al. 1999, Poliachik et al. 
1999, Schmidt and Roessling 2006, Unger et al. 2001].  
 
2.10.2.1 Capsules 
Micro/nano encapsulation via co-axial EHDA is of particular importance for drug 
delivery [Barisci et al. 2000, Xie et al. 2008], food industry [Yoshii et al. 2001], and 
specific material processing [Burlak et al. 2001, Lee et al. 2001]. Lopez- Herrera et 
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al. investigated the electrified co-axial jets of two solutions evolved from a 
structured cone jet [Lopez-Herrera et al. 2003]. The group introduced the driving-
liquid concept and studied the linear scaling law for predicting jet diameters as 
described in Section 2.5. However, their work did not specify the criteria that 
determine the structure of the capsules. Loscertales et al. demonstrated the 
production and control of monodisperse capsules in different size ranges from 0.15 
to 10 micrometres [Loscertales et al. 2002]. They also showed that the diameter of 
capsules was influenced by several parameters including the operational parameters 
such as the applied flow rates and voltage, the physical properties of solutions, and 
the interaction between inner and outer solutions during the spray. Chen et al. 
investigated co-axial jet electrospraying using an ethanol/ glycerol/TWEEN mixture 
and cooking oil as the two solutions and found that the properties of the outer liquid, 
which was very viscous and electrically conductive, played a key role in controlling 
the process [Chen et al. 2005]. 
 
Many studies have focused on the encapsulation of bioactive agents. Paclitaxel (a 
hydrophobic anticancer drug) has been encapsulated in biodegradable polymeric 
particles by electrospraying, with particle sizes in the range 1 to 15 µm [Ding et al. 
2005]. Pareta and Edirisinghe (2006) demonstrated the preparation of polymer-
coated starch/bovine serum albumin (BSA) microspheres using a co-axial system. 
The mean diameter was 5–6µm and 75% of the BSA was released over a 7 day 
period [Pareta and Edirisinghe 2006]. In addition, co-axial jetting producing 
oligodeoxynucleotide encapsulated lipoplex nanoparticles for either intravenous 
injection or potential pulmonary delivery, has been demonstrated [Wu et al. 2009b]. 
The diameter of the particles was about 190 nm and the particles provided an 
efficient medium for gene delivery. Capsules with micro- and nanoscale anisotropy 
have received increasing interest for their ability to simultaneously present different 
physical and chemical properties. In a study, it was demonstrated that gold 
nanocrystals (NC) could be selectively incorporated into one compartment of 
anisotropic polymer particles. Stable bicompartmental particles were prepared via 
electrohydrodynamic co-jetting of aqueous nanoparticle suspensions followed by 
thermal cross-linking [Lim et al. 2010]. Bicompartmental particle populations with 
different NC densities were obtained by varying the NC concentration in the jetting 
suspension. This study delineates a new approach for preparation of 
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inorganic/organic composite particles with precisely engineered, anisotropic 
nanoparticle distributions and may contribute to further developments in emerging 
scientific areas, such as smart materials or particle-based diagnostics. 
 
2.10.2.2 Microbubbles 
The co-axial EHDA principle can be used to prepare microbubbles with a near 
monodisperse size distribution [Farook et al. 2007a]. Preparation of microbubbles is 
an area of significant interest in a range of biomedical application areas, from use as 
contrast agents for ultrasound imaging to drug delivery; and the EHDA method can 
offer unique advantages compared with e.g. microfluidic devices and simple 
agitation [Pancholi et al. 2007]. Farook et al. were the first to demonstrate that 
suspensions containing bubbles less than 10 µm in diameter with a narrow size 
distribution can be prepared by EHDA. In this process, glycerol was injected through 
the outer needle of the two needle set arrangement while air flowed through the inner 
needle at the same time [Farook et al. 2007a]. The process was then adapted to 
prepare phospholipid-coated microbubbles with a high yield (109 bubbles min-1) 
[Farook et al. 2009b]. EHDA bubbling shows three characteristic spray modes: 
bubble dripping, coning and continuous bubbling; the latter mode being the most 
suitable for the preparation of microbubbles for biomedical applications.  
 
 
Figure 2.13 Optical micrographs of lipid-coated microbubbles collected at ambient 
temperature at a flow rate combination of (a) 5 µl s-1 : 5 µl s-1 and (B) 10µl s-1: 5µl s-1 
[Farook et al. 2009b]. 
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Fig. 2.13 shows phospholipid-coated microbubble suspensions with a mean diameter 
of 6.6 µm and a standard deviation of 2.5 µm. These bubbles were found to be very 
stable at ambient temperature, while at human body temperature (37°C), the mean 
bubble diameter fell rapidly initially and stabilized at 1–2 µm after 20 min [Farook et 
al. 2009a]. The stability of the microbubbles prepared by EHDA can be further 
improved and the polydispersivity index controlled be adding a dispersant such as 
Tween to the phospholipid [Farook et al. 2009a]. 
 
2.10.2.3 Hollow spheres 
Chang et al. (2009) demonstrated that using a volatile liquid (perfluorohexane PFH) 
instead of air, polymer (polymethylsilsesquioxane, PMSQ) capsules could be 
generated using co-axial EHDA with an even higher degree of control over their 
characteristics. It provides a means of controlling the content of the capsules via 
heating the suspension to the boiling point of the PFH (Fig. 2.14). 
 
 
Figure 2.14 SEM micrograph of PFH encapsulated in PMSQ after 48 hrs drying 
[Chang et al. 2009]. 
 
Core-shell particles were obtained in a single step, which is clearly preferable 
compared with multistep processes such as emulsification. Dye encapsulation was 
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achieved by evaporation of the PFH core to enable inward diffusion of the liquid 
[Chang et al. 2009]. This method has been further developed for the preparation of 
monoporous hollow microspheres [Chang et al. 2010] which provide high effective 
diffusivity [Guan et al. 2007]. Chang et al. showed that the geometry and the 
porosity of these microspheres with or without a single surface pore can again be 
controlled by varying the process control parameters of the co-axial system. Among 
these, the flow rate plays a significant role in the final structure which can be varied 
to control the pore size of the hollow microsphere. 
 
 
Figure 2.15 SEM image of the one-hole microspheres (PMSQ flow rates at 600 µl 
min-1 and PFH was fixed at 300 µl min-1) [Chang et al. 2010]. 
 
The formation of the surface pore occurs during the spraying process and may be 
attributed to evaporation flux of the perfluorohexane solvent (Fig. 2.15). This 
method overcomes several processing challenges associated with the existing 
methods of fabricating this type of structure; for example, requirement for highly 
specialised equipment, presence of highly controlled processing environment and the 
use of surfactants and other additives [Guan et al. 2007]. The size of the prepared 
monoporous hollow spheres ranged from 275 to 860 nm with the pore size of 35 to 
135 nm. The ability to tune the pore size of the monoporous hollow sphere through 
the co-axial EHDA system is of interest for applications in the areas of drug/gene 
delivery vehicles, targeting, and catalysis. 
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2.10.3 The application of multi-capillary EHDA 
Different combinations of needles provide versatile capabilities of encapsulation. 
Ahmad et al. (2008) showed the flexibility of using three co-axially arranged needles 
to form a variety of novel morphologies (Fig. 2.16). 
 
 
Figure 2.16 Schematic representation of the experimental set-up used for three 
needles set of (a) concentric arrangement and (b) co-planar arrangement [Ahmad et 
al. 2008, Roh et al. 2006]. 
 
The resulting electrohydrodynamic flow enables the preparation of: double-layered 
bubbles, porous encapsulated threads and nanocapsules containing three layers (Fig. 
2.17). The ability to process multilayered structures can provide multistage 
controlled release [Ahmad et al. 2008], and in situ encapsulation of nanoparticles, 
liquids and/or gases [Ahmad et al. 2008, Kalra et al. 2009]. However, it is not 
necessary to arrange the needles concentrically. Langer and Yamate (1969) used two 
droplets with opposite charges emitted from two separate capillaries and 
demonstrated that microcapsules can be obtained due to Coulomb attraction [Langer 
and Yamate 1969]. Borra et al. (1997) utilized this idea to develop a chemical 
reactor for different reacting compounds [Borra et al. 1997]. 
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Figure 2.17 Droplet, nanocapsule and thread formation using two- and three-needle 
co-axial devices. (a) co-axial two needle product with olive oil and glycerol; (b) non-
concentric co-axial two-needle encapsulation; (c) co-axial tri-needle encapsulation 
with air, glycerol and olive oil; (d) high magnification scanning electron micrograph 
of nanocapsules showing different regions (densities); (e) transmission electron 
micrograph of nanocapsule with non-concentric multiple layers; (f) transmission 
electron micrograph of nanocapsule with concentric multiple layers; (g) air 
encapsulation in twin-layered thread with olive oil and PEO solution; (h) instabilities 
during thread formation; and (i) two-needle (third needle switched off) co-axial non-
concentric thread encapsulation using olive oil and PEO solution [Ahmad et al. 
2008]. 
 
Furthermore, by reducing the coplanar distance of two needles, biphasic 
nanocolloids can be used as anisotropic imaging probes with short-term 
biocompatibility [Yoshida et al. 2007]. The concept of electrified co-jetting was 
further extended by Roh et al. (2006) and triphasic nanocolloids with three distinct 
compartments were obtained by simultaneous injection of three distinct liquid flows 
[Roh et al. 2006] (Fig. 2.16b). 
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2.11 Polymers and drug delivery systems 
Polymers, the most versatile class of materials, have been widely used in drug 
delivery systems [Li and Vert 1999]. Polymers can be degradable or non-degradable. 
The use of biodegradable and biocompatible polymers for the administration of 
therapeutic agents has been increased rapidly. Biodegradable polymers can be either 
natural or synthetic. In general, synthetic polymers have several advantages over 
natural polymers as their properties can be tailored and they have lower toxicity. An 
important point to consider when choosing a drug carrier is to match the degradation 
rate to the needs of the application [Uhrich et al. 1999]. 
 
As mentioned above, the synthetic polymers used for drug encapsulation often 
include esters such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), the 
copolymer poly (lactic-co-glycolic acid) (PLGA) and poly (ε-caprolactone) (PCL). 
These are considered as aliphatic polyesters which have attracted much interest as 
drug carriers due to their biocompatibility and biodegradability. This class of 
polymers degrade via the hydrolytic cleavage of the ester bonds in their backbone 
[Fu et al. 2000, Sinha and Trehan 2003]. More details about PLA, PGA and the 
PLGA and PCL copolymers (two copolymers used in this research) are given below. 
2.11.1 Poly (lactic acid) (PLA) 
The basic monomeric unit of poly (lactide) or poly (lactic acid) (PLA) is lactic acid. 
PLA can be synthesised by ring-opening polymerization of the cyclic dimer lactide 
in a moisture-free atmosphere under heat (105-185 °C) and with the use of a catalyst 
(Fig. 2.18).  
 
 ` 
Figure 2.18 Synthesis of poly (lactide) or poly(lactic acid) (PLA). 
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PLA degrades into water-soluble monomers of lactic acid via hydrolysis of the ester 
linkage, and also undergoes enzymatic hydrolysis when its molecular weight 
becomes lower than~10,000 g/ml. The lactic acid eventually becomes incorporated 
in the tricarboxylic acid cycle (Kerbs cycle) and is excreted by the lungs as carbon 
dioxide and water. The degradation rate is progressively reduced with an increase in 
molecular size [Li and Vert 1999, Jalil and Nixon 1990]. 
 
2.11.2 Poly (glycolic acid) (PGA) 
The synthetic monomeric unit of poly (glycolide) or poly(glycolic acid) (PGA) or 
glycolic acid, PGA is synthesised from the ring-opening polymerisation of the cyclic 
dimmer glycolide in a moisture-free process under heat and with the use of a catalyst 
(Fig. 2.19). PGA is semi-crystalline (45-55%) with a high Tm (220-225 °C) and a Tg 
just below or around body temperature (35-40 °C). Unlike PLA and other polyesters, 
PGA is not soluble in most common organic solvents due to its high degree of 
crystallinity, except in highly fluorinated organic solvents. Sutures of PGA lose 
about 50% of their strength after two weeks and 100% at four weeks. The 
degradation time for full resorption of PGA could be between 6 and 12 months [Li 
and Vert 1999, Jalil and Nixon 1990]. 
 
 
Figure 2.19 Synthesis of poly(glycolide) or poly(glycolide acid) (PGA). 
 
Apart from hydrolytic degradation, PGA is additionally broken down by nonspecific 
esterases and carboxy peptidase in vivo to produce water-soluble glycolic acid. This 
can then be excreted in the urine or undergo further enzymatic conversion and 
reaction before eventually entering the tricarboxylic acid cycle (Krebs cycle). 
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2.11.3 Poly (lactic acid-co-glycolic acid) (PLGA) 
Lactic acid is more hydrophobic than glycolic acid and hence lactide-rich PLGA 
copolymers are less hydrophilic, absorb less water, and subsequently degrade more 
slowly [Witschi and Doelker 1998]. The physical properties such as the molecular 
weight and the polydispersity index affect the mechanical strength of the polymer 
and its ability to be formulated as a drug delivery device. Also these properties may 
control the polymer biodegradation rate and hydrolysis. PLGA is synthesised by 
means of random ring-opening co-polymerisation of two glycolic acid and lactic acid 
monomers. During polymerisation, successive monomeric units (of glycolic or lactic 
acid) are linked together in PLGA by ester linkages, thus yielding linear, aliphatic 
polyester as a product (Fig. 2.20). The commercially available PLGA polymers are 
usually characterised in terms of intrinsic viscosity, which is directly related to their 
molecular weights. The mechanical strength, swelling behavior, capacity to undergo 
hydrolysis, and subsequently the biodegradation rate are directly influenced by the 
crystallinity of the PLGA polymer. The resultant crystallinity of the PLGA 
copolymer is dependent on the type and the molar ratio of the individual monomer 
components (lactide and glycolide) in the copolymer chain [Jalil and Nixon 1990]. 
PLGA polymers containing 50:50 ratio of lactic and glycolic acids are hydrolysed 
much faster than those containing higher proportion of either of the two monomers 
[Sinha and Trehan 2005]. 
 
The Tg (glass transition temperatures) of the PLGA copolymers are above the 
physiological temperature of 37°C and hence they are glassy in nature. Thus, they 
have a fairly rigid chain structure which gives them sufficient mechanical strength to 
be utilised in drug delivery devices. Jamshidi et al. have reported that the Tg of 
PLGAs decreases with decreasing content of lactide in the copolymer composition 
and decreasing molecular weight [Jamshidi et al. 1988]. 
 
A three-phase mechanism for the PLGA biodegradation has been reported [Cai et al. 
2000]:  
1. Random chain scission process. The molecular weight of the polymer decreases 
significantly, but there is no appreciable weight loss and no soluble monomer 
products formed. 
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2. In the middle phase a decrease in molecular weight is accompanied by rapid loss 
of mass and soluble oligomeric and monomer products are formed. 
 
3. Soluble monomer products are formed from soluble oligomeric fragments. This 
phase corresponds to complete polymer solubilisation.  
 
 
Figure 2.20 Synthesis of poly(lactide-co-Glycolide) or poly(lactic acid-co-glycolic 
acid) (PLGA). 
 
2.11.4 Poly(ε-caprolactone) 
Poly (ε-caprolactone) (PCL) is an aliphatic polyester which is synthesised by the 
ring-opening polymerization of the cyclic monomer ε-caprolactone (Fig. 2.21) 
[Benoit et al. 1999].  
 
Figure 2.21 Synthesis of poly (ε-caprolactone). 
There are various mechanisms which affect the polymerization of PCL and these are 
categorised as anionic, cationic, co-ordination and radical. Each mechanism is 
affected by the molecular weight (Mn), molecular weight distribution, end group 
composition and chemical structure of the copolymers. PCL is a semi-crystalline 
polymer having a glass transition temperature of −60°C and a melting point ranging 
between 59 and 64°C, depending upon its crystallinity. The number average 
molecular weight of PCL samples may vary from 10,000 to 42,500 and it is graded 
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according to the molecular weight (Mn). PCL is soluble in chloroform, 
dichloromethane, carbon tetrachloride, benzene, toluene, cyclohexanone and 2-
nitropropane at room temperature. It has low solubility in acetone, 2-butanone, ethyl 
acetate, dimethylformamide and acetonitrile and is insoluble in alcohol, petroleum 
ether and diethyl ether. PCL can be blended with other polymers to improve stress 
crack resistance, dyeability and adhesion. Polycaprolactone is used in combination 
with polymers such as cellulose propionate, cellulose acetate butyrate, polylactic 
acid and polylactic acid-co-glycolic acid for manipulating the rate of drug release 
from microcapsules [Chang et al. 1986]. 
2.12 Controlling and regulating drug release profiles  
Polymer based controlled release systems are used to reduce the amount of drug 
required to acheive a given therapeutic effect in patients. The main goal of these 
systems is to deliver the drug at the target site and to release it at a specified rate 
over a defined period of time. One strategy to achieve this aim and to increase the 
efficiency of the system is to control the burst release phase, which is the period of 
high release rate during the 24 hours following administration. Another strategy is to 
use external stimuli to non-invasively promote release from carrier particles “on 
demand”. This type of release profile regulation is applicable in pulsatile drug 
delivery systems. In this thesis, ultrasound is investigated as the external stimulus on 
account of its excellent track record in medical imaging and various therapeutic 
applications. The existing literature relevant to both strategies will be discussed in 
the following sections. 
 
2.12.1 Significance of the burst release in drug delivery systems 
It was mentioned earlier (Section 2.2) that drug-loaded biodegradable polymer 
particles have been investigated extensively for their potential to release bioactive 
agents in a sustained way. However, these particles still suffer from a key technical 
problem, the ‘burst release’ (Fig. 2.22). It normally occurs over a short time 
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compared to the whole release profile [Huang and Brazel 2001, Wang et al. 2002, 
Zhang et al. 2005, O’Donnell and Mcginity 1997]. 
 
Figure 2.22 The burst release effect in drug delivery systems with a zero-order 
release pattern [Huang and Brazel 2001]. 
 
Table 2.1 Desirable application and negative effects of burst release.  
Positive burst release situations Negative burst release effects 
Wound treatment (burst release followed by a 
diminishing need for drug) 
Local or systemic toxicity (from high drug 
concentrations) and short half-life of drugs  
Targeted delivery (triggered burst release) Economically and therapeutically wasteful of 
drug 
Pulsatile release Shortened release proﬁle; requires more 
frequent dosing 
 
This phenomenon can be associated with toxicity and reduces the lifetime of the 
therapeutic system, making it a major obstacle in the utilisation of these types of 
delivery system. Hence, burst release is often regarded as an undesirable and 
negative phenomenon. There are certain situations however, in which rapid initial 
release may be desirable (Table 2.1). For instance, in many pulsatile delivery 
systems, repeated burst release is one of the objectives, so that the active agent can 
be delivered rapidly at a specific time. Also, there are some therapeutic agents that 
need to be administered at different rates. For example, the drugs used at the first 
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stage of wound treatment, need to have high initial release rates to provide instant 
pain relief followed by a sustained and prolonged release to help gradual healing 
[Setterstrom et al. 1984]. Few studies have focused on the mechanism of the initial 
release and the control of this phenomenon. Burst release may be attributed to two 
causes. First, the heterogeneous distribution of the drug in the polymeric particles. 
Second, morphology of the drug loaded particles, as the drugs can escape from the 
polymeric particles through the porous structure that forms during the fabrication 
process [Huang and Brazel 2001, Yang et al. 2001]. 
 
However, in most of the previous studies, surface-associated drugs have been 
identified as the key factor determining the burst release phase [Cohen et al. 1991]. 
This phenomenon mainly occurs due to rapid water intake by the particle surface, 
which subsequently causes swelling of polymer chains close to the surface and 
tremendously enhances the diffusion process of the therapeutic agent molecules 
dispersed in this region. Another reason for the presence of drug on the surface of 
the drug carrier could be the fact that some drugs become trapped on the surface of 
the polymer matrix during the fabrication process [Batycky et al. 1997]. This 
happens particularly if the drug loading is too high [Brazel and Peppas 1999]. Also, 
the diffusion and migration of drugs during drying and storage steps may result in a 
heterogeneous distribution of drug. For example, as water moves to the particles’ 
surfaces and evaporates, drugs may diffuse by convection with the water, leaving an 
uneven drug distribution across the particles, with higher concentrations at the 
surface (Fig. 2.23) [Kishida et al. 1998, Mallapragada et al. 1997]. 
 
 
Figure 2.23 Potential drug redistribution due to convection during the drying 
process. 
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2.12.1.2 Controlling the burst release phase 
Several strategies can be applied for controlling the burst release such as:  
 
Reducing the rate of water intake, this can be performed by increasing the 
hydrophobicity of the carrier,  
Increasing the diffusional resistance to the drug by increasing the length of the 
diffusion pathways to the drug molecules, 
Prevention of drug on the surface of the particles, 
These three strategies can be made effective by increasing polymer concentration, 
manipulating particle size and surface modification [Yamaguchi et al. 2002, Huang 
and Brazel 2001, Ravivarapu et al. 2000]. There are various surface modification 
methods such as:  
Surface extraction, this method is effective at reducing burst phase because the 
drug is removed from the outer layers of controlled release devices, but one 
important issue is the cost of extraction and the reduction in the effective use of  
(often expensive) drugs.  
Surface modification via chemical couplings, this is a complex procedure which 
involves two steps: surface activations and coupling reaction. 
Surface modification via co-incorporation of surface modifying agents into the 
particles, in this process, surface modifying agents are co-incorporated into the 
particle matrix during the particle formulation protocol. This technique involves over 
night stirring, ultracentrifugation and in some cases elevated temperature which may 
cause defunctionalisation of the active agent. 
 
Overall, of the suggestions that have been given to prevent burst, many involve 
additional costly steps, which also result in reduced drug loading percentages and 
reduced efficiency of the drug delivery system. However, there is other method 
which is surface modification via additional coating which is an effective means 
of executing all three of the aforementioned strategies, by providing an outer drug-
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free layer. This is a cost effective and more efficient method compare to the methods 
mentioned above. In this coated particulate drug release system, the amount of drug 
release is controlled by the dissolution or erosion of the outer coat which is applied 
to the drug loaded polymeric particles (Fig. 2.24). Time dependent release of the 
active ingredient can be obtained by optimising the thickness of the outer coat. 
However the processing parameters such as the type of the coating agent, the coating 
method and the concentration of the coating materials should be optimised carefully. 
 
 
Figure 2.24 Schematic diagram of a delivery system with erodible coating layer. 
 
Because of the important role of the burst release, the final section of this thesis is 
mainly focused on the study of this phenomenon and how to control it. One of the 
most important questions in developing controlled release devices is how to control 
release and to quantify it in advance.  
 
2.12.2 Ultrasound stimulated drug release  
Ultrasound is a subsection of acoustics that relates to vibratory or stress waves at 
frequencies which are higher than the human hearing range i.e., >20 kHz [Wu and 
Nyborg 2008]. Ultrasound has been used for over 30 years in diagnostic imaging of 
the body and has been used for other therapeutic applications such as: nerve 
regeneration [Paik et al. 2002, Lazar et al. 2001], thrombolysis, fracture healing 
enhancement [Dalecki 2004, Warden 2003], collagen repair promotion [Demir et al. 
2004] and drug delivery enhancement including facilitating the delivery of drugs 
across the skin and delivering chemotherapeutic drugs into tumours. 
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In ultrasound stimulated pulsatile systems, ultrasonic waves promote the erosion of 
the polymeric matrix thereby modulating drug release. Miyazaki et al. studied the 
influence of ultrasound (at a frequency of 1 MHz) on the release rates of bovine 
insulin from ethylenevinyl alcohol copolymer drug delivery systems. They found 
that insulin release was enhanced by exposure to ultrasound, giving rise to a 
dramatic reduction in blood glucose level [Miyazaki et al. 1988]. Also, Kost et al. 
studied the effect of ultrasound on the degradation of biodegradable polymers 
(polyanhydrides, polyglycolides and polylactides) and the release rate of the 
molecules incorporated within those polymers. Up to 20-fold increases in the release 
rate of the molecules incorporated were observed and the feasibility of ultrasonically 
augmenting of polymer degradation and drug release were demonstrated [Kost et al. 
1989]. 
 Table 2.2 Diseases that require pulsatile drug delivery systems. 
Disease Chronological behaviour Drugs used 
Peptic ulcer Acid secretion is high in the afternoon and at night H2 blockers 
Asthma Precipitation of attacks during night or at early 
morning hour 
β2 agonist, 
Antihistaminics 
Cardiovascular 
diseases 
Blood presure is at its lowest during the sleep cycle 
and rises steeply during the early morning 
awakening period 
Nitroglycerin, Calcium 
channel blocker 
Arthritis Pain in the morning and more pain at night NSAIDs, 
Glucocorticoids 
Diabetes mellitus Increase in the blood sugar level after meal Sulfonylurea, Insulin 
Attention deficit 
syndrome 
Increase in DOPA level in afternoon Methylphenidate 
Hypercholesterolemia Cholesterol synthesis is generally higher during 
night than during day time 
HMG CoA reductase 
inhibitors 
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A further application of ultrasound is the stimulation of drug release in pulsatile 
systems. As above, pulsatile drug delivery systems have attracted the attention of 
many researchers for their treatment of various diseases in which the drug release is 
required at different time intervals. Table 2.2 shows some diseases, which need to 
use pulsatile drug delivery systems. 
 
2.12.2.1 The physiological effects of ultrasound 
Ultrasound has two main types of physiological effect upon tissue: thermal and non-
thermal. When thermal effects of ultrasound are desired, non-thermal effects will 
also occur, but via variation of the exposure parameters, non-thermal effects can be 
obtained in the absence of thermal effects. 
Thermal bioeffects of ultrasound: Thermal effects occur with an increase in tissue 
temperature to 40-45 oC for more than 5 minutes which can produce a number of 
responses including: blood flow enhancement, muscle spasm reduction and 
improved extensibility of collagen fibers [Barnett et al. 1994]. Higher temperature 
rises can lead to protein denaturation and tissue ablation. 
 
Non-thermal bioeffects of ultrasound: Non-thermal effects of ultrasound exposure 
are predominanly based on two processes: cavitation and acoustic streaming. The 
former in particular can play significant role in delivering a therapeutic agent to the 
targeted tissue and is of primary interest in this thesis. 
 
Cavitation is the formation and subsequent oscillation of gas and/or vapour filled 
bubbles that expand and compress due to ultrasonically induced pressure changes in 
a medium exposed to ultrasound [Barnett et al. 1994]. Although it is still a somewhat 
contentious area of research, conventionally, two different types of cavitation are 
defined: ‘’stable’’ or ‘’non-inertial’’ cavitation and ‘’transient’’, ‘’inertial’’ or 
‘’collapse’’ cavitation. In stable cavitation, the induced pressure in the medium 
produces a fairly stable oscillation in bubble size [Marmottant and Hilgenfeldt 
2003]. This oscillation produces a circulating fluid flow, called ‘acoustic 
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microstreaming’, around the bubbles. In other words, it is the unidirectional 
movement of fluids along cell membranes. The amplitude of the oscillation controls 
the velocities and shear rates of microstreaming. For instance, microstreaming is 
capable of shearing open red cells [Rooney 1970] as well as drug carriers such as 
liposomes [Marmottant and Hilgenfeldt 2003] at high amplitudes. If the shear stress 
exceeds the strength of the vesicle, it will rupture and spill its contents. 
 
The other type of cavitation, inertial or collapse cavitation occurs when the 
ultrasonic intensity increases. For a given bubble size and ultrasound frequency there 
is a critical pressure above which the inertia of the surrounding fluid cannot be 
supported by the pressure of the gas inside the bubble during compression [Brennen 
1995]. Consequently the bubble collapses violently, producing shock waves and also 
very high temperatures and pressures (and free radicals due to these conditions) 
inside the bubble. The collapse process can thus inflict significant damage upon both 
cells and drug carriers. Smaller bubbles may also be produced by fragmentation of 
the original bubble during collapse. This then acts as a further cavitation nucleus, 
growing by absorbing gas from the surroundings, so the process is repeated [Brennen 
1995]. In the case of a bubble collapsing near a solid surface, asymmetrical collapse 
will occur which may produce a high speed fluid jet towards the solid surface [Jenne 
2001]. The jet may be strong enough to pierce the surface e.g in the case of a 
relatively rigid drug carrier. Figure 2.25 illustrates this type of collapse. 
 
 
Figure 2.25 Illustration of an asymmetric collapse of a bubble near a surface, 
producing a jet of liquid towards the surface [Pitt et al. 2004]. 
 
In addition, the acoustic shock wave caused by collapsed cavitation may enhance 
drug release rate by damaging the surface of the carrier. Recently, it has been shown 
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that ultrasound can effectively control drug release from liposomes and micelles by 
inducing both thermal and non-thermal effects. For instance, the existence of 
cavitation near the liposomes and micelles was found to enhance drug and gene 
delivery substantially [Ferrara 2008, Suzuki et al. 2007, Unger et al. 2001].  
 
The basic mechanism of ultrasound and microbubbles in drug delivery could be 
summarised as follows: upon exposure of the particles to ultrasound, microbubbles 
form due to increased temperature and decreased pressure caused by the ultrasound, 
these microbubbles undergo cavitation, leading to the formation of pores on the 
surface of the particles, causing the drug to be released to the surrounding medium. 
The second step is the enhanced permeability of the cellular membrane, most likely 
as a result of microstreaming, leading to enhanced penetration of the drug into the 
cells [Lentacker et al. 2010].  
 
To conclude, an ideal drug delivery system would be one in which the drug is 
sequestered inside a carrier until it can be released at the targeted point in space and 
time. The subsequent chapters in this thesis will describe the investigations 
conducted with a view to developing a drug delivery system prepared using EHDA 
consisting of drug loaded particles, whose release profile can be controlled through 
either an external stimulus (ultrasound) or through a particulate coating.
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Chapter 3 
Experimental details 
 
3.1 Introduction 
This chapter describes the materials and procedures used for the experiments 
subsequently detailed in this Thesis. The materials used, corresponding suppliers and 
product details are given. The methods used to characterise the materials and 
solutions are described. A detailed description of the equipment used in the single 
and co-axial electrohydrodynamic processing is also given. Finally, the experiments 
conducted for in vitro characterisation of the drug loaded particles are also discussed.  
 
3.2 Materials 
The main materials used in the experiments were poly (lactic-co-glycolic acid) 
(PLGA), polycaprolactone (PCL), estradiol and dimethylacetamide (DMAC). Other 
subsidiary materials used were ethanol, evans blue dye (EB), gelatin, chitosan, ethyl 
acetate (EA) and simulated body fluid (SBF). Evans blue was used as a model drug 
and chitosan and gelatin were used as the coating agents.  
 
3.2.1 Poly (lactic-co-glycolic acid) (PLGA) 
Poly (lactic-co-glycolic acid) is a copolymer of glycolic and lactic acid which has 
been approved by the Food and Drug Administration (FDA) for uses in therapeutic 
devices because of its biodegradability and biocompatibility. Depending on the ratio 
of lactide to glycolide used for the polymerisation, different forms of PLGA can be 
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obtained: these are usually identified in terms of the monomer ratio used. In this 
research the PLGA copolymer 50:50 Resomer RG503H (Boehringer Ingelheim, 
Germany) was used with the molecular weight 33000 kDa composed of 50% lactic 
and 50% glycolic acid.  
 
3.2.2 Polycaprolactone (PCL)  
Polycaprolactone (PCL) is an important polymer due to its mechanical properties, 
miscibility with a large range of other polymers and biodegradability. It has a low 
melting point of around 60°C and a glass transition temperature of about −60°C. The 
molecular weight of polycaprolactone used in this work was 14000 kDa and was 
purchased from Sigma Aldrich (Poole, UK). 
 
3.2.3 Dimethylacetamide (DMAC) 
Dimethylacetamide is a colourless, water miscible, high boiling point liquid 
compound (formula : C4H9NO ,molecular weight : 87.12 g/mol, density 0.937 g/cm3, 
Sigma Aldrich, Poole, UK) which was used as a solvent in the study. 
 
3.2.4 Ethanol 
General purpose research grade ethanol (C2H5OH 99%, density 790 kg m-3, 
molecular weight 46, viscosity 1.3 mPa s, Sigma Aldrich, Poole, UK) was used in 
this research. The particle collecting slides were covered by a thin film of ethanol as 
described below in Section 3.5.2. In addition, ethanol was also used for the 
calibration of the characterisation apparatus and for the cleaning of capillary needles 
which were essential components of the experimental set-up. 
 
3.2.5 Evans blue (EB) 
Evans blue, (6,6_-[(3,3_-dimethyl-[1,1_-biphenyl]-4,4_-diyl)bis(azo)]bis[4-amino-5-
hydroxy-1,3-naphthalenedisulfonic acid]), is a compound dye. It is usually used as a 
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diagnostic tool for estimating blood volume. The dye is injected into the bloodstream 
and after a sufficient period of time samples of the blood are taken to determine the 
degree of dilution of the dye. However, in the experiments, it was used in the 
preliminary encapsulation and in vitro release studies as the inner encapsulated 
material. It provided a means of visualising the encapsulation process and detecting 
the blue inner solution surrounded by the outer polymer solution in different EHDA 
modes. Also, it fluoresces with excitation peaks at 470 and 540 nm and an emission 
peak at 680 nm [Hed et al. 1983] making it detectable in the in vitro release study. It 
was purchased from Sigma Aldrich (Poole, UK). 
 
3.2.6 Estradiol  
Estradiol (linear formula: C18H24O2 and molecular weight of 272.38) was used as a 
model drug in this research and was also purchased from Sigma Aldrich (Poole, UK). 
It is the most potent female sexual hormone and represents the major estrogen in 
humans. Estrogen deficiency due to loss of ovarian function at menopause is mainly 
responsible for the development of various metabolic abnormalities and such 
conditions can be made reversible with estrogen replacement therapy. Numerous 
epidemiological studies suggested that postmenopausal estradiol treatment reduces 
the risk of cardiovascular disease by up to 50%. This is a significant drug which is 
used in estrogen replacement therapy for conditions such as female hypogonadism, 
ovariectomy, or primary ovarian failure, and in treatment of abnormal uterine 
bleeding, vasomotor menopausal symptoms (such as hot flashes, and vaginal 
dryness, burning, and irritation) and postmenopausal osteoporosis. Estradiol is 
sometimes used as part of cancer treatment in advanced breast or prostatic 
carcinomas [Mittal et al. 2007]. 
 
Estradiol’s primary function is the control of sexual characteristics, but it is also of 
great importance in the regulation of brain development. Long-term estrogen 
replacement therapy has proved to be beneficial in the prevention of Alzheimer’s 
disease and in the therapy of schizophrenia [Valles et al. 2010]. 
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3.2.7 Gelatin 
Gelatin is a natural polymer that is derived from collagen found in animals. It has 
many applications in the pharmaceutical and medical fields due to its 
biocompatibility and biodegradability in physiological environments [Ikada and 
Tabata 1998, Yamamoto et al. 2001, Yao et al. 2004]. Gelatin has been used widely 
as an ingredient in drug formulations and as a sealant for vascular prostheses, due to 
these characteristics [Kuijpers et al. 2000a and 2000b]. In this study gelatin from 
porcine skin (type A) was purchased from Sigma Aldrich (Poole, UK). It was used 
as a coating agent in the experiments. The manufactured/fabricated PLGA particles 
were coated with gelatin to investigate its effect upon the burst release phase in the 
drug release profile. 
  
3.2.8 Chitosan 
Chitosan is also a natural polymer with numerous potential biomedical and 
pharmaceutical applications because of its biodegradability, biocompatibility and 
non-toxicity. It is a natural linear biopolyaminosaccharide which is derived by 
alkaline deacetylation of chitin. It is the second most abundant polysaccharide after 
cellulose. Chitin is the main constituent of defensive cuticles of crustaceans such as, 
prawns, shrimps, crabs, and lobsters [Felt et al. 1998]. In this study, chitosan (75-
85% deacetylated) was purchased from Sigma Aldrich (Poole, UK). It was also used 
as a coating agent because of its biodegradation characteristics. The produced PLGA 
particles were coated with chitosan solutions with different concentrations again 
with a view to controlling the burst release phase.  
 
3.2.9 Ethyl acetate (EA) 
Ethyl acetate (C4H8O2, Molar mass: 88.105 g/mol, density: 0.897 g/cm3, Sigma 
Aldrich (Poole, UK)) was used as a solvent in this study. Ethyl acetate is generally 
recognized as safe by the FDA as a synthetic flavoring substance or adjuvant for 
food (21 CFR 182.60). EPA’s oral reference dose (daily oral exposure likely to be 
without an appreciable risk of deleterious effects during a lifetime) of ethyl acetate is 
0.9 mg/kg/day [Coopman et al. 2005 and Pohanish 2002]. 
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3.2.10 Simulated body fluid (SBF) 
SBF is a combination of various chemicals that when combined have a similar 
composition to human blood plasma [Swain and Pattanayak 2008, Oyane et al. 
2003]. Reagent grade chemicals such as NaCl, KCl, CaCl2·2H2O, MgCl2·6H2O, 
NaHCO3, K2HPO4, Na2SO4·10H2O, tris buffer (tris-hydroxymethyl-aminomethane, 
H2NC(CH2OH)3) and 1M HCl were used for SBF preparation. The total ion 
concentrations in SBF are presented in Table 3.1 [Kokubo et al. 1990]. All of these 
reagents were purchased from Sigma Aldrich (Poole, UK) with analytical grades. 
Also, the pH of the solution was adjusted to 7.4 using 1M HCl. The preparation 
procedure is described below. 
 
500 ml of deionised water was put into a one litre polyethylene bottle and covered 
with a transparent glass lid. The reagents were dissolved one by one in the order 
given in Table 3.2 with constant stirring. The temperature of the solution in the 
bottle was maintained at 36.5°C by being placed in a water bath, and the pH of the 
solution was adjusted to 7.4 by titration with 1M HCl solution. The total volume of 
the solution was made up to 1L by adding deionised water.  
 
Table 3.1 Ion concentrations (mM) of SBF and Human blood plasma [Kokubo et al. 
1990 and Ohtsuki et al. 1995]. 
Ion SBF Blood plasma 
 
Na+ 142.0 142.0 
K+ 5.0 5.0 
Mg2+ 1.5 1.5 
Ca2+ 2.5 2.5 
Cl- 148.8 103.0 
HCO3- 4.2 27.0 
HPO42- 1.0 1.0 
SO42- 0.5 0.5 
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Table 3.2 Reagents for preparing SBF [Kokubo et al. 1990 and Ohtsuki et al. 1995]. 
Order 
 
Reagent 
 
Amount 
 
1 NaCl 7.996 g 
2 NaHCO3 0.350 g 
3 KCl 0.224 g 
4 K2HPO4･3H2O 0.228 g 
5 MgCl2･6H2O 0.305 g 
6 1M-HCl 40 mL 
7 CaCl2 0.278 g 
8 Na2SO4 0.071 g 
9 (CH2OH)3CNH2 6.057 g 
 
3.3 Characterisation of the solutions 
3.3.1 Density 
The density of the liquids/solutions used was measured using a 25 ml standard 
density bottle (VWR International, Lutterworth, UK). The mass of the empty bottle 
and the mass of the bottle filled with liquid/solution were obtained using an 
electronic balance (AND HF-1200G A&D Instruments Ltd., Japan). The density (ρ) 
was calculated as follows: 
 
The mass of the empty density bottle = W1   g                                          (3.1) 
 
The mass of the density bottle filled with liquid /solution = W2    g               (3.2) 
 
Therefore, the mass of liquid/suspension/solution only = (W2-W1)    g         (3.3) 
 
Therefore, the density of liquid /solution = (W2-W1)/25      g cm-3                (3.4) 
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The mean value of five such consecutive calculations was taken as the density of 
liquid/solution and reported in this thesis. Measurements were taken at the ambient 
temperature (~25 °C) and pressure. 
 
3.3.2 Viscosity 
The dynamic viscosities of the solutions were determined using a U-tube viscometer 
(BS/U type, Schott Instruments GmbH, Germany). A calibrated U-tube (size C, 
nominal constant 0.03) was used. The time taken for a standard volume of solution 
to pass through the capillary of the U-tube was noted for five passes and the mean 
value of the time was calculated. Then, the kinematic viscosity (ν) was obtained by 
multiplying the nominal constant (C) by the time (t):  
 
ν = Ct      (3.5) 
 
The dynamic viscosity (η) was then calculated by multiplying the kinematic 
viscosity by the density (ρ) of the solution: 
η = νρ                                                (3.6) 
 
If equations (3.5) and (3.6) are combined, 
η = Ctρ     (3.7) 
 
Ethanol was used to calibrate the viscometer. The mean value of five readings was 
taken as the dynamic viscosity of the sample. For U-tube viscometers that are not 
calibrated by manufacturers, use of a calibrating liquid is essential as the viscosity 
value cannot be calculated without comparing with another liquid. 
 
3.3.3 Surface tension 
The surface tension of the solutions was measured using a Kruss Tensiometer K9 
(Standard Wilhelmy’s plate method). The plate was hung from the hook and the 
beaker containing the sample was placed on the platform. The plate was completely 
immersed into the sample whose surface tension was to be measured. The plate was 
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then gradually lifted and the surface tension value was directly read when the plate 
was just about to detach from the liquid surface. In order to minimize errors, the 
plate was cleaned thoroughly with ethanol and dried in a drier before each 
measurement. The mean values of five readings were taken as the surface tension of 
the sample. 
 
3.3.4 Electrical Conductivity 
Electrical conductivity was measured using a HI-8733 (Hanna Instrument, USA) 
conductivity probe. The electrode was always cleaned with distilled water and dried 
before measurements. The electrode was kept immersed in the solution up to the 
point marked on the electrode for 10 min and the reading shown on the meter was 
recorded. The mean value of five consecutive readings was taken as the electrical 
conductivity of the sample. 
 
3.4 Preparation of solutions 
3.4.1 Preparation of PLGA solutions 
PLGA solutions of different concentrations (2 wt%, 5 wt% and 10 wt%) were 
prepared by combining appropriate amounts of PLGA polymer and DMAC and 
mechanically stirring for 900s to obtain clear solutions indicating the total 
dissolution of the PLGA. 5 wt% PLGA:EA was also prepared for the study 
described in Chapter 4. 
3.4.2 Preparation of drug-dye and drug solutions 
10 wt% estradiol was dissolved in methanol. To assist visualisation in the 
preliminary experiments, evans blue dye (0.01g) was dissolved in distilled water (5 
ml) and then added to the methanol solution and thoroughly mixed to prepare a drug-
dye solution. This was used to determine the feasibility of encapsulating this solution 
and whether the cone-jet mode was achievable using both the polymer and drug 
solutions. Subsequently, the drug solution was used without dye. 
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3.4.3 Preparation of PCL solutions 
Appropriate quantities of PCL were dissolved in DMAC. The weight ratio of the 
polymer to the solvent was 30:70. The polymeric solution was stirred mechanically 
at the ambient temperature (25 °C) to ensure the polymer had completely dissolved 
(~15 min).  
 
3.5 Characterisation of generated particles 
3.5.1 Optical microscopy 
Particles were collected on glass slides covered by a thin film of ethanol for 
preliminary structural study. An optical microscope (Nikon Eclipse ME 600, Nikon, 
Japan) was extensively used for all the investigations described in Chapters 4 and 5. 
The measurements were carried out by means of ‘Acquis’ digital imaging software 
(Synoptics Ltd., Cambridge, UK). 
 
3.5.2 Scanning electron microscopy (SEM) 
The morphology and structure of the prepared particles were determined using a 
scanning electron microscope (JEOL JSM-6301F field emission SEM). It was 
equipped with an emitter that can achieve a resolution of ~ 1.5 nm. The accelerating 
voltage was set at 6 kV and the working distance between the emitter and the sample 
was 20 mm.  
 
Particles were collected on glass slides covered by a thin film of ethanol for the 
morphology and structural study but for the degradation studies, particles were kept 
in SBF and at fixed time points 0.05 ml samples of the solution were taken out and 
allowed to dry under ambient conditions for 2 h. After that, the glass slides were 
placed inside a desiccator for further drying for at least two days under ambient 
conditions before SEM examination. 
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Since the polymer used for the preparation of particles is nonconductive, the SEM 
sample was gold coated for 2 min using a sputtering machine (Edwards sputter 
coater S 1 50B) to enable conduction of the sample surface and avoid charging 
which can cause damage when gold is used to make surface conductive. The sample 
was then placed on an aluminium stub with a carbon sticker upon it and was placed 
in the SEM chamber. The diameter of the particles was measured from the SEM 
images using the image-processing program UTHSCSA Image Tool (Image Tool 
Version 2, University of Texas, USA). 
 
3.5.3 Focused ion beam microscopy (FIB) 
 
Figure 3.1 Carl Zeiss 1540 XB cross-beam Focused Ion Beam. 
 
The internal structure of the particles was also studied using SEM, in combination 
with a focussed-ion-beam (FIB) microscope for sectioning the particles (Carl Zeiss 
XB1540 “Cross-Beam”) as shown in Fig. 3.1. This system was comprised of a field 
emission SEM system of top-down Gemini SEM column from Carl Zeiss and an 
add-on focused ion beam (FIB) system of Orsay Physics Canion 31 FIB column, 54 
deg related to the SEM column. Both columns can operate at up to 30 kV. For the 
FIB studies, particles were collected on glass microscope slides and dried under 
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ambient conditions (25°C) in a desiccator. Prior to the FIB studies, dried samples 
were sputter coated with gold for 60 s. The accelerating voltage ranged from 5 to 10 
kV during scanning. 
 
3.5.4 Fourier Transform Infrared (FTIR) spectroscopy  
Fourier Transform Infrared (FTIR) spectroscopy was used to show the presence of 
different functional groups of chitosan and gelatin on the surface of the particles. A 
Perkin-Elmer Spectrum 2000 spectrophotometer was used. A resolution of 4 cm-1 
and 32 scans were chosen. FTIR spectra were obtained by the KBr disk method. In 
this method, 200 mg of dried, spectrophotometric-grade KBr powder was used to 
make each KBr disk. The KBr powder is fused into a transparent disk using a 
hydraulic press. KBr disks were dried overnight at 110° C and then stored in a 
desiccator to eliminate moisture interference.  After preparation of the KBr disks, the 
particles were directly electrosprayed for 2 seconds on to the surface of the KBr 
disks. The samples were kept in a desiccator for 24 hours prior to FTIR 
spectroscopy. 
 
3.6 In vitro release measurement 
The release of the encapsulated materials (the dye or the estradiol) from the 
polymeric particles was determined via two methods: colorimetry and UV 
spectroscopy. Samples collected in glass vials, containing SBF, were kept at 37°C 
with continuous stirring. In both studies, at discrete time intervals they were 
centrifuged for 45 min at 4300 rpm and the entire supernatant was extracted and its 
absorbance was measured by colorimeter and UV spectroscopy. Fresh SBF solution 
was added immediately after the solution to be measured was removed. Samples 
without EB dye and the therapeutic agent were also monitored so that any 
contributions to the measured absorbance from the polymer could be evaluated. All 
the measurements were repeated four times. 
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3.6.1 Colorimetry  
EB dye release profile was monitored using a colorimeter (Biochrom Fisher, model 
45, operating at an optical wavelength of 580 nm). This instrument measures in 
absorbance and percentage transmission mode, enabling changes in absorbance over 
time and reaction rates to be determined. It can be used in the 400 – 700 nm 
wavelength range as it has an integral, colour coded rotating wheel containing filters 
at 440, 470, 490, 520, 550, 580, 590 and 680nm. 
 
3.6.2 UV spectroscopy  
Estradiol release profiles were also measured using an UV spectrophotometer. In this 
section a brief description is given about how UV absorption spectra can be used to 
identify compounds and to measure the concentrations of it in a solution. In UV 
spectroscopy, light in the ultra-violet wavelength range is transmitted through a 
sample such as a drug solution. Different components in the sample may absorb 
certain wavelengths of the light. The amount (intensity) of light absorbed at a given 
wavelength will thus be related to the concentration of the component in the sample. 
At sufficiently low concentrations of the absorbing component in the sample, a linear 
relationship exists between absorbance and concentration of material. This is 
expressed by the Beer-Lambert law [Mitschele 1996 and Calloway 1997]: 
 
                                                           (3.8) 
                                               (3.9) 
                                                                (3.10) 
 
where A is the absorbance, I is the intensity of transmitted light, Io is the incident 
intensity, ε is the extinction coefficient of the material (compound in the sample), L 
is the path length through the sample, and C is the concentration of the species under 
consideration (mol/ml). 
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A calibration curve of the amount of light absorbed by a solution versus solution 
concentration must be prepared and then used to find the concentration of an 
unknown solution. In order to plot a calibration curve, a number of standard 
solutions with different known concentrations of the drug compound need to be 
prepared [Thompson et al. 2005, Iglesias et al. 2003, Cavrini et al. 1989]. A sample 
of an UV calibration curve is given in Fig. 3.2. 
 
 
Figure 3.2 A sample of an UV calibration curve. 
 
As previously mentioned, estradiol release profiles were measured using an UV 
spectrophotometer (UV-2401PC spectrophotometer, Shimadzu). The specifications 
of the system were as follows: optical system: double-beam, spectral bandwidth: 0.1, 
0.2, 0.5, 1, 2 and 5nm, wavelength range: 190 to 900nm, accuracy: ±0.3nm, 
repeatability: ±0.1nm, photometric readout: absorbance, % transmittance, % 
reflectance. The first step in calculating drug release and encapsulation efficiency 
was determining the calibration curve and the second step was finding out the linear 
range for the relationship between estradiol concentration and the corresponding 
absorbance. These two steps will be described further in the next sections. 
 
3.6.3 Measuring estradiol encapsulation 
The amount of estradiol encapsulated during PLGA-estradiol and PCL-estradiol 
particle synthesis was determined as follows. Estradiol absorbs light with a 
wavelength of 280 nm. Different samples with a known concentration of estradiol 
were dissolved in 50:50 SBF: ethanol (v/v) and the absorbance of each sample was 
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measured with UV spectroscopy (Table 3.3). All the measurements were repeated in 
triplicate. The spectra of each sample are shown in Fig. 3.3. 
 
Table 3.3 Light absorbance (Abs) of estradiol in 50:50 SBF:ethanol with various 
known concentrations. 
Estradiol 
concentration 
(mg/ml) 
Abs#1 Abs#2 Abs#3 
Average 
Of Abs 
0.01 0.733 0.746 0.741 0.740 
0.02 1.359 1.311 1.301 1.323 
0.04 2.511 2.522 2.518 2.517 
0.06 4.013 4.011 4.011 4.011 
0.08 5 4.98 4.99 4.99 
 
 
Figure 3.3 UV spectra of SBF:ethanol 50:50 media with different known estradiol 
concentration. 
 
50:50 SBF:ethanol (v/v) solution was chosen because of the low solubility of 
estradiol in water or buffered solutions. It was important that the solubility of 
estradiol was high enough in the release solution so that it would be the rate of drug 
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release due to polymer degradation and release that was measured, not the rate of 
estradiol dissolution. The calibration curve for the quantification of estradiol was 
linear over the range of standard concentrations of estradiol at 0-0.12 mg/ml with a 
correlation coefficient of R2=0.9963 at light absorbance of 280 nm. The linear 
relation between estradiol concentration and absorbance is shown in Fig. 3.4. The 
equation between the concentration of estradiol and the absorbance was determined 
as follows: 
Abs = 61.296C + 0.1017            (R2 = 0.9963)             (3.8) 
 
 Figure 3.4 The linear relation between estradiol concentration and absorbance at 
280 nm 
 
The amount of unencapsulated drug in the supernatant was measured to determine 
the encapsulation efficiency. 10 mg of particles were collected in 10 ml release 
medium and then immediately centrifuged for 45 min at 4300 rpm. The supernatant 
was drawn out carefully and the concentration of the unencapsulated estradiol in the 
supernatant was measured using UV spectrometry. The encapsulation efficiency was 
calculated as the mass ratio between the amount of estradiol incorporated into the 
particles and that which was used in the particle preparation. 
3.7 Ultrasound exposure setup 
The effect of ultrasound exposure on the drug release profile was investigated. First, 
a preliminary study was carried out to study the influence of ultrasound exposure 
time on the release profile of PLGA particles fabricated via co-axial 
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electrohydrodynamic processing. PLGA solution of three different concentrations (2 
wt%, 5 wt% and 10 wt %) and estradiol were used as the polymeric coating material 
and encapsulated drug, respectively. The prepared particles were exposed to 
ultrasound using an ultrasonic cell disruptor (XL2000 Misonix Inc. Farmingdale, 
NY, USA; probe diameter 3 mm, operating centre frequency 22.5 kHz). Particles 
were collected in  10 cc SBF:ethanol (50:50) and then gently poured into a 
waterproof elastic rubber (latex) tube which is relatively transparent to ultrasound at 
kHz frequencies [Fatemi and Greenleaf 1998]. The tube and the ultrasound probe 
were immersed in a beaker of water with an estimated distance of 40 mm between 
them. The probe was held at an angle of approximately 45° to the vertical so that the 
particles were not directly in line with the probe axis and thus exposed to relatively 
low intensity ultrasound1. Continuous wave ultrasound was applied for either 15 or 
30 s, after which the sample was returned to the vial and UV spectroscopy 
measurements were carried out. Control measurements were carried out to ensure 
there was no change in the UV spectroscopy readings due to transfer of the particles 
between the vial and the tube. 
 
 
 
                                                
1 With the available apparatus it was not possible to determine the intensity of the ultrasound to 
	  
(a) 
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3.5 Sonication and the released energy:
Two different concentrations of PLGA were tested with three different duty cycles with
three repetitions for each. Therefore, a total of 18 samples were collected for the US
effect study. These samples were compared with a total of 6 samples, two concentrations
of PLGA with three repetitions for each, to demonstrate the results with the lack of US.
These results will represent the baseline for the US-treated particles. All vials were
incubated at 37ºC to resemble the human body’s physiological temperature.
For the US set, samples were placed in a latex tube with an acoustic impedance that is
similar to the surrounding fluid (Enayati et al., 2010) and then placed in a water bath. A
sonifier probe (Branson Sonifier 250 A) was used as an US source with its tip being
immersed at about 1 cm below the water surface. The sonifier, which has a frequency of
20kHz (20,000Hz), was placed vertically to avoid direct exposure of the particles. A
hydrophone was also placed in the water bath, which was connected to an oscilloscope
(Figure 10). The same distance between the samples, the sonifier, and the hydrophone
were maintained throughout the whole experiment. The hydrophone will receive the
transmitted waves from the cavitating microbubbles and transform them to an electrical
signal while the oscilloscope will convert the electrical signal to a displayed spectrum.
The oscilloscope is then connected to a computer and MATLAB will be used to analyse
all results. These results will reflect the energy released from the cavitating microbubbles.
A pulsed ultrasound waves were used with a duty cycle of 10, 15, and 20%. Out put
power was set at 6 and the duration of US exposure at 60s through out the experiment. As
pointed out previously, 6 does not indicate the actual value of the acoustic power used.
Figure 10: Sonication set used for the released energy study.  
Figure 3.5 (a) Schematic and (b) real apparatus used for ultrasound exposure and 
acoustic emission measurements.  
 
After preliminary study, a better understanding of the phenomena involved was 
required to facilitate a reliable measure of control over the release process. 
Therefore, more thorough investigations were carried out to elucidate the effects of 
different ultrasound parameters (duty cycle, intensity and exposure time) on the 
release profile. For this study, the prepared estradiol-loaded PLGA particles were 
exposed to ultrasound using a programmable sonicator (Branson Sonifier S250A, 
Branson Hartford, CT; probe diameter 10 mm, nominal operating centre frequency 
20 kHz). The real and schematic experimental set up used in the investigation is 
shown in Fig. 3.5a and 3.5b. The particle suspensions were gently poured into a 
waterproof elastic rubber (latex) tube. The tip of the sonicator probe was immersed 
approximately 1 cm below the water surface. The particles were not directly in line 
with the probe axis and thus exposed to relatively low intensity ultrasound2. 
Following exposure, the samples were returned to the vial for further spectroscopy 
measurements. In each case the estradiol concentration in the solution was measured 
immediately before and after ultrasound exposure. The combinations of exposure 
                                                
2	  Due	  to	  the	  low	  frequency	  and	  intensity	  of	  the	  sound	  field	  even	  at	  the	  lowest	  power	  setting	  it	  was	  
not	  possible	  to	  accurately	  map	  the	  sound	  field	  incident	  upon	  the	  particles	  due	  to	  lack	  of	  availability	  
of	   a	   suitable	  hydrophone.	  Hence	  only	   relative	  measurements	  of	   the	  effect	  of	   increasing	   sonicator	  
output	  power	  could	  be	  made	  as	  described	  below.	  
(b) 
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conditions (sonicator output power, duty cycle and exposure time) and number of 
samples per set of conditions are detailed in Section 5.2. 
 
3.7.1 Acoustic emissions 
In this study, the acoustic emissions from the samples produced during ultrasound 
exposure were recorded using a broadband unfocussed transducer (Harisonic, 
Olympus NDT, nominal centre frequency 150 kHz). This transducer was selected so 
as to measure the non-linear emissions from the microbubbles (3rd harmonic and 
above) which would be indicative of cavitation activity rather than simply scattering 
of the sonicator field. The initial experiments indicated that broadband emissions 
were generated under each set of conditions tested. The transducer was positioned 
with its axis perpendicular to that of the sample holder and at approximately 45 
degrees to that of the sonicator probe. The water in the bath was sonicated several 
times prior to the start of the experiments so that its dissolved gas content would be 
much lower than that of the samples and hence the majority of the cavitation activity 
would originate from these. 
 
The emissions were sampled randomly3 over the course of each exposure via a 
digital oscilloscope (LeCroy 9310M Dual 300 MHz) controlled through a computer 
via a GPIB interface (software written in LabVIEW, National Instruments Corp. 
Austin, TX, 2007). The signals were subsequently processed using MATLAB 
(version 7.8.0 (R2009a)) as follows: (i) the frequency spectrum for each captured 
signal was obtained via Fast Fourier Transform (after normalising each trace with 
respect to its mean); (ii) signal integration was performed over the frequency range 
for which the sensitivity of the receiving transducer was constant (for this reason 
convolution with the transfer function was not performed); (iii) the average and 
standard deviation emitted energy for each set of conditions (n = 4).  
                                                
3	  Ideally	   the	   emissions	   would	   have	   been	   recorded	   throughout	   the	   exposure	   with	   a	   much	   higher	  
sampling	  rate,	  but	  this	  was	  not	  possible	  using	  the	  available	  system.	  The	  authors	  recognise	  this	  as	  a	  
shortcoming	   of	   this	   aspect	   of	   the	   experimental	  work,	   the	   implications	   of	  which	  will	   be	   discussed	  
later	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3.8 Co-axial and single needle EHDA setup 
Needle set-up: In the co-axial EHDA setup, a three-needle stainless steel co-axial 
device was coupled to a high power voltage supply (Glassman Europe Ltd., Tadley, 
UK). In this case, the central needle and outer needles were used and the inner 
needle was disabled. The central needle carried the drug solution, the outer needle 
was perfused with a given PLGA solution to produce the polymeric carrier. The 
external and internal diameters of the central needle were 1.5 mm and 0.9 mm and 
those of the outer needle were 2.8 mm and 1.9 mm, respectively. The tip of the inner 
needle was held 0.5 mm inside and above the tip of the outer needle. The schematic 
of the needle configuration is given in Figure 3.6. However, in the single needle 
EHDA setup, the internal diameter of a single stainless steel needle was 600 µm.  
 
Figure 3.6 Schematic of the needle configuration of co-axial EHDA set-up. 
 
Ground electrode: A ring (inner diameter 15 mm and outer diameter 20 mm) 
electrode was placed ~30 mm below the tip of the outer needle as shown in Figures 
3.7a and 3.8b. The electrical stress is determined by the strength of the electric field 
between the needle and the ground electrode. 
 
Syringe pumps: The needles were connected by silicone tubing to plastic syringes 
(BD PlasticTM, VWR, Lutterworth, UK) containing the solutions. The flow rates of 
Chapter	  3:	  Experimental	  details	  
	  
81	  
the solution through the needles were controlled by high precision Harvard syringe 
pumps (Infuse/Withdraw PHD 4400 Hpsi programmable syringe pump, Harvard 
Apparatus Ltd., Edenbridge, UK). The capacity of the syringes used for the solutions 
were 5 ml. The pumps were calibrated frequently using ethanol. In the co-axial 
setup, the two liquids were introduced simultaneously into the device using the 
precision syringe pumps at appropriate at inner and outer needle flow rates of 2 
µl/min and 10 µl/min, respectively. This combination of flow rates was determined 
empirically to provide a suitable compromise between jet stability and the required 
range of particle sizes. 
 
High voltage power supply: The needles and the ground electrode were connected 
to a high voltage DC power supply unit (FC30 P4 12w, Glassman Europe Limited, 
Bramley, UK) using a high voltage power cable. The output voltage range of the unit 
was 0-30 kV and the output current range was 0-4 mA. At an applied voltage of 
between 6 and 7 kV between the needles and a ground ring electrode; a stable cone-
jet was obtained, with fine encapsulated droplets emerging from the cone apex.  
 
Data recording unit: The jet and droplet formation process was monitored using a 
LEICA S6D JVC-colour video camera attached to a zoom lens and a data DVD 
video recorder MP- 600 using CDV Recorder/Editor DN-100 with a video screen for 
real time monitoring. 
 
The experimental setup used for all the investigations is shown in Figures 3.7a and 
3.7b. In co-axial processing, the droplets were collected at a working distance of 20 
mm below the device exit directly into glass vials containing 50% simulated body 
fluid (SBF) and 50% ethanol. Samples were collected for 600 s and were used for 
the in vitro release studies. Specimen samples were also collected on glass slides 
covered by a thin film of ethanol for microscopy as above. The single needle EHDA 
setup was similar to the co-axial set up (Fig. 3.7b). However, the apparatus consists 
of a single stainless steel needle which is coupled to a high voltage power supply. 
The introduction and subsequent flow rate of individual polymeric solutions in the 
needle were controlled by the high precision syringe pump PHD4400. 
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Figure 3.7 Experimental set up used for the production micro and nanoparticles (a) 
co-axial setup (b) single needle setup. 
 
                                                                                                         
(a) 
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Chapter 4 
Results and discussion 
 
Production of polymeric drug carriers via single needle and 
co-axial EHDA processing 
Overview 
Methods for producing particles with a predictable narrow size distribution are in 
high demand for a wide range of biomedical applications. Therefore, various 
preparation techniques have been studied with a view to generating drug-carriers 
with the required size distribution. In this chapter, single needle and co-axial EHDA 
processing methods were used to explore their capability for preparing polymeric 
drug carriers with different sizes. In the first set of experiments (Section 4.1), the 
aim was to optimise the combination of several key processing parameters in order 
to obtain a stable ‘cone jet’ and subsequently produce polymeric particles with a 
narrow size distribution. The next set of experiments (Section 4.2), investigated the 
capability of using single needle EHDA processing for the fabrication of polymeric 
particles with various surface morphologies and shapes. The final set of experiments 
(section 4.3), involved using a co-axial EHDA method to incorporate secondary 
materials into the polymeric particles and to study the encapsulation process. 
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4.1 EHDA mode mapping and controlling the size of the fabricated particles via 
systematic processing parameter variation 
4.1.1 Introduction 
One of the most important characteristics of drug delivery systems is the size of the 
constituent particles [Panyam and Ladhasetwar 2003]. This has a significant effect 
upon different in vivo functions of drug carriers such as: circulation time, 
extravasation, targeting, immunogenicity, internalization, intracellular trafficking, 
degradation, flow properties, clearance and uptake mechanisms [Mitragotri and 
Lahann 2009]. For instance, micrometre size particles are important in passive drug 
targeting such as in pulmonary drug delivery. Nano-size particles have also certain 
unique applications in drug delivery [Monsky et al. 1999] in that they can penetrate 
small capillaries, allowing enhanced accumulation of nanoparticles at target sites 
[Lanza et al. 2002]. 
 
Polycaprolactone was used as a polymer in this study due to its suitability for drug 
delivery and its biocompatibility and non-toxicity [Murthy 1997]. It was dissolved in 
DMAC (solvent) and the weight ratios of the polymer to the solvent were as follows; 
(PCL:DMAC) 2:98, 5:95 and 10:90. A systematic investigation of the effects of 
several key processing parameters specifically: voltage, flow rate, solution properties 
(such as viscosity and electric conductivity) and polymer concentration on the modes 
of EHDA processing was carried out and a range of operating parameters were 
identified for the ideal processing window of stable jetting (cone-jet). Also, it was 
determined how the size and size distribution of the particles generated can be 
controlled by systematically varying the polymer concentration in the solution (and 
thereby its viscosity and electrical conductivity). In the final section, 15 wt% 
estradiol was also added to the individual solutions. Estradiol is the drug which was 
used in all the experiments in this thesis. As mentioned in Section 3.2.6, it is one of 
the main estrogens in human body that has several applications in the treatment of 
different diseases. Estradiol loaded PCL particles were produced and the effect of 
estradiol loading on particle size and morphology was studied. 
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4.1.2 Characteristic of PCL solutions with various concentrations 
The electrohydrodynamic process by which the particles are produced is governed 
by the physical properties of the solutions (such as surface tension, viscosity, density 
and electrical conductivity), and also on the processing parameters (flow rate and 
applied voltage). Different combinations of these variables enable the generation of 
different jetting modes [Cloupeau and Prunetfoch, 1990]. Therefore, the first step 
was to characterise the properties of the solutions used (Table 4.1).  
 
Table 4.1 Properties of the solutions and solvents used in this study. 
Sample 
Density 
(kg m-3) 
Viscosity 
(mPa s) 
Surface 
tension 
(mN m-1) 
Electrical 
conductivity 
(µS m-1) 
DMAC 940 2.0 29 5.6 
PCL:DMAC 2:98 946 2.6 29 3.4 
PCL:DMAC 5:95 951 4.6 29 1.8 
PCL:DMAC 10:90 958 11.1 32 0.8 
PCL:DMAC 2:98 + 
15% ET 
947 2.6 29 4.1 
PCL:DMAC 
5:95+15% ET 
951 4.6 29 2.5 
PCL:DMAC 10:90+ 
15% ET 
958 11.2 32 1.1 
 
The electrical conductivity of the solutions decreased more than four times as the 
concentration of the polymer increased up to 10 wt% from 2 wt% due to the 
insulating characteristics of PCL. Polymer solutions which were further mixed with 
estradiol demonstrated a slight increase in their electrical conductivities when 
compared to their parent solutions, suggesting that estradiol causes an increase in the 
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electrical conductivity, while PCL reduces the electrical conductivity. The density of 
the solutions did not change significantly in samples with different polymer 
concentrations but the viscosity increased significantly as a function of this 
concentration. 
4.1.3 Classification of EHDA jetting modes of the PCL polymeric solutions  
 
Figure 4.1 Flow of 5 wt% PCL solution under an electric field showing with flow 
rate set at 10 µl/min, (a1) no flow (a2) dripping mode (a3) micro-dripping mode (a4) 
rapid dripping mode (a5) unstable cone-jet mode (a6) stable cone-jet mode and (a7) 
multi-jet mode (a8) irregular instabilities mode. Scale bar= 600 µm. 
 
The geometrical features of the jet and the various types encountered as a function of 
operating parameters, including the electric field, have been classified into various 
modes [Jaworek and Krupa 1999a]. These include dripping, microdripping, rapid 
microdripping, unstable cone-jet, stable cone-jet, multijet and irregular instability 
modes (5 wt% PCL and flow rate: 10 µl/min) (Fig. 4.1).  
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The cone-jet is the most stable and the most used mode, as it generates a near 
uniform particle size distribution [Cloupeau and Prunetfoch, 1990]. In this study, the 
‘dripping mode’ (0-4 kV) did not differ significantly from dripping under electrically 
neutral conditions. The drops took the shape of regular spheres detaching from the 
capillary as the gravitational force (and the small electric force) overcame surface 
tension (Fig. 4.1a2). An increase in the voltage stabilised and shaped the ‘cone-jet’ 
(9.5 -12.5 kV) (Fig. 4.1a6) which results as a balance of liquid pressure, liquid 
surface tension, gravity, electric stresses at the liquid surface, the liquid inertia and 
the liquid viscosity [Hartman et al., 2000]. Further increasing the voltage (13-15 kV) 
caused ‘multijet modes’ to evolve. When irregular instabilities are encountered, one 
possible form the jet can take is shown in Fig 4.1a8, where intermittent droplet 
formation occurs. Although the images may look similar there is a considerable 
difference in the stability in real time compared with rapid dripping (Fig 4.1a4), (due 
to technical shortage, the high speed camera was not able to capture many frames per 
second; therefore it was harder to frame the irregular instability mode). 
 
4.1.4 Parametric mode maps of applied voltage vs. flow rate for three different 
polymer concentrations 
EHDA modes were investigated in detail for three different polymer concentrations. 
The most appropriate processing parameters to obtain the desired cone-jet were also 
determined. The findings are presented as maps in the parametric space of applied 
voltage vs. flow rate (Fig. 4.2). Mode mapping of these solutions showed that in 
more viscous solutions the upper and lower limits of the voltage required for forming 
the stable cone-jet increased. For instance, at a flow rate of 2 µl/min, the lower limit 
of the applied voltage for the least viscous solution (2.6 mPa s) was 7.5 kV, whereas 
that for the most viscous solution (11.1 mPa s) was 11 kV (Fig. 4.2d). This is due to 
the lower conductivity and higher surface tension of the more viscous solutions. 
Therefore, a stronger and dominant electric field (voltage) needed to be applied to 
overcome the surface tension and liquid viscosity to form a cone jet [Li and Yin 
2006].  
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Figure 4.2 Operating ranges in order to obtain different spraying modes (a) 
PCL:DMAC 2:98 (wt%) (b) PCL:DMAC 5:95 (wt%) (c) PCL:DMAC 10:90 (wt%). 
(d) Comparison of the cone-jet mode region of different solutions. 
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In less viscous solutions the regions for different jetting modes occupied a smaller 
area in the parametric space and transition between modes occurred more quickly as 
the applied voltage is increased (Fig. 4.2a, 4.2b and 4.2c). The cone jet area 
increased as the flow rate increased, and this could be due to the presence of a 
greater volume of liquid which maintains the balance between the surface tension 
and electrical forces.  
 
4.1.5 Effect of applied voltage and flow rate on the mean size of the particles 
 
 
Figure 4.3 Variation of mean particle size obtained as (a) a function of applied 
voltage and flow rate and (b) highlighting the cone-jet region for PCL:DMAC 5:95 
wt% solution. 
 
In this section, the effect of applied voltage and flow rate on the mean size of the 
particles was studied (Fig. 4.3a). Prior to the attainment of the stable cone-jet region, 
Chapter	  4:	  Results	  and	  discussion;	  Production	  of	  particles	  via	  various	  EHDA	  setups	  	  
	  
91	  
the reduction in droplet size was enhanced by increasing the voltage as the mode of 
jetting changed from dripping to unstable cone-jet. The size of droplets 
electrosprayed from the stable-cone jet was found to decrease as the applied voltage 
increased but this phenomenon was more noticeable at higher flow rates, for instance 
the mean size of particles produced from PCL 5 wt% decreased from 700 nm to 500 
nm at 2 µl/min flow rate as the voltage increased (10 kV to 12 kV), whereas at 50 
µl/min flow rate, the mean size reduced from 1400 nm to 900 nm (Fig. 4.3b). This is 
because at a lower flow rate insufficient solution was available to affect the 
electrohydrodynamic forces on the droplet, [Pancholi et al. 2008] thus the 
appropriate range of applied voltages for forming the cone-jet was narrow and as a 
result, the influence of applied voltage on particle size was relatively small. 
 
4.1.6 Effect of viscosity on size, size distribution and polydispersivity index 
Droplet diameter is known to be greatly influenced by the processed solution 
viscosity [Jayasinghe and Edirisinghe 2002]. The mean size of the particles obtained 
with solutions with different viscosities (PCL:DMAC 2:98 (2.6 mPa s), PCL:DMAC 
5:95 (4.6 mPa s), PCL:DMAC 10:90  (11.1 mPa s)) is shown in Fig. 4.4. 
     
Figure 4.4 Relationship between mean particle size generated, the electrical 
conductivity with the viscosity of the PCL solutions used (flow rate: 10 µl/min, 
applied voltage: 10 kV). 
 
As the concentration of PCL was varied from 2 to 10 wt%, the viscosity and the 
electrical conductivity of the PCL solutions changed from 2.6 (mPa s) to 11 (mPa s) 
and from 3.4 (µS m-1) to 0.8 (µS m-1), respectively. This also results in an increase in 
mean particle size from 300 nm to 4.5 µm. This is due to the local shear viscosity 
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decreasing sufficiently and resulting in the formation of smaller droplets under the 
action of electrohydrodynamic forces [Jaworek and Krupa 1999b]. The particle size 
distributions are shown in Fig. 4.5. All the samples displayed monomodal size 
distributions; however, the more viscous solutions generated a narrower distribution.  
 
 
Figure 4.5 Size distribution of PCL particles produced using different concentrations 
of PCL solution (a) PCL 2wt%, (b) PCL 5wt%, (c) PCL 10wt%, (flow rate: 10 
µl/min, applied voltage: 10 kV), (d) Polydispersivity index of particles produced in 
the cone-jet region as a function of flow rate (applied voltage: 10 kV).  
 
Further investigations were carried out to determine the impact of viscosity and flow 
rate on the polydispersivity of the samples. It was observed that the polydispersivity 
index increased at the upper and lower limits of flow rate for the stable cone-jet 
region and this influence was more noticeable at lower viscosities (Fig. 4.5d). This 
may be attributed to the reduced stability of the cone-jet in these zones which can 
dictate the size distribution of the generated morphologies. With the increase in flow 
rate, the charge on the liquid jet increases, and the repulsion force due to the electric 
charge competes with the surface tension of the liquid. With much higher surface 
charge, the repulsion force of the charge becomes stronger, resulting in jet oscillation 
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which produces satellites droplets [Hartman et al. 2000]. Therefore, the number of 
satellite droplets and secondary droplets depends on the liquid flow rate and their 
quantity will increase at higher flow rates, which in turn results in a higher 
polydispersivity index [Hartman et al. 2000]. 
 
4.1.7 Effect of drug loading on the size and morphology of the particles 
 
Figure 4.6 Optical micrographs (a1, b1 & c1) and SEM images (a2, b2 & c2) of 
particles prepared at different polymer concentrations. (a: 2 wt% PCL, b: 5 wt% PCL 
& c: 10 wt% PCL), flow rate = 10 µl/min, collecting distance = 150 mm, voltage ~ 
10 kV.  
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Figure 4.7 Scanning electron micrographs of PCL particles incorporating estradiol a: 
10 wt% PCL, b: 5 wt% PCL & c: 2 wt% PCL) with each contains 15 wt% estradiol, 
flow rate = 10 µl/min, collecting distance = 150 mm, voltage ~ 10 Kv. 
 
Table 4.2 Size of “blank” and drug loaded particles at various polymer 
concentrations. 
Sample      (weight 
ratio) 
Mean size of the blank 
particles /µm 
Mean size of the particles loaded 
with 15 wt% estradiol /µm 
PCL:DMAC 2:98 0.31 0.34 
PCL:DMAC 5:95 0.71 0.8 
PCL:DMAC 10:90 4.4 4.6 
 
 
 
 
 
 
 
(a) (c)  (b) 
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4.2 Single needle elctrohydrodynamic atomization and fabrication of drug 
carriers with different shape and size  
4.2.1 Introduction 
Recently, it has been shown that shape is another important characteristic of drug 
delivery systems and there is increasing evidence that suggests shape can play a 
significant role in the effectiveness of drug delivery and other biological processes 
[Mitragotri and Lahann 2009]. This includes, for example, shape-related 
phagocytosis by macrophages [Champion and Mitragotri 2006] and varying the rate 
of cellular internalisation of particles based on their shape [Gratton et al. 2007]. With 
these findings, the need to further understand shape and size related drug delivery 
behaviour is essential. This requires comparison of the potential of spherical and 
non-spherical particles with different sizes as suitable carriers for drug delivery and 
in order to do this a convenient means of preparation for these is essential. 
 
In this study, the capability of single needle EHDA processing for producing 
biodegradable particles of different shapes and sizes was investigated. Poly (lactic-
co-glycolic acid) (PLGA) and polycaprolactone (PCL) were used. The weight ratios 
of the polymers to solvents were as follows; PLGA:EA 5:95 and PCL:DMAC 30:70 
and particles were produced using the method described in Section 3.6. The effect of 
different parameters such as applied voltage, collecting distance, flow rate and 
polymer concentration on inducing shape and size differences for these particles was 
studied. 
 
4.2.2 Effect of collecting distance on the morphology and size of the PLGA 
particles 
The 5 wt% PLGA solution was used to investigate the role of collecting distance on 
the shape and size of the particles. The solution was introduced into the processing 
needle and maintained at a flow rate of 20 µl/min, with stable cone-jet generation at 
8 kV. Three collecting distances were selected and the glass slides were placed under 
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the cone-jet at these distances. Optical and scanning micrographs of the particles are 
shown in Fig. 4.8.  
 
Figure 4.8 SEM images of particles fabricated at different collecting distance (CD), 
flow rate = 20 µl/ml, voltage~ 7 kV, polymer solution = PLGA:EA (5:95 wt. ratio).  
(a) CD = 100 mm, (b) CD = 150 mm, (c) CD = 400 mm.  
 
It was observed that as the collecting distance increased, the size of the particles 
significantly decreased from tens of micrometres to hundreds of nanometres. Fig. 
4.8a1 shows an optical image of particles collected at a working distance of 100 mm 
from the needle outlet. A closer examination of the surface of these structures shows 
the particles contained corrugated features. In comparison, samples collected at a 
working distance of 150 mm, display a slightly reduced particle size (Fig. 4.8b1) and 
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have smoother surfaces as shown in Fig. 4.8b2. The difference in size and surface 
morphology can be attributed to excess residual solvent on collection. When the 
collection distance is increased, more solvent is lost as vapour and as a consequence 
there is reduced solvent mixing with the thin film of the ethanol during collection on 
the substrate. When the collection distance is increased significantly (400 mm) the 
production of nano-particles is achieved (Fig. 4.8c1). The relative drying time 
(directly proportional to deposition distance) for these particles is far greater than for 
the previous two samples and the surfaces of these particles (Fig. 4.8c2) are also 
smooth. 
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Figure 4.9 Size distribution of the PLGA particles, (a) CD = 100 mm,(b) CD = 150 
mm, (c) CD = 400 mm. 
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The results show that both nano- and micro-scale particles can be prepared using this 
method, which addresses a key demand of the pharmaceutical industry [Panyam and 
Labhasetwar 2003, Pilcer et al. 2009]. The surface features are also an important 
factor for interaction with living systems and the ability to produce structural 
variations is desirable in assessing particle-cellular interactions for drug delivery 
[Mitragotri and Lahann 2009].  
 
The size distribution of the PLGA particles for the different collecting distances is 
shown in Fig. 4.9. The differences in the particle size, as a function of the collecting 
distance, is clearly a feature which can be used to control particle size, and the 
surface morphology can also be changed simultaneously from smooth to textured. 
All the samples had narrow monomodal size-distributions. The mean size and the 
polydispersivity index of the particles collected at 100 mm (sample a) were 10 µm 
and 12% respectively, whilst the mean size of particles collected at 400 mm (sample 
c) was five times smaller, but the polydispersivity index was almost the same. The 
key values are shown in Table 4.3. 
 
Table 4.3 Size distribution data for different spherical particles generated. 
Sample 
Number of 
particles studied 
Mean size 
(µm) 
Standard 
deviation 
Polydispersivity 
(%) 
a 265 10 1.22 12 
b 307 8 1.08 13 
c 313 0.2 0.02 11 
 
4.2.3 Effect of polymer concentration, applied voltage and flow rate  
The effect of concentration of PCL in solution on the size and size distribution of the 
carrier particles was studied using concentrations of 2, 5 and 10 wt%. The particles 
generated were spherical in shape and the mean sizes for 2, 5 and 10 wt% were 0.3, 
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0.7 and 4.4 µm, respectively. As the concentration increases, the viscosity of the 
solution increases, resulting in the production of larger polymer particles, as 
discussed above. 
 
It is a well established principle in electrohydrodynamic processing that by 
increasing the viscosity of a medium the transition from spraying droplets to 
spinning fibres can be realised [Morota et al. 2004]. Therefore, to explore and 
demonstrate the variations in the shape of the particles generated by this process, 
requires the use of a much higher polymer concentration. The polymer solution used 
for this was again PCL (being the most economical) and its concentration in solution 
was 30 wt%. In contrast to the low concentration polymer solutions used to generate 
particles, the more concentrated PCL polymer solution is ideal for undergoing chain 
entanglement, thereby considerably increasing the viscosity of the solution, which is 
crucial in order to obtain shape changes. 
 
The influence of the applied voltage and flow rate on the structure of the particles 
was investigated with the collection distance fixed at 150 mm. In the electrospinning 
process, the fibres generated undergo a whipping motion as a result of the applied 
electric field [Jaworek et al. 2008], which also leads to drying and thinning of the 
fibres emitted prior to collection. By increasing the applied voltage, this effect can be 
increased and may result in the breakdown of fibres into smaller constituents. Fig. 
4.10 shows scanning electron micrographs of structures obtained as a result of 
variations in the applied electric field, with a fixed flow rate of 5 µl/min and a 
collecting distance of 150 mm. At an applied voltage of 6 kV, polymeric micro-
particles were generated with diameters ranging from 1-3µm, with smooth outer 
surfaces (Fig. 4.10a). When the applied voltage was increased to 8 kV, the particle 
size distribution became narrower, with the size range between 100nm and 1µm 
(Fig. 4.10b). As the voltage was increased further to 14 kV, the particle shape began 
to change as a direct consequence of the increased electric field. This resulted in 
needle like structures (Fig. 4.10c) with a constant width of 100nm and length 
varying between 1-3 µm. Similar structures were formed when the applied voltage 
was increased to 16 kV (Fig. 4.10d). The formation of such structures could be due 
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to one of two reasons. The first is due to intermediary fibre formation, where the 
transition between droplets to fibres is not complete. The second could be due to the 
whipping effect, where fibre generation has been achieved but the mechanical 
strength of the fibres is weak, causing them to break up during whipping and 
subsequent ejection. Other experiments have demonstrated structural changes as a 
function of the applied voltage, which can lead to bead formation in fibres using 
electrospinning [Zhang et al. 2006]. The jet and fibre size have also been shown to 
reduce as the applied voltage is increased during processing [Pham et al. 2006]. 
 
The exact applied voltage needed for a change in shape depends on the polymer 
concentration and properties of the solution such as viscosity and conductivity. The 
shape change is a transition from spherical to oblong to a more needle-like shape, 
and mapping the transition as a function of applied voltage is currently being 
investigated. A further area of interest is the identification and characterisation of the 
different particle shapes. Optical and electron microscopy clearly provide means of 
determining and quantifying variation in particle shape and size but these require 
careful sample preparation.  
 
Such structural changes from spherical to needle-shape have potential application for 
drug delivery and in particular, in understanding how biological systems respond to 
shape orientated micro- and nano- scale particles. “Worm-shaped” drug delivery 
particles have been shown to inhibit phagocytosis compared with spherical particles 
of equal volume, indicating that the high curvature of spherical particles may play a 
role in inducing phagocytosis. Needle-like structures like those shown in Fig. 4.10c 
and 4.10d have a much lower curvature compared with those prepared in Fig. 4.10a 
and hence have increased potential as drug delivery carriers [Champion and 
Mitragotri 2006]. Furthermore, cylindrical particles which are geometrically similar 
to the fabricated needle-like particles in this work (Fig. 4.10 and Fig. 4.11) have 
been shown to internalise into cells without causing any toxicity [Gratton et al. 
2007].  
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Figure 4.10 SEM images of particles fabricated at different applied voltages, flow 
rate= 5 µl/ml, CD = 150 mm, polymer solution= PCL:DMAC(30:70 wt. ratio) (a) 
voltage=6 kV, (b) voltage= 8 kV, (c) voltage= 14 kV, (d) voltage= 16 kV. 
 
Another important parameter in electrohydrodynamic particle processing is the 
solution flow rate and this is perhaps the most important factor influencing the size 
of the structures generated [Ganan-Calvo et al. 1997a and 1997b]. The relationship 
between droplet size and processing variables has been expressed by the following 
scaling laws in the cone-jet model [Hartman et al. 1999, Hartman et al. 2000]:  
 
6/1
2
4
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Ι
∝
Qd ρ                                            (4.1) 
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Where d is the droplet diameter, Q  is the liquid flow rate, ρ  is the liquid density, 
and Ι  is the current. The equation shows that the droplet size decreases with a 
reduction in the flow rate of the medium, in this case the polymer solution. In the 
present study, the size of the particles was found to decrease with decreasing 
polymer solution flow rate as shown in Fig. 4.11. Here, the flow rate of the 30 wt% 
PCL solution was changed from 5 µl/min to 2 µl/min and the same conditions were 
applied as before with the gradual changes to the applied voltage. The characteristics 
of the products were similar in terms of shape, but with regards to size there is a 
marked reduction.  
 
 
 
 
 
 
 
 
 
 Figure 4.11  SEM images of particles fabricated in different applied voltage, flow 
rate = 2 µl/ml, CD = 150 mm, polymer solution = PCL:DMAC (30:70 wt. ratio), (a) 
voltage= 6 kV, (b) voltage= 8 kV, (c) voltage= 14 kV, (d) voltage= 16 kV. 
 
A flow rate of 2 µl/min and an applied voltage of 6kV resulted in spherical particles 
with a mean size of 1µm (Fig. 4.11a). When the electric field was increased by 
increasing the voltage to 8kV the particles were smaller with a mean size of 300 nm. 
When the applied voltage was increased to ≥14kV the formation of needle like 
structures was evident again (Fig. 4.11c) although the aspect ratio was reduced when 
compared to those generated using a flow rate of 5µl/min as there was a reduction in 
(d) 
(a) (b) 
 
(c) 
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the particle length. Finally, this ratio was reduced further by increasing the applied 
voltage to 16 kV and preparation of rod like particles is achieved with a particle 
length ≥ 1µm (Fig. 4.11d). Controlling the aspect ratio of rod and needle 
morphologies is another important feature in drug delivery systems. It has been 
shown that using cylindrical particles, the aspect ratio of particles can influence the 
rate of internalisation within cells [Gratton et al. 2007]. 
 
In summary, it was shown that a variety of structures can be prepared via single 
needle electrohydrodynamic processing. Also, the length and width of the particles 
and hence the aspect ratio can be controlled. The structures and morphologies of 
different generated carriers were shown in Fig. 4.12. These include the common 
spherical particles to more needle like structures. The aspect ratio of these particles 
can also be controlled to reduce the particle shape from the micro to the nano scale.  
 
 
Figure 4.12 Morphologies of drug-delivery carriers generated in this study.  
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4.3 Co-axial electrohydrodynamic production of drug-loaded micro- and nano-
particles 
4.3.1 Introduction 
One of the limitations in using single needle method is that the sprayed solution 
should have an electrical conductivity within a suitable range. The requirement is 
often achieved by dissolving additives in spray solutions. For some applications, 
suitable additives are very difficult to identify. For instance, some biomedical 
materials are very sensitive to the solution pH, and a small amount of acid additive 
will cause denaturalisation. This problem can be solved by using the co-axial EHDA 
method which proposes to coat more electrical charges on particles by sheathing the 
biomaterial suspension (in the inner capillary) with highly conductive and volatile 
liquid in the outer capillary during the spraying process. 
 
However, it was shown that single needle EHDA process had great potential in 
producing polymeric particles with various sizes and shapes, the next step is to study 
the capability of co-axial EHDA process in encapsulation of a therapeutic agent in 
the polymeric carriers and fabrication of drug-loaded nanometre and micrometre 
scale particles as a drug delivery system. Thereafter, the influence of processing 
parameters, specifically the polymer concentration and applied voltage on size and 
size distribution of the drug-loaded particles were studied. 
 
Biodegradable and biocompatible polylactic-coglycolic acid (PLGA 50:50) was used 
as the polymeric carrier material. Estradiol and evans blue dye (EB) were used as the 
encapsulated materials. The polymeric solution and the drug solution were pumped 
individually through the outer and inner needle of the co-axial setup, respectively. 
The characteristics of PLGA and estradiol drug were discussed in Chapter 3 
(Section 3.2.1 and 3.2.6). 
 
4.3.2 Encapsulation process and particle formation 
In this study, co-axial EHDA was used to prepare polymeric drug-loaded particles 
with different size ranges. PLGA solutions of different concentrations (2 wt%, 5 
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wt% and 10 wt%) and the drug-dye solution were prepared as described in Section 
3.4.1 and 3.4.2. The central needle carried the drug/EB solution, the outer needle was 
perfused with a given PLGA solution to produce the polymeric coating. All 
characteristics of the co-axial setup were as explained in Section 3.8. 
 
 
 
 Figure 4.13 Flow of liquid under an electric field using a single (central) needle 
showing (a1) no flow (a2) dripping mode and (a3) cone jet mode. Single needle (outer 
needle) showing (b1) no flow (b2) dripping mode and (b3) cone jet mode. Co-flowing 
solutions showing (c1) no flow (c2) dripping mode demonstrating immiscibility and 
(c3) cone jet for encapsulation. 
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The jetting modes generated for flowing liquids under the influence of an electric 
field are functions of the applied voltage, the working distance between the needle 
outlet and the collecting plane, the flow rate of the liquid, needle diameter and the 
properties of the flowing liquids [Jaworek and Krupa 1999a]. As the applied electric 
field strength increases due to either an increase in the applied voltage or by 
reducing the working distance, the atomisation mode can be transformed from the 
dripping to the cone-jet mode. The cone-jet mode is the preferred atomisation mode 
because it can produce uniform, stable and continuous particle generation with a 
controllable jet size [Amsden and Gossen 1997]. A stable cone-jet can be obtained 
for liquids satisfying the condition iσ > oσ where σ is the liquid-dielectric 
atmosphere surface tension and subscripts i and o refer to the inner and outer 
solution, respectively [Ku and Kim 2002]. Another factor influencing the stability of 
the cone-jet is the ability of the electric field to be able to interact with at least one of 
the solutions, which is sometimes referred to as the driving medium, and must be 
selected carefully to satisfy the requirements for electrical conductivity and surface 
tension [Lopez-Herrera et al. 2003].  
 
As shown in Fig. 4.13, stable cone-jet generation was found to be easily achievable 
for both the inner and outer solutions used in this study; separately (Fig. 4.13a3 and 
4.13b3) and under simultaneous flow (Fig. 4.13c3). The inner blue coloured solution 
(drug with dye added to enable visualisation), was clearly encapsulated by the outer 
straw-yellow coloured polymeric solution. As the applied voltage was increased, the 
desired co-axial cone-jet formed (Fig. 4.13c3).  
 
4.3.3 Particle Characteristics 
4.3.3.1 Structural characterization of PLGA particles loaded with EB dye 
A preliminary morphological and structural study was carried out on the fabricated 
PLGA particles loaded only with EB. (Fig4.14). It was observed that the jet broke up 
to form fine droplets and particles with various size ranges (nano to micro) with 3 
different polymer concentrations. The mean diameters of the particles fabricated 
from 2, 5 and 10wt% polymer solutions were 110, 120 and 2500 nm, respectively. 
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Figure 4.14 Optical microscopy (a1, b1 & c1) and SEM images (a2, b2, c2) of particles 
prepared with different polymer concentrations. (a: 2 wt% PLGA, b: 5 wt% PLGA & 
c: 10 wt% PLGA) loaded with EB dye.  
 
4.3.3.2 Structural characterization of PLGA particles loaded with estradiol 
Further morphological and structural characterisation was carried out on PLGA 
particles loaded with estradiol which was the main model drug in our study. The 
optical images (Fig. 4.15a1, 4.15b1 & 4.15c1) demonstrate that very small particles 
were obtained when polymer concentrations of 2 wt% and 5 wt% were used. 
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Detailed analysis using SEM showed that all particles were spherical with a smooth 
outer surface (Fig. 4.15a2, 4.15b2 & 4.15c2).  
 
 
Figure 4.15 Optical microscopy (a1, b1 & c1) and SEM images (a2, b2, c2) of particles 
prepared with different polymer concentrations. (a: 2 wt% PLGA, b: 5 wt% PLGA & 
c: 10 wt% PLGA).  
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Figure 4.16 External and Internal morphology  of the particles fabricated from 10 
wt% PLGA solution using dual beam FIB-SEM. (a) prior to FIB sectioning (b,c) 2 
particles following FIB sectioning. 
 
It was also observed that the mean particle diameter decreased as the polymer 
concentration was reduced. Particles with a diameter of 120 nm were produced using 
2 and 5 wt% polymer solution. Particles prepared from the higher polymer 
concentration (10 wt %) agglomerated due to the presence of residual solvent during 
drying. The higher polymer concentration leads to larger particles being produced 
(a) 
(b) 
(c) 
500 nm 
 
500 nm 
 
5 µm 
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and thus reduces the degree to which the solvent can diffuse out of the particles over 
the fixed working distance. These results, as expected from previous studies [Xie et 
al. 2006a and 2006b], confirmed that the concentration of polymer in the liquid has a 
significant impact on the size of the particles produced. In this study FIB was also 
used to examine cross-sections of the PLGA particles using a dual beam FIB-SEM 
instrument. This showed that the particles had a porous internal structure with certain 
degree of vacuolation (Fig. 4.16b & 4.16c). 
 
 
 
Figure 4.17 Size distribution of particles prepared (a: 2 wt% PLGA, b: 5 wt% PLGA 
& c: 10 wt% PLGA). 
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The diameters of the particles were measured from the SEM images using the image-
processing program UTHSCSA (Image Tool Version 2, University of Texas, USA). 
Particles prepared from 2 wt% PLGA had a bimodal size distribution with two 
peaks. 70 % of the particles were <120 nm in diameter and 20 % of them were >500 
nm (Fig. 4.17a). In this case the wider variation in particle size can be attributed to 
the generation of different types of droplets (“primary” and “satellite”) during the 
processing [Hartman et al. 2000, Tang and Gomez 1994 and 1995]. More than 90% 
of the particles prepared using 5 wt% PLGA were <120 nm in diameter (Fig. 4.17b). 
The particles produced from the 10 wt% PLGA, 95% had diameters >2 µm (Fig. 
4.17c).The polydispersivity index of the 5 wt% PLGA was the lowest (Table 4.4). 
These results confirmed that the concentration of polymer in the liquid has a 
significant impact on size of the particles produced and this is caused primarily by 
the increase in viscosity with polymer concentration which results in larger droplets 
being formed [Jayasinghe and Edirisinghe 2002].  
 
 Table 4.4 Size characteristics of the prepared particles. 
 
Although production of the polymeric particles via both single and co-axial EHDA 
was simple to perform, attaining exactly the desired particle size, size distribution, 
and morphology might be challenging. The right parameters have to be 
experimentally found for every case and the correct instrumentation set-up used. The 
results showed that smaller particle size was achieved via co-axial method. The size 
range for PCL particles produced via single needle EHDA was from 310 nm to 4.4 
µm, whereas the PLGA particles produced via co-axial EHDA was from 100 nm to 
2.5 µm. 
Sample 
Number of 
particles studied 
Mean size 
(nm) 
Standard deviation 
(nm) 
Polydispersivity 
(%) 
PLGA 2 wt% 300 250 100 38 
PLGA 5 wt% 300 100 10 11 
PLGA 10 wt% 150 2500 400 16 
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Summary 
This study demonstrates the successful preparation of micro and nano scale 
polymeric carriers using both single needle and co-axial electrohydrodynamic 
atomization methods. These methods overcome some of the disadvantages of other 
conventional methods for producing polymeric drug carriers, such as the need for 
elevated temperatures, multiple processing steps, and the use of surfactants and other 
additives.  
First, the key processing parameters such as flow rate, applied voltage and the 
properties of the solutions were optimised to obtain a stable cone jet. The cone-jet 
mode was of particular interest, as this resulted in a near-uniform distribution of 
particles upon jet break-up. The flow rate and applied voltage were varied from 2-50 
µl/min and 0-15 kV, respectively. It was shown that the particle sizes were reduced 
at higher applied voltages and this effect was more noticeable at higher flow rates. 
The size distribution of all samples was monomodal but it was found that the 
polydispersivity index of the particles increased at the upper limit and lower limit of 
flow rates in the cone-jet region. Furthermore, the effect of these parameters on the 
size and polydispersivity of the particles were determined. For instance, the size 
range of generated particles from PCL solutions with different concentrations were 
varied from 310 nm to 4.4 µm (flow rate = 10 µl/min, voltage ~ 10 kV).  
Second, it was shown that the polymer concentration (PLGA and PCL solutions), the 
flow rate and the collecting distance can control the particle size, shape and 
morphology. Specifically the collecting distance not only has a great effect on the 
mean size of the particles but also it has a key role in changing the surface 
morphology of the produced PLGA particles from a crinkled surface to a smooth 
surface. Furthermore, it was elucidated that in the case of using viscous PCL 
polymer solution (30 wt%), there is a transition between electrospraying and 
electrospinning, in which the needle-like shape particles is generated.  
Third, it was shown that the co-axial EHDA method has a great potential for 
encapsulating a therapeutic agent inside a polymeric carrier. The structures, size and 
size distribution of the particles were investigated. The mean size of the estardiol 
loaded PLGA particles were varied from 100 nm to 2.5 µm. 
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Chapter 5 
Results and discussion 
 
In vitro release study: controlling and regulating the release 
profile 
 
Overview 
The main objective of a delivery system is to release therapeutics at the desired 
anatomical site and to maintain the drug concentration within a therapeutic band for 
a desired duration. Therefore, in the first set of experiments (Section 5.1), the 
capability of the drug-loaded PLGA particles produced in providing controlled 
release of the estradiol in a sustainable dose over extended periods was studied. 
Advanced treatment of diseases requires particles that can deliver their payload in a 
highly regulated manner to achieve the desired therapeutic effect. Therefore, in the 
next sets of experiments (Section 5.2), the effect of ultrasound exposure upon the 
estradiol release profiles was studied. In addition, “burst release” is one of the major 
challenges to overcome in drug encapsulated particle systems. In most cases, the 
burst release is an ineffective form of drug usage from both therapeutic and 
economic standpoints. For this reason, the final goal in the development of the 
estradiol loaded PLGA particles was to reduce the initial burst and achieve a 
controlled drug released thereafter. Therefore, in the last sets of experiments 
(Section 5.3), the aim was to modify the release profile via a coating method in order 
to minimize the burst release phase. 
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5.1 In vitro release study of micro- and nano-particles produced via co-axial 
electrohydrodynamic processing 
5.1.1 Introduction 
In this section, further in vitro investigations were carried out on the evans blue and 
estradiol loaded PLGA particles, which were produced in Section 4.3. The aims 
were to study the efficiency of the encapsulation process, to determine the capability 
of the polymeric particles designed for releasing their payload and to measure the 
amount of drug released over an extended period.  
 
In the first part of this study, the evans blue release profile was investigated using a 
simple and qualitative colorimetric method. Subsequently, estradiol was used as the 
encapsulated drug. The encapsulation efficiency and drug release profile were 
measured using the UV spectrophotometer method which is a more accurate and a 
quantitative method. 
 
5.1.2 Evans blue dye and estradiol release studies 
Drug release from polymeric particles can take place by several mechanisms 
including diffusion, surface and bulk erosion, desorption and disintegration. From 
PLGA particles it occurs initially by diffusion from the polymer matrix, whereas 
during the later phases the release is mediated through both drug diffusion and 
degradation of the polymer matrix itself. PLGA degrades by means of hydrolysis 
[Schliecker et al. 2003]. The inwards diffusion of the aqueous phase causes 
degradation of the polymer chains, which in turn facilitates outwards diffusion of the 
entrapped drug [Zhang et al. 2008]. 
 
In the first step of the in vitro release study, a colorimetric method was used to 
measure the EB dye release profile. The aim was to study the feasibility of EB 
encapsulation in the PLGA particles and to study whether these PLGA carriers are 
able to release the loaded EB dye. 
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The colour change of the solutions in the vial over time (t) was measured. These 
colour changes were apparent to the naked eye over prolonged periods as shown in 
Fig. 5.1, where t1<t2<t3.  
 
     
Figure 5.1 Changing the colour of the medium as function of time t1<t2<t3. 
 
However, more subtle colour changes over a 10 day period were assessed at fixed 
time intervals using a colorimeter. The release profile obtained using the colorimeter 
is shown in Fig. 5.2a.  The results show that the optical absorption increased in all 
samples and the profiles had two different stages: initial burst release in the first 8 to 
10 hours followed by a slow increase as the EB dye diffused out of polymer matrix. 
The release rate for the particles produced from the more concentrated solution 
(PLGA:DMAC 10 wt%) was lower than that for those produced from the less 
concentrated solutions ( PLGA:DMAC 2 & 5 wt%). The colorimeter could detect the 
released EB dye up to 5, 7 and 10 days in PLGA 2 wt%, PLGA 5 wt% and PLGA 10 
wt% samples, respectively. This method is applicable for showing the feasibility of 
encapsulation by qualitatively measuring the colour change of the solution in the vial 
over time (t).  
 
The next step of the in vitro release study was to investigate the behaviour of the 
drug (estradiol) release from the PLGA particles using UV spectroscopy. Clear 
absorbance peaks were achieved at the expected wave length for estradiol (280 nm) 
indicating that the drug was not damaged during the encapsulation process (Fig. 
5.2b). It was observed that estradiol release was time-dependent and all the drug-
t1 t2 t3 
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loaded nano and micro particulate formulations showed a biphasic release pattern (as 
for the results from colorimetric release study) wherein there is a burst release 
followed by a period of sustained release (Fig. 5.2b).  
 
 
 
 
Figure 5.2 Release profile of PLGA particles prepared from different concentrations 
(a) PLGA particle loaded with EB dye (using colorimetry method) (b) PLGA 
particles loaded with estradiol (using UV spectroscopy method). 
 
The release rate for the particles produced from the more concentrated solution 
(PLGA:DMAC 10 wt%) was lower than that for those produced from the less 
concentrated solutions (PLGA:DMAC 2 & 5 wt%). This could be explained by the 
fact that the particles fabricated from the more dilute solutions were smaller in size 
and, with a decrease in particle size, the surface area to volume ratio increases 
leading to increased buffer penetration and faster drug diffusion. In the last stage, the 
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release rate for PLGA 10 wt% sample increased significantly, as degradative 
hydrolysis of the polymer particles took place and the region, which would be 
expected to contain a higher concentration of drug, was exposed. The encapsulation 
efficiencies for the particles prepared from 2 wt%, 5 wt% and 10 wt% polymer 
solution were 65%, 68% and 75%, respectively. This slight increase with polymer 
concentration may be due simply to the fact that an increase in the polymer 
concentration would result in higher resistance to outwards drug diffusion during 
processing. 
 
Generally, it was shown that colorimetric method is a fast, simple, and qualitative 
method indicating the feasibility of the encapsulation and the UV method is a 
sensitive, accurate and quantitative method showing the release behaviour of the 
encapsulated materials over time. It was observed that the estradiol release rate was 
time-dependant. All samples with various size ranges (from 100 nm to 2.5 µm) 
showed controlled release profiles with no fluctuations. However, all release profiles 
had burst release phase in the beginning.  
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5.2 Effect of ultrasound exposure on the release profile of PLGA nano and 
micro particles 
5.2.1 Introduction 
In this chapter, further investigation was carried out on the particles which were 
fabricated in Section 4.3. As mentioned in Section 1.2, the final objective of this 
study was to tailor and control the drug release profile to produce a more efficient 
system. As mentioned in Section 2.12.2, one way to stimulate the drug release is to 
expose the particles to ultrasound. First, some preliminary experiments were carried 
out using an ultrasonic cell disruptor, in order to test the feasibility of this technique. 
Continuous wave ultrasound was applied for either 15 or 30 s, after which the 
sample was returned to the vial and UV spectroscopy measurements were carried 
out. 
 
After, demonstrating an enhanced drug release rate, a better understanding of the 
phenomena involved was required to facilitate a reliable measure of control over the 
release process. Therefore, systematic investigations were carried out to determine 
the effect of various ultrasound exposure parameters, in particular: output power, 
duty cycle and exposure time, on the release rate. For this study, the prepared 
estradiol-loaded PLGA particles were exposed to ultrasound using a programmable 
sonicator (Branson Sonifier S250A). 
 
5.2.2 Preliminary study on the effect of ultrasound exposure on the drug release 
profile  
The release profiles for prepared particles with different sizes (100 nm to 2.5 µm) 
were clearly affected by exposing the particles to ultrasound. Ultrasound has been 
used in various drug delivery applications to enhance the release of pharmaceuticals 
in target tissues [Mitragotri 2005]. As discussed in Chapter 2, the main mechanism 
for increased release is thought to be related to acoustic cavitation, which is the 
formation and/or activity of gas or vapour-filled bubbles in the medium exposed to 
ultrasound [Larina et al. 2005]. 
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Figure 5.3 Estradiol release profile for PLGA particles following exposure to 
ultrasound (15 and 30 s). (a) PLGA:DMAC 2:98, (b) PLGA:DMAC 5:95 and (c) 
PLGA:DMAC 10:90.  
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In this study, an increase in the amount of drug released was observed for all the 
samples exposed to ultrasound (Fig. 5.3 and Table 5.1) with a greater increase 
obtained for longer exposures as would be expected. It was found that ultrasound 
had a slightly greater effect on larger particles. This may be due to the higher 
probability of gas entrapment in or on the particles’ surface, or simply of a particle 
encountering a bubble due to its larger size. 
 
Table 5.1 Release characteristics of particles exposed to ultrasound. 
 
5.2.3 Preliminary study on degradation 
Although PLGA is insoluble in water, it is hydrolytically unstable and degrades by 
hydrolytic attack of its ester bonds. Through this hydrolytic attack, random chain 
scission occurs, causing it to degrade into lactic and glycolic acids. 
 
One interesting feature of the surface of particles during degradative hydrolysis was 
the variation in porosity as a function of time. The quantity and the size of pores 
have been observed to increase for PLGA based implantable devices over prolonged 
periods in vivo [Schliecker et al. 2003]. The surface morphology of 10 wt% PLGA 
particles incubated in deionised water was studied over 30 days. The surface of the 
particles became porous (Fig. 5.4), a characteristic of PLGA degradation, which 
would explain the drug release patterns in Table 5.1. 
 
Sample 
Drug released difference 
after 15s US 
(%) 
Drug released difference 
after 30s US 
(%) 
PLGA 2wt% +3.5 +5.7 
PLGA 5wt% +4.4 +6.8 
PLGA 10wt% +6.3 +7.8 
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Figure 5.4 Surface morphology of the capsule prepared from 10 wt% PLGA as a 
function of time, a: t = 0, b: t = 15 days, c: t = 30 days, (all samples were incubated 
in deionised water during the experiments). 
 
Structural study was also carried on particles exposed to ultrasound. It was observed 
that the surfaces of the particles exposed to ultrasound were rougher and contained 
more pores in comparison with the samples which were not exposed to ultrasound 
(Fig. 5.5). This may have been due to both mechanical damage (e.g. formation of 
10 µm 
1 µm 
10 µm 
(a) 
(b) 
(c) 
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liquid jets from collapsing bubbles) and also faster polymer degradation as a result of 
increased agitation of the surrounding liquid due to the motion of the bubbles. Also, 
the internal pores closer to the surface (Fig. 4.16) may become broken due to the 
agitation, revealing pores upon the surface.  
 
Figure 5.5 Surface morphology of the microcapsules exposed to ultrasound as a 
function of time, a:t=0, b: t=15 days, c: t=30 days, (all samples were incubated in 
deionised water during the experiments).   
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5.2.4 Effect of sonicator output power on the release profile 
 
Figure 5.6 Estradiol release profiles for PLGA micro and nano particles following 
ultrasound exposure at various output powers (P1, P2 & P3) (a) sample S1 with 
particles containing PLGA 2wt%, (b) sample S2 with particles containing PLGA 5 
wt%, (c) sample S3 with particles containing PLGA 10 wt% (error bars represent the 
standard deviations, n ≥ 4); The cumulative drug release was calculated by 
measuring the percentage drug released at each specific time plus the entire drug 
which released before that specific time. Please note the longer timescale in (c) 
results from the fact that the mean particle size was larger and hence the degradation 
rate lower. 
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After the preliminary experiments, more extensive studies were carried out on 
ultrasound mediated drug release. First, the in vitro release behaviour of the control 
samples which were not exposed to ultrasound was determined. These profiles (the 
blue curves Fig. 5.6) showed burst release followed by a period of sustained release. 
The encapsulation efficiencies for the particles prepared from 2 wt%, 5 wt% and 10 
wt% polymer solutions were 65%, 68% and 75%, respectively. This slight increase 
with polymer concentration may simply be due to the fact that an increase in the 
polymer concentration would result in a higher resistance to outwards drug diffusion 
during fabrication. Next, the effect on the release profile of varying the sonicator 
output power4 was investigated. Three different power settings on the sonicator (P1, 
P2 & P3 corresponding to settings 2, 4 & 6) were used with a fixed duty cycle and 
exposure time. Each sample was exposed to ultrasound three times during the period 
over which the release profile was measured, to ensure the effect could be 
distinguished from other factors (e.g. disintegration of the particles).  
 
It was also observed, as would be expected, that the active-period of the drug carriers 
(i.e. the duration over which the drug delivery system can effectively release the 
loaded therapeutic agent) was shortened as the power of the ultrasound increased. 
The results for the particles with different polymer concentrations were qualitatively 
similar. The frequency spectra for the corresponding acoustic emissions were 
obtained and their mean energy calculated as described befor in section 3.7.1. The 
mean energy increased with increasing output power as would be expected, since 
there would be a higher probability of bubble formation and the oscillations of those 
bubbles would be of larger amplitude. 
 
The correlation between mean energy and drug release enhancement was examined 
and the relationship was found to be linear again as would be expected based on the 
linear relation between sonicator power setting and output. Visual observations in a 
                                                
4 It would be preferable to investigate the effect of ultrasound intensity, but as indicated befor it was not feasible to measure 
this directly. An attempt was made to use laser vibrometry to indirectly quantify the intensity by measuring the motion of the 
sonicator probe tip, but this was not possible in water due to the scattering of the light by bubbles. Measurements in air were 
performed and whilst these could not provide an accurate measure of intensity in water they did indicate a linear progression in 
probe tip displacement and velocity (and hence intensity) with the sonicator power setting. 
Chapter	  5:	  Results	  and	  discussion;	  in	  vitro	  release	  study;	  regulating	  the	  release	  profile	  	  
	  
125	  
water bath containing freshly drawn water confirmed that bubble formation occurred 
under all conditions i.e. the threshold for bubble formation in terms of acoustic 
pressure was always exceeded. This was also indicated by the appearance of the 
exposed particles as discussed in Section 5.2.3. 
 
5.2.5 Effect of duty cycle and exposure time on the release profile 
The effects on the release profile of varying the duty cycle (30%, 60% & 90%) and 
the exposure time (15 s, 45 s & 90 s) were also investigated at each output power 
setting. Both were found to be positively correlated with the drug release rate (c.f. 
Table 5.2), e.g., for an exposure time of 45s, increasing the duty cycle from 30% to 
90% increased the release rate enhancement from 6.9% to 13.5%. No significant 
changes or trends were observed, in either the frequency content or the mean energy 
of the acoustic emissions (Table 5.2). This might seem to be somewhat unexpected 
given that higher duty cycles and longer exposure times would correspond to higher 
energy input. Total energy input does not, however, always correspond to greater 
cavitation activity and reports in literature have been correspondingly contradictory 
on the effect of the duty cycle on cavitation activity. An extensive review is given by 
Hodnett et al. 2004. This is due to the fact that there are a number of competing 
processes. If the pressure amplitude of the incident field is sufficiently high, bubbles 
will form during the negative portion of the cycle in [Hodnett et al. 2004]. Over 
subsequent cycles they may grow through rectified diffusion and will oscillate and 
may undergo violent collapse, again depending on the pressure amplitude. If the duty 
cycle is too low, the bubbles will dissolve back into the liquid before they have 
grown to sufficient size and/or had sufficient time to produce any effect upon the 
particles. If the duty cycle is too high, on the other hand, then the bubbles will 
collapse and fragment very rapidly and only a small proportion may interact with the 
particles. Moreover, for a given temperature and pressure there will be a finite 
amount of gas dissolved in the liquid which will progressively be driven out of the 
solution during sonication, so prolonging the exposure time or increasing the duty 
cycle will not increase the number of bubbles. 
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Table 5.2 Drug release enhancement and change in energy of measured acoustic 
emissions for different ultrasound exposure times and duty cycles (output power P2) 
Samples 
 
Ultrasound 
exposure 
Time (s) 
Duty 
cycle 
(%) 
Drug release 
rate enhancement 
(%) 
Difference of 
ultrasound energy in 
each set (%) 
S1:PLGA 2 
wt% 
45 
45 
45 
30 
60 
90 
6.9 
9 
11.7 
4.7 
S2:PLGA 5 
wt% 
45 
45 
45 
30 
60 
90 
7.3 
9.7 
12.7 
3.8 
S3:PLGA 10 
wt% 
45 
45 
45 
30 
60 
90 
7.4 
10.1 
13.5 
2.2 
 
S1:PLGA 2 
wt% 
 
15 
45 
90 
 
60 
60 
60 
 
7.3 
9 
9.8 
3.2 
S2:PLGA 5 
wt% 
15 
45 
90 
60 
60 
60 
7.8 
9.7 
10.5 
2.5 
S3:PLGA 10 
wt% 
15 
45 
90 
60 
60 
60 
8.2 
10.1 
11.3 
1.1 
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5.2.6 Effect of ultrasound exposure on particle microstructure and degradation 
PLGA is well known to be highly hygroscopic and to undergo degradation in an 
aqueous environment. The degradation of PLGA normally involves four stages: 
hydration, initial degradation, further degradation, and solubilisation [Cai et al. 2000, 
Loo et al. 2005] the last of these normally occurring at a lower rate [Cohen et al. 
1991, Loo et al. 2005]. It has been observed in previous studies that during 
ultrasound exposure, the rate of erosion of the polymeric matrix and hence release of 
the drug is increased [Miyazaki et al. 1988]. Similarly, in this study a clear 
difference was observed between exposed and unexposed particles (Fig. 5.7 & 5.8). 
In terms of the effect of specific exposure parameters: it was observed that when the 
duty cycle or the exposure time increased, there was a slight increase in the apparent 
roughness of the particles. The ultrasound output power also had an effect on the 
particle morphology with an increasing number of surface pores becoming visible 
(Fig. 5.8). 
 
It is interesting to consider these observations in relation to the measurements of the 
release profile and the acoustic emissions. As discussed above, duty cycle, exposure 
time and output power all had significant effects on the release rate enhancement 
(Fig. 5.6 & Table 5.2). Only output power, however, had a noticeable effect upon 
the acoustic emissions and the particle morphology. The presence of the surface 
pores may be attributed to bubbles collapsing in close proximity to the particles 
(microjetting), the probability of which would be expected to increase with 
increasing ultrasonic power. The resulting increase in surface diffusivity and rate of 
particle degradation would in turn account for the enhanced drug release rate. The 
fact that there was no increase in pore formation observed with increasing duty cycle 
or exposure time is consistent with the lack of increase in acoustic emissions and 
would seem to indicate that there may be more than one mechanism determining the 
drug release rate. It may be hypothesised that, unlike cavitation-mediated particle 
degradation, these other mechanisms are directly related to the energy of the 
ultrasound field and may be associated with diffusion enhancement as a result of 
agitation of the liquid and/or a temperature rise (although as noted above this would 
be expected to be small). 
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Figure 5.7 Effect of ultrasound duty cycle (DC) on the morphology of the particles 
produced from PLGA 10 wt% (a) without ultrasound exposure (b) DC: 30 % (c) DC: 
60% (d) DC: 90%, (exposure time: 45s and ultrasound out-put power: 4). 
 
 
Figure 5.8 Effect of output power of ultrasound on the morphology of the particles 
produced from 10 wt% PLGA (a) without ultrasound exposure (b) P1: 2 (c) P2:4 (d) 
P3:6, (ultrasound exposure time: 45s, ultrasound duty cycle: 60 %). 
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5.3 Characterization and modification of release pattern for estradiol from 
PLGA particles with improved burst release characteristics 
5.3.1 Introduction 
As discussed earlier, the objective in engineering many drug delivery systems is to 
achieve a drug release profile with the desired characteristics in terms of time and 
rate of drug release. Understanding of the burst effect during controlled release is 
still limited but knowledge continues to grow as researchers realise both the 
economic and therapeutic importance of the burst period. Controlling the release 
requires controlling the properties affecting release, including particle size, size 
distribution, polymer properties, and surface properties. In this part of the work, a 
coating method was used to tailor the in vitro drug release profiles by changing the 
surface properties of the PLGA carriers. The influence of coating the particles and 
the concentration of the coating agent on the release profile were investigated. Also, 
the size and size distribution of the particles generated were controlled by 
systematically varying the polymer concentration in the processed solution and their 
influences on the burst release phase were studied. In this study, the ‘burst release’ 
phase is defined as the amount of drug released between 0-24 hours. And, the 
amount of drug released in between 0 to 72 hours is defined hereafter as the ‘initial 
release’ phase. 
 
In order to modify the surface properties, first, the coating technique was optimised 
by examining the effect of coating on the morphology of the particles. The next part 
of the study then focused on tailoring the release profiles to achieve minimum initial 
release and investigating the effects of different coating materials on the in vitro 
release profile of the drug-loaded carriers. The challenging part was finding a simple 
coating method which can provide a homogenous outer layer on the surface of the 
particles without having the agglomeration problem. Also, this method should be 
engineered in such a way that it is capable of controlling the burst release phase 
without affecting the rest of the release profile. The strong point of this manuscript 
was optimizing all the involved parameters such as type and concentration of the 
coating agent. This made it possible to have an effective coating that does not 
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dissolve quickly (before passing the burst release phase) or slowly (lasts after the 
burst release phase and slows down the rest of release profile). Therefore, this part of 
the study needs to find out a smart strategy which can meet all the criteria mentioned 
above. In all experiments, PLGA solutions with different concentrations (1 wt%, 2 
wt%. 5 wt%, 10 wt% and 15 wt%) were used in order to study the effect of particle 
size on the burst release phase. Again, estradiol was used as a model drug. 
 
5.3.2 Particle characteristics 
The most significant solution properties that affect the generation of polymer 
particles by the EHDA method are density, electrical conductivity, surface tension, 
viscosity, and polymer concentration. Specifically, the size of the fabricated particles 
is controlled mainly by the electrical conductivity and viscosity of the solutions 
[Hartman et al. 2000, Cloupeau and Foch 1990]. The viscosity increased and 
electrical conductivity decreased as the concentration of PLGA increased from 1 
wt% to 15 wt% (Table 5.3). Also, PLGA concentration was found to affect the 
surface tension of the polymer solutions, with an increase of the concentration from 
1 wt% to 15 wt%, the surface tension increased from ~33 to 41 m Nm-1. 
 
Table 5.3 Properties of the solutions and the solvent used in this study. 
Sample 
Density 
(kg m-3) 
Viscosity 
(mPa s) 
Surface 
tension 
(mN m-1) 
Electrical 
conductivity 
(µS m-1) 
DMAC 940 2.0 29 5.6 
PLGA:DMAC 1:99 948 0.6 33 4.7 
PLGA:DMAC 2:98 950 0.8 33 4.7 
PLGA:DMAC 5:95 958 1.7 34 3.1 
PLGA:DMAC 10:90 970 4.9 39 1.5 
PLGA:DMAC 15:85 990 11.7 41 0.9 
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Figure 5.9 SEM micrograph and size distribution of PLGA particles fabricated with 
5 different concentrations: (a) 1 wt% PLGA (b) 2 wt% PLGA  (c) 5 wt% PLGA (d) 
10wt% PLGA (e) 15 wt% PLGA. 
 
The structure and size of the particles were determined prior to investigating the 
effect of particle size on burst release phase. Representative SEM micrographs and 
size distributions plots for PLGA particles prepared using various polymer 
concentrations are shown in Fig. 5.9.  As can be seen, the majority of the particles 
were spherical with smooth surfaces and without visible pores. This may be 
attributable to the fact that the high boiling point (164-166°C) of the 
dimethylacetamide slowed the evaporation rate during jetting, thus decreasing 
formation of pores. Particles prepared from the highest polymer concentration (15 
wt%) were slightly agglomerated due to the presence of residual solvent during 
drying. The mean size of the particles was calculated by measuring the diameter of 
~300 particles using Image Tool. The mean size of the fabricated particles ranged 
from 100 nm to 4.5 µm. 
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In the size distribution study, most of the samples had monomodal size distributions, 
and particles made from the more viscous solutions had narrower size distributions. 
More than 90% of the particles prepared using 5 wt% PLGA were <120 nm in 
diameter (Fig. 5.9c). For the particles produced from the 10 wt% PLGA solution, 
95% had diameters >2 µm (Fig. 5.9d). Particles prepared from 15 wt% PLGA had a 
narrow bimodal size distribution, and the mean size of the particles was 4.5µm (Fig. 
5.9e). The polydispersivity index (PI=standard deviation/mean size) of the particles 
made from 15 wt% solutions was slightly higher than (< 2%) the PI of the particles 
made from 10 wt% solution. This was due to the presence of some particles with 
diameters larger than the mean size, which shifted the monomodal size distribution 
to a bimodal one.  
 
However, particles prepared from 1 wt% and 2 wt% PLGA solutions, had bimodal 
size distributions. The mean size of these particles was also higher than that made 
from the 5 wt% solution. This wider variation in particle size can be attributed to the 
generation of different types of droplets (“primary” and “satellite”) during the 
processing [Hartman et al. 2000, Tang and Gomez 1994 and 1995]. The presence of 
some larger particles at the higher range of the size distribution graph, (see second 
peak in Fig 5.9a and 5.9b) was clear. These few but significantly larger particles 
among the small particles made from 1 wt% and 2wt% solutions had a significant 
role in mathematical size distribution analysis which causes a noticeable increase in 
both mean size, polydispersivity and standard deviation of the particles (Fig. 5.10). 
 
The increase in PI for the 1 wt% and 2wt% samples is attributed to the stability of 
the cone-jet which can dictate the size of the generated droplets and their particle 
relics. The concentration of the solutions in these two samples was below the critical 
range to achieve a stable cone-jet. The apex of the cone-jet shifts away from the 
centre of the cone, which is no longer symmetrical and takes the form of an “off-
centered” jet which may alter the balance of interacting forces. Therefore, a 
symmetrical cone-jet could not be established and this results in oscillation and 
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instability which produces some large droplets, which in turn results in a higher 
polydispersivity index. 
 
 
 
Figure 5.10 SEM images of particles prepared with (a) 1 wt% and (b) 2 wt% 
polymer concentrations, the evidence of the presence of large particles. 
 
The polydispersivity index of the particles made from the 5 wt% PLGA solution was 
the lowest (Table 5.4). These results confirmed that the concentration of polymer in 
the liquid has a significant impact on the size of the particles produced and this is 
caused primarily by the increase in viscosity with polymer concentration, which 
results in larger droplets being formed [Edwards et al. 1997].  
 
Chapter	  5:	  Results	  and	  discussion;	  in	  vitro	  release	  study;	  regulating	  the	  release	  profile	  	  
	  
136	  
Table 5.4  Particle size characteristics of the prepared polymeric carriers. 
 
5.3.3 Effect of particle size on burst release phase  
The main goal of designing sustained and controlled delivery systems is to reduce 
the frequency of dosing and provide uniform drug release. The total amount of 
estradiol used in the release study was the same for all formulations, and the PLGA 
formulations were prepared under the same processing conditions. One factor 
affecting the drug release kinetics is the particle dimension [Gaumet et al. 2007] as 
particles with different dimensions, have different surface areas, and thus, have 
different total surface areas available for drug release. Figure 5.11 compares the 
estradiol release profiles from PLGA particles with different diameters. The burst 
release is commonly attributed to the release of drug located close to the surface of 
particles [Pitt 1990, Cohen et al. 1991]. Also, it is related to the porosity of the 
particles. A high surface porosity correlates with a large surface area and rapid 
penetration of the release medium and consequently a very significant burst release 
[Musante et al. 2002].The release profile of particles made from PLGA solutions 
with concentrations of 5 wt% was more biphasic (Fig. 5.11). The release pattern 
consisted of a burst release followed by zero-order like release phase where a steady 
amount of drug is released over time. The release profiles of microparticles made 
from PLGA solutions with concentrations of 10 wt% and 15 wt% were triphasic; a 
Sample 
Mean size 
(nm) 
Polydispersivity 
(%) 
Standard 
deviation 
(nm) 
Number of 
particles studied 
PLGA 1wt% 250 50 130 464 
PLGA 2wt% 250 38 100 300 
PLGA 5wt% 100 11 11 300 
PLGA 
10 wt% 
2500 16 400 
 
150 
PLGA 
15 wt% 
4500 18 800 483 
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burst release phase followed by a slow release phase and then a second, more rapid 
release phase. The release profiles of PLGA 1 wt% and PLGA 2wt% samples 
showed that the few large particles which increased the mean size did not have a 
significant effect on the overall release profile. 
 
 
Figure 5.11 Estradiol release profile from PLGA particles produced with various 
solution concentrations. 
 
These results also showed that the burst release was lower for the larger particles. 
This is most likely to be because the total surface area of a constant total volume of 
particles decreases when the size of the particles increase. In addition, increasing the 
size of the particles, increases the length of diffusion pathways for the estradiol 
molecules. Thus, these molecules have to traverse a longer distance within the 
polymer matrix to reach the surface. However, the products of polymer degradation 
also have to travel a longer distance before they can dissolve in the release medium. 
The trapped products change the localised pH within the polymer matrix (especially 
in the bigger particles), which accelerates the polymer degradation due to 
autocatalysis. This accelerates the rate of loss of molecular weight within the matrix 
leading to faster drug diffusion in the final fast release phase. However, in the 
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smaller particles (<300 nm), autocatalysis is insignificant [Shive and Anderson 
1997]. The overall significant impact of increasing the diffusion pathways (by 
increasing the particle diameter) is reducing the burst release phase. This result 
indicates that the burst release is a diffusion-based process, which is influenced by 
the morphology of the particles while the subsequent release is a function of the 
polymer degradation. 
 
5.3.4 Coating particles  
5.3.4.1 Feasibility of method 
As mentioned in Section 2.12.1.2, burst release could be minimized by: first, 
inducing a reduction in water intake, second, providing longer diffusion pathways to 
the drug molecules, and third, eliminating the amount of drug on the surface of the 
carriers. Therefore, the above mentioned parameters that effect on initial burst can be 
fulfilled by surface modification by additional coating steps to provide an outer layer 
with no drug. For instance, in a study where alginate beads were coated three times 
with a polycation, either poly(L-lysine HBr) or poly(vinyl amine), to avoid the burst 
release of biomacromolecules including proteins and dextrans [Wheatley et al. 
1991]. It was discovered that increasing the polycation concentration decreased the 
burst release, and caused the release profile to be more sustained. 
 
Three PLGA concentrations; 2 wt%, 5 wt% and 10 wt% were chosen for further 
investigation since they had desirable size distributions (both in nano and micro 
scale) and estradiol release characteristics. The particles were coated with chitosan 
and gelatin coating agents, however, the viability of the coating method was studied 
for just chitosan coated particles. Coating the particles with a thin layer of material 
such as chitosan and gelatin, means the therapeutic molecules have to pass through 
an additional layer increasing the diffusional resistance. Therefore, slowing down the 
release process and, in particular, reducing the initial release phase. The release 
profiles of chitosan coated particles showed a noticeable reduction in the initial 
release rate between 0 to 72 hours. 
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Figure 5.12 Influence of coating method on surface morphology of chitosan coated 
PLGA particles. (a) uncoated (b) dipped (c) in situ.  
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Two physical coating methods, dip-coating and in situ coating, were used. In the 
former method, coating was achieved by carefully spreading a drop of solution of 
chitosan on the surface of the particles following preparation and then mixing it to 
ensure that the particles were coated evenly. The coating protocol was later modified 
to an in situ coating method. Here electrosprayed PLGA particles were collected in 
an aqueous solution. Then, chitosan was added to the particulate suspension straight 
after collection to form chitosan solutions with specific concentrations while 
mechanically stirring for 300s. The coated particles were centrifuged and were 
separated from the solutions. This technique promotes uniform chitosan coating on 
the particle surface and prevents agglomeration of the particles (Fig. 5.12). As 
shown in Fig. 5.12, chitosan-coated PLGA particles which were coated using the in 
situ method were spherical and uniform (Fig. 5.12b) while the other particles coated 
via dipping were agglomerated and clustered (Fig. 5.12c). Therefore, the in situ 
coating technique was chosen for further investigation in this work (Section 5.3.4.2 
and 5.3.5). 
 
Figure 5.13 FTIR spectroscopy of uncoated PLGA particles, chitosan solution and 
PLGA particles coated with chitosan solution of three different concentrations. 
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The presence or absence of the chitosan coating was confirmed via FTIR 
spectroscopy to show the presence of different functional groups and to study the 
feasibility of the coating process. The chemical structure of pure PLGA particles, 
chitosan solution and chitosan-coated PLGA particles is shown in Fig. 5.13. The 
interpretation of infrared spectra involves the correlation of absorption bands in the 
spectrum of an unknown compound with the known absorption frequencies for 
different types of bond. The FTIR spectrum of chitosan solution has some 
characteristic absorption bands at about 3422 cm-1 (N-H and O-H), 1652 cm-1 (-
CONH-) and 1076 cm-1 (C-O-C) [Wu et al. 2005]. The spectrum for the chitosan-
coated particles was compared with the spectrum of chitosan solution and pure 
PLGA particles (Fig. 5.13). The existence of the chitosan moiety in the chitosan-
coated sample was proved by two peaks around 3422 cm-1 and 1652 cm-1, which are 
the particular peaks assigned for N-H/O-H and –CONH- groups. C–O–C group 
belongs to both PLGA and chitosan. The C–O–C peak was observed around 1090 
cm-1 and 1080 cm-1 in the pure PLGA particles and chitosan samples, respectively. 
The strong shift of the C–O–C peak about 1089 cm-1 was observed in the coated 
sample, which also confirms the presence of chitosan, which attached to PLGA. 
These results showed that the coating process of the PLGA particles was successful.  
 
The effect of the chitosan concentration on the coating process was also studied 
using FTIR spectroscopy. All the particles were physically coated and the coating 
process is solely due to physical adsorption or electrostatic interactions between the 
polymer chains and the coating material. Figure 5.13, presents the FTIR spectra of 
the PLGA particles made from 10 wt% solutions which were coated with chitosan of 
three different concentrations (0.5 wt%, 1 wt% and 1.5 wt%). The transmission 
intensities of chitosan bands at 3422 cm-1 (N-H and O-H) and 1652 cm-1 (-CONH-) 
increased with the chitosan concentration. These results suggest that when a more 
viscous solution is used, more coating material covers the surface of the particles. 
These results were also confirmed with cross-section study of the particles. The 
cross-section and the coating thickness were elucidated using FIB and SEM 
microscopy. It was found that the particles had porous inner microstructures (Fig. 
5.14), while the surface of the particles were not porous (the inset figure in Fig. 
5.14c).  
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Figure 5.14 Cross section structure of the PLGA 10 wt%  particles and the thickness 
of the coating (a: coated with 0.5 wt%  chitosan solution, b: coated with 1 wt% 
chitosan solution, c: coated with 1.5 wt%  chitosan solution), scale bar: 500 nm. 
 
(a) 
(b) 
(c) 
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The additional coating layer was observable in the FIB micrographs. For the more 
viscous chitosan solutions (1 wt% and 1.5 wt%) the coating layers were more clearly 
observable. The thickness of the chitosan coating was increased from 20 nm to 70 
nm as the concentration of the chitosan increased from 0.5 wt% to 1.5 wt%. 
 
5.3.4.2 Stability 
For further investigation, PLGA particles were in situ coated with either chitosan or 
gelatin. The stability of both chitosan and gelatin on the surface of PLGA particles 
was again studied using FTIR (Fig. 5.15). According to Fig. 5.15a, FTIR 
spectroscopy of chitosan coated PLGA particles at 0, 24, 48 and 72 hours of release 
showed similar trend with various intensities. The peaks at 3422, 1649 and 1076 cm-1 
were due to the stretching of O-H/N-H, -CONH-, and C-O-C, respectively. The 
intensity of the FTIR spectrum of the  chitosan coated PLGA particles was decreased 
as a function of time, which indicated that ionic desorption between chitosan and 
PLGA ions was started after 24 h of the release test. These results showed that the 
coating lasts for up to 72 hours on the surface of the particles. Also, the in vitro 
release studies showed that the coated particles had a less pronounced initial release 
phase between 0 to 72 hours. The evidence suggests that chitosan can be used 
successfully as a coating material which limits the burst release phase. 
 
(a) 
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Figure 5.15 FTIR spectra of coated PLGA particles with 1 wt% solution at 0, 24, 48 
and 72 hours of release testing, (a) chitosan coated (b) gelatin coated. 
 
The FTIR spectroscopy of the gelatin molecules on the surface of PLGA particles is 
shown in Fig. 5.15b. The C–O–C peak of the PLGA particles was observed around 
1090 cm-1 and 1080 cm-1 in the gelatin coated PLGA particles. Gelatin has two 
intense bands at 1641 and 1557 cm–1 assigned to amide bonds (amide I and amide II 
modes, respectively). These two peaks were clearly seen in the FTIR spectrum of the 
gelatin coated samples straight after the coating process. But, after keeping the 
sample in the release medium, the intensity of the band was significantly reduced 
after 24 hours. These results suggest that the stability of gelatin on the surface of the 
PLGA particles was less than the stability of chitosan. This is likely to be due to the 
fact that gelatin is more hydrophilic and can dissolve/degrade in the aqueous release 
medium faster than chitosan. 
 
5.3.5 Effect of coating on release profile 
The release profiles of estradiol from both chitosan and gelatin coated PLGA 
particles fabricated from various PLGA, chitosan and gelatin concentrations are 
shown in Fig. 5.16 and 5.17 (the uncoated release profiles are given as references).  
(b) 
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Figure 5.16 Estradiol release from different PLGA particles coated of chitosan 
solution of various concentrations  (a) PLGA 2 wt%, (b) PLGA 5 wt%, (c) PLGA 10 
wt%.  
 
(a) 
(b) 
(c) 
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The initial release might be attributed to the fact that estradiol macromolecules were 
loosely bound onto PLGA particles by ionic interaction, which could be easily 
desorbed in an ionic environment [Pitt 1990, Cohen et al. 1991]. As depicted in Fig. 
5.16a, in PLGA particles made using the 2 wt% polymer solution, 44 % of the drug 
was released in the first 24 hours followed by 60% release after 72 hours.  
 
Table 5.5 Estradiol release data for chitosan coated PLGA particles and the effect of 
coating on burst and initial release5. 
Sample 
Burst release 
% (released 
between 0 to 
24)  
Initial 
release 
% 
(released 
between 
0 to 72) 
Drug released 
reduction in 
72 hr (%) 
Encapsulation 
efficiency (%) 
Uncoated PLGA 2wt%  44 60 --------------- 65 
PLGA 2 wt% + 
chitosan 0.25 wt%  
40 56 4 65 
PLGA 2 wt% + 
chitosan 0. 5 wt% 
36 56 4 65 
PLGA 2 wt% + 
chitosan 0.75 wt% 
25 40 20 65 
PLGA 2 wt% + 
chitosan 1 wt% 
15 23 37 65 
PLGA 2 wt% + 
chitosan 1.25 wt% 
10 16 44 65 
PLGA 2 wt% + 
chitosan 1.5 wt% 
5 14 46 65 
Uncoated PLGA 5wt%  38 54 ----------------- 68 
                                                
5	  continued	  on	  the	  next	  page	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PLGA 5 wt% + 
chitosan 0.25 wt%  
34 50 4 68 
PLGA 5 wt% + 
chitosan 0. 5 wt% 
31 46 8 68 
PLGA 5 wt% + 
chitosan 0.75 wt% 
22 36 18 68 
PLGA 5 wt% + 
chitosan 1 wt% 
10 22 32 68 
PLGA 5 wt% + 
chitosan 1.25 wt% 
8 17 37 68 
PLGA 5 wt% + 
chitosan 1.5 wt% 
4 11 43 68 
Uncoated PLGA 
10wt%  
30 50 ----------------- 75 
PLGA 10 wt% + 
chitosan 0.25 wt%  
26 46 4 75 
PLGA 10 wt% + 
chitosan 0. 5 wt% 
21 41 9 75 
PLGA 10 wt% + 
chitosan 0.75 wt% 
15 37 13 75 
PLGA 10 wt% + 
chitosan 1 wt% 
9 29 21 75 
PLGA 10 wt% + 
chitosan 1.25 wt% 
7 12 38 75 
PLGA 10 wt% + 
chitosan 1.5 wt% 
3 10 40 75 
 
Six concentrations (0.25 wt%, 0.5 wt%, 0.75 wt%, 1 wt%, 1.25 wt% and 1.5 wt%) of 
chitosan solution were prepared for coating the PLGA particles with different sizes 
(Fig. 5.16). It was observed that as the concentration of chitosan increased, the burst 
release rate and the initial release rate of estradiol became lower in the first 24 and 
Chapter	  5:	  Results	  and	  discussion;	  in	  vitro	  release	  study;	  regulating	  the	  release	  profile	  	  
	  
148	  
72 hours, respectivly. However, samples coated with more concentrated chitosan 
solution (more than 1 wt%) were agglomereted together. For instance, in samples 
coated with 1.5 wt% chitosan solution, the release rate decreased even after 72 
hours, this may be attributed to agglomeration even in the presence of stiring the 
particle solutions throughout the release profile determination. This problem was not 
observed in the samples coated with 1 wt% chitosan solution. For instance, the burst 
release from PLGA 2 wt% samples coated with 1 wt% chitosan solution was 15 % in 
the first 24 hours which followed by 23 % release within 3 days. These results 
showed reductions of 34% and 37% in the drug release over the first 24 and 72 
hours, respectively. 
 
 
 
(b) 
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Figure 5.17 Estradiol release profile from PLGA particles with various sizes coated 
with gelatin solution (a) PLGA 2 wt%, (b) PLGA 5 wt%, (c) PLGA 10 wt%.  
 
The total amount of estradiol released from the chitosan coated PLGA particles in 72 
hours was reduced compared to the drug released from uncoated PLGA particles. In 
all samples (PLGA 2wt%, PLGA 5wt% and PLGA 10 wt% samples) coated with 1 
wt% chitosan solution the initial release was reduced by 37%, 32% and 21 %, 
respectivley, for the first 72 hour. This was then  followed by controlled and 
sustained estradiol release over 30 days (Table 5.5). 
 
The smaller amount of estradiol released from chitosan coated PLGA particles might 
be explained by the fact that there are strong interactions between the polymers 
(chitosan and PLGA) and estradiol. The initial release is also reduced because now 
the surface region contains less drug since the coated chitosan layer is devoid of 
drug. Additionally, the presence of the chitosan layer could slow down the diffusion 
of estradiol from the polymeric carrier, which also prolongs the release time of 
estradiol. The release studies indicated that coating of chitosan onto PLGA 
encapsulate estrodiol particles could improve the release of the drug. 
 
Table 5.6 Estradiol release data for gelatin coated PLGA particles and the effect of 
coating on burst and initial release. 
(c) 
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Sample 
Burst release 
% (released 
between 0 to 
24)  
Initial release % 
(released 
between 0 to 72) 
Drug 
released 
reduction in 
72 hr (%) 
Encapsulation 
efficiency (%) 
Uncoated PLGA 
2wt%  
44 60 ----------------- 65 
PLGA 2 wt% + 
gelatin 0. 5 wt% 
42 58 2 65 
PLGA 2 wt% + 
gelatin 1 wt% 
40 57 3 65 
PLGA 2 wt% + 
gelatin 1.5 wt% 
35 55 5 65 
Uncoated PLGA 
5wt%  
38 54 ---------------- 68 
PLGA 5 wt% + 
gelatin 0. 5 wt% 
36 50 4 68 
PLGA 5 wt% + 
gelatin 1 wt% 
33 46 8 68 
PLGA 5 wt% + 
gelatin 1.5 wt% 
31 46 8 68 
Uncoated PLGA 
10wt%  
30 50 --------------- 75 
PLGA 10 wt% + 
gelatin 0. 5 wt% 
29 49 1 75 
PLGA 10 wt% + 
gelatin 1 wt% 
21 41 9 75 
PLGA 10 wt% + 
gelatin 1.5 wt% 
18 41 9 75 
 
Release profiles of estradiol from gelatin coated PLGA particles are shown in Fig. 
5.17. As a biomaterial, gelatin has several advantages: it is a natural polymer that has 
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not shown antigenicity [Young et al. 2005] and it is completely resorbable in vivo. 
However, the in vitro release profile of the gelatin coated samples proved that gelatin 
did not last for 72 hours on the surface of the PLGA particles. The gelatin coating 
did not have a noticeable influence on the estradiol release profiles. This could be 
attributed to its lower stability at body temperature [Curcio et al. 2010]. Gelatin acts 
as a hydrophilic moiety on the surface morphology of the PLGA particles and it is 
soluble in the human body enviroment. The release profiles of the samples showed 
initial release reductions of 3, 8 and 9 percent in samples made from 2wt%, 5 wt% 
and 10 wt% PLGA solutions in the first 72 hours (Table 5.6). 
 
In terms of effectiveness as a coating material, chitosan controlled both burst and 
initial release more effectively than gelatin. A number of –OH and – NH groups in 
chitosan, provide more opportunities for intermolecular hydrogen bonding with the 
surface of PLGA partcles. Chitosan forms an entangled network layer on the particle 
surface and limits the infiltration and diffusion of water into the drug carrier. 
Therefore, the diffusion of drug molecules from the particles surface to the release 
medium is restricted by the entanglements caused by the chitosan layer, which 
reduces the burst and initial release. 
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Summary 
This study showed that drug loaded polymeric particles fabricated in previous 
studies (described in Chapter 4) are able to release their payload in a controllable 
manner. Furthermore, two strategies were applied in order to achieve more regulated 
and sustained drug release profiles: first, using ultrasound as a potentially 
extracorporeal stimulus to enhance the drug release when required; second, changing 
the surface properties of the particles via a coating method, in order to control the 
burst release phase. 
 
In Section 5.1, it was shown that evans blue and estradiol loaded PLGA particles 
had release profiles which began with a burst release phase followed by a period of 
sustained release. The amount of drug released from the particles produced from the 
more concentrated solution was lower than that for those produced from the less 
concentrated solutions. In Section 5.2, the feasibility of ultrasonically augmenting 
drug release and polymer degradation was demonstrated. The amount of drug 
released increased as the power of the ultrasound increased, whereas, the active-
period of the drug carriers was shortened. In Section 5.3, it was found that particle 
size and the surface properties of the carriers have a key role in controlling the burst 
release phase. Smaller particles showed more pronounced burst release which was 
due to the fact that the total surface area of a constant weight of particles increases. 
An efficient coating method was demonstrated to prevent the burst release. Coating 
the particles provides an additional layer with no drug on the surface which increases 
the diffusional resistance to the drug. For instance, 37 % reduction in drug released 
in the first 72 hours was observed with the chitosan coated PLGA particles 
fabricated using 2 wt% solution and coated with 1 wt% chitosan solution. 
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Chapter 6 
Conclusions and future work 
 
6.1 Conclusions 
The main contribution of the research described in this thesis is the demonstration of 
electrohydrodynamic processing as an alternative and viable technique for preparing 
micro and nano size particles with narrow size distributions, and which satisfy the 
requirements for particles used in controlled release systems. The ultimate objective 
for the fabricated drug-loaded polymeric carriers was to have a regulated release 
profile so that they would release their payload in the correct quantity at the correct 
time. This objective was fulfilled via two approaches including ultrasound stimulated 
drug release and controlling the burst release phase using a coating technique. The 
following conclusions are drawn from the extensive investigations carried out to 
achieve this objective. 
 
6.1.1 On size mapping of polycaprolactone particles using single needle EHDA 
processing 
Biodegradable polycaprolactone polymer particles with different sizes were prepared 
using a single needle EHDA technique. A method of particle production providing 
systematic variation of size and size distribution has been demonstrated at ambient 
temperature and pressure, with adjustable applied voltage and flow rate serving as 
the process control parameters. The range of operating parameters in terms of flow 
rate (2-50 µl/min), applied voltage (0-15 kV) and the inherent properties of the 
processed solutions such as viscosity and electrical conductivity were identified for 
the ideal processing window of stable jetting (cone-jet). An increase in the applied 
voltage (~15kV) resulted in a reduction in particle size and this was more 
Chapter	  6:	  Conclusions	  and	  future	  work	  
	  
154	  
pronounced at high flow rates (such as; 30, 40 & 50 µl/min) in the same region. The 
size distribution in more cases was monomodal but the carrier particles were more 
polydisperse at the peripheral regions of the stable cone-jet mode, as defined in the 
applied voltage-flow rate parametric map. It was found that in more viscous 
solutions the upper and lower limits of the required voltage for forming the stable 
cone-jet increased from 7.5 kV to 11 kV. The size of the particles obtained within 
the stable cone-jet mode window was found to decrease as the applied voltage 
increased, but this phenomenon was more noticeable at higher flow rates. Particle 
diameter was greatly influenced by viscosity. The mean size of the particles changed 
from 310 nm to 4.4 µm as the viscosity increased from 2.5 mPa s to 11 mPa s. It was 
observed that adding 15 wt % estradiol as a model drug to the PCL solutions, 
changed the electrical conductivity of the solutions and increased the size of the 
particles but did not have a significant impact on the morphology of the particles. 
 
This study demonstrates electrohydrodynamic atomization method has a definite 
clear advantage over conventional methods for the fabrication of the polymeric 
particles (such as emulsion-solvent evaporation and spray drying) as it both provides 
control over particle size and size distribution; and avoids the use of elevated 
temperatures and pressures. Previous studies in the literature on 
electrohydrodynamic atomization have mostly focused on one fixed applied voltage 
and flow rate. This study investigated a wide range of operating parameters (applied 
voltage, flow rate and solution properties) to provide a more comprehensive view on 
the effect of processing parameters on EHDA mode mapping and size distribution. 
 
6.1.2 On preparing polymeric carriers with different shape and size using single 
needle EHDA processing 
Simple manipulations of the electric-field, flow rate and collecting distance, and 
varying the polymer concentration during electrohydrodynamic jetting were shown 
to provide a means of producing biodegradable PLGA and PCL drug carriers with 
different sizes, shapes and surface morphologies. It was shown that, in addition to 
the solution properties, applied voltage and flow rate, the collecting distance has a 
significant impact on the size of the generated structures. When the collection 
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distance was changed from 100 mm to 400 mm, a dramatic reduction in the particle 
size by at least an order of magnitude (10µm-200nm) was observed accompanied by 
a change from a crinkled surface to a smooth surface. 
 
Increasing the viscosity of the solution was found to be essential in order to obtain 
shape changes. In contrast to the low concentration polymer solutions used to 
generate particles, the more concentrated PCL polymer solution (30 wt%) was found 
to be ideal for promoting chain entanglement and the corresponding shape change 
observed was a transition from spherical to oblong to a more needle-like shape. It 
was also observed that another key factor that can determine the shape of the particle 
is voltage. As it was increased, the particle shape could again be changed from a 
spherical to a needle-like structure. However, the exact applied voltage needed for 
change in shape depended on the polymer concentration and properties of the 
solution such as viscosity. Also, the aspect ratio of the needle-like shape particles 
was found to be reduced when the flow rate decreased from 5 µl/min to 2 µl/min, as 
there is a reduction in the particle length. This ratio could be reduced further by 
increasing the applied voltage to 16 kV and preparation of rod-like particles was 
achieved with a particle length ≥ 1µm. Available techniques to produce non-
spherical polymer particles are limited and complicated, usually involving multiple 
processing stages, often using combinations of techniques, such as lithography, 
microfluidic processing and photopolymerisation. This study demonstrated for the 
first time that EHDA, which is less complicated and easier to control compared to 
the current methods, can be used to fabricate non-spherical (needle-like shape) 
particles in a single step. 
 
6.1.3 On co-axial electrohydrodynamic production of drug-loaded micro- and 
nano-particles 
In this part of the study, a co-axial EHDA system was utilised instead of a single 
needle. The aim was to directly encapsulate a second material in the polymeric 
carrier. In the preliminary study, a dye (EB) was encapsulated in the PLGA particles. 
The mean diameters of the particles fabricated from 2, 5 and 10wt% PLGA polymer 
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solutions were 110, 120 and to 2.5 µm, respectively. It was shown that the 
encapsulation of a second material (the EB dye solution) into the polymeric carrier 
was feasible via co-axial EHDA. A colorimetric in vitro release method confirmed 
that the produced PLGA carriers were able to release the loaded EB dye in a 
sustained manner. 
 
In the next part of this study, estradiol which represents the major estrogen in 
humans was used as the model therapeutic agent. The PLGA solutions and the 
estradiol solution were pumped individually through the outer and inner needle of 
the co-axial EHDA setup, respectively. Estradiol loaded PLGA particles with a mean 
size ranging from 100 nm to 2.5 µm and corresponding polydispersivity of 11% to 
38% were produced with encapsulation efficiency ranging between 65% and 75%. 
Detailed analysis using SEM showed that all particles were spherical with a smooth 
outer surface. Particles prepared from 2 wt% PLGA had a bimodal size distribution 
with two peaks. 70 % of the particles were <120 nm in diameter and 20 % of them 
were >500 nm. In this case the wider variation in particle size can be attributed to the 
generation of different types of droplets (“primary” and “satellite”) during the 
processing. More than 90% of the particles prepared using 5 wt% PLGA were <120 
nm in diameter. The particles produced from the 10 wt% PLGA, 95% had diameters 
>2 µm. 
 
Encapsulation is a method of enclosing the therapeutic agent in individual and 
protective polymeric carriers. This study confirmed the successful encapsulation of a 
drug, estradiol, in different size ranges of PLGA particles. A few studies have 
reported the encapsulation of estradiol in PLGA particles and most of the cases 
employed the solvent evaporation method as the fabrication technique, which has 
some disadvantages such as relatively low encapsulation efficiency specifically in 
preparation of drug loaded particles in nano scale, defunctionalisation of drugs under 
extreme processing conditions and multisteps processing (see Section 2.7.1). 
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6.1.4 On in vitro release study of micro- and nano-particles produced via co-
axial electrohydrodynamic processing  
The in vitro release profiles from estradiol loaded PLGA particles were studied. It 
was observed that estradiol release was time-dependent and all the release profiles 
start with an initial “burst” release followed by a period of sustained release. In the 
last stage, the release rate for all the samples increased significantly as degradative 
hydrolysis of the polymer particles took place and the central region which would be 
expected to contain a higher concentration of drug was exposed. The release rate 
from particles produced from PLGA:DMAC 10 wt% solution was markedly slower 
than from particles produced from PLGA:DMAC 2 & 5 wt% solutions. This could 
be explained by the fact that the particles fabricated from the more dilute solutions 
were smaller in size and, with a decrease in particle size, the surface area to volume 
ratio increases leading to increased buffer penetration and faster drug diffusion. 
Release of the entrapped therapeutic agent from PLGA matrix occurs through 
diffusion and degradation mediated processes. During the early phases, release 
occurs mainly through diffusion in the polymer matrix; while during the later phases, 
release is mediated through both diffusion of the therapeutic agent and degradation 
of the polymeric carrier itself. It was confirmed that the encapsulated drug was 
released in a sustained manner over 30 days. However, the release profiles still 
suffered from the undesirable burst release phase, which is addressed in the final 
section of this thesis. 
 
6.1.5 On studying the effect of ultrasound exposure on the release profile  
Most studies in the literature have investigated the effect of ultrasound on the 
stimulation of the drug release from lipid-based drug delivery vehicles such as 
micelles and liposomes. This study, investigated ultrasound exposure on 
biodegradable particulate carriers. The release profile of the drug from PLGA 
carriers was clearly affected by exposing the particles to ultrasound in the 
preliminary studies. An increase in the rate of drug release was observed for all the 
samples exposed to ultrasound with a greater increase obtained for longer exposures. 
It was found that ultrasound had a slightly greater effect on the larger particles. 
Exposing the PLGA particles to 22.5 kHz ultrasound for 30s enhanced the rate of 
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release by 7.8% and was also seen to increase the porosity of the particles’ surface. 
Both effects were thought to be related to cavitation activity. 
 
Further investigations were then carried out to study the effect of the different 
ultrasound parameters (such as duty cycle, intensity, and exposure time) on the 
release profile. Estradiol loaded PLGA particles with a mean size ranging from 100 
nm to 2.5 µm were produced with encapsulation efficiencies ranging from 65% to 
75%. Samples were exposed to ultrasound at a range of powers, duty cycles and 
exposure times and the rate of drug release, acoustic emissions during exposure and 
effect upon particle surface morphology were all examined. All three exposure 
parameters were seen to have a significant enhancing effect upon the drug release 
rate. Only output power, however, had a discernable effect upon the energy of the 
acoustic emissions and the appearance of the particles. The former increased linearly 
with output power, whilst the surface of the particles showed an increasing number 
of pores. Both of these observations may be attributed to increasing cavitation 
activity and indicate that cavitation-mediated degradation is an important contributor 
to drug release enhancement. The lack of correlation between the energy of the 
acoustic emissions or changes in the particle appearance with duty cycle and 
exposure time, however, indicates that there may be an additional mechanism 
relating to the energy of the incident ultrasound field, which requires further 
investigation. Nevertheless, this investigation further demonstrates a promising 
biomedical application of ultrasound: controlling and regulating the release profiles 
of a therapeutic agent where diffusion and degradation rates are the main limiting 
factors, and currently restrict the efficiency of the process. 
 
6.1.6 On modification of the initial release characteristics of estradiol 
encapsulated in PLGA particles  
The main objective in developing drug delivery systems is to achieve an effective 
therapeutic administration via a sustained drug release over an extended period of 
time with a minimum dosing frequency. The release profile was modified by 
manipulating the characteristics of the polymeric carriers with the aim of achieving 
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an ideal controlled drug release system, i.e. one which operates as a steady state 
system, capable of keeping the drug dosage within the therapeutic window for the 
vast majority of the treatment with minimum burst release. 
 
Estradiol loaded PLGA particles were produced by co-axial electrohydrodynamic 
processing. The three most important factors affecting drug release were identified 
as: particle size, type and concentration of the coating agent. The drug release 
profiles for particles with the size range 100 nm to to 4.5 µm were studied. The 
‘burst release’ defined as the amount of drug released between 0-24 hours, was 
lower for the larger particles. Furthermore, the initial release, defined as the amount 
of drug released between 0-72 hours, was also studied. The initial release was lower 
for the larger particles. This was because the total surface area of a constant weight 
of particles decreases when the size of the particles increases. Also, in larger 
particles the diffusion pathways were longer which leads to a lower release rate and 
lower initial release. 
 
Two different biocompatible coating agents (chitosan and gelatin) were studied. 
Chitosan was found to control the burst and initial release more effectively compared 
to gelatin. The FTIR stability results confirmed that chitosan was stable on the 
surface structure of the PLGA particles for approximately 3 days. It acts as a rate-
limiting layer, which controls the diffusion rate and protects the drug from the living 
environment. Also, it was observed that as the chitosan concentration increased, the 
coating tickness increased from 20 nm to 70 nm. Coating the particle surface with 
chitosan considerably reduces the burst and initial release, without significantly 
affecting the release rate. For instance, in all samples (PLGA 2wt%, PLGA 5wt% 
and PLGA 10 wt% samples) coated with 1 wt% chitosan solution the initial release 
were reduced by 37%, 32% and 21 %, respectivly in the first 72 hours. While, the 
release profiles of the gelatin coated particles showed initial release reductions of 
3%, 8% and 9% in samples made from 2 wt%, 5 wt% and 10 wt% PLGA solutions 
in the first 72 hours. 
 
These results showed a great improvement in controlling the burst release phase as 
the coating technique reduces the burst without changing the rest of the release 
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profile. For instance, in previous literatures the minimum burst from chitosan coated 
PLGA  (50:50) nanoparticles were aproximatly 36%; while in this study, 15% burst 
release was achieved. Both particle size and surface coating were found to have a 
significant effect on the release profile. The release profile from estradiol loaded 
PLGA particles can be tailored to achieve the desired characteristics by selective 
manipulation of particle properties. These principles can be applied to a general 
drug-polymer system after taking into account the specific interactions involved in 
the system. 
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6.2 Future work 
Ideally, synthesised particulate capsules should possess the following features: high 
loading efficiency, controlled drug distribution and release characteristics, uniform 
size and shape. The processing technique should be able to generate these features, 
be efficient in terms of time and material usage, convenient and easily scalable. 
EHDA processing techniques have shown great promise in terms of these criteria 
offering a versatile tool for the generation of uniform particles and encapsulated 
structures. As it was shown in this thesis, EHDA techniques can achieve uniform 
dispersion of drug within a polymeric matrix with high loading capacity and minimal 
drug loss. However there are still several aspects of future work recommended as 
follows: 
 
6.2.1 Encapsulation of different therapeutic agents  
Effective drug delivery strategies are becoming more significant as more specific 
drugs become available with increasing knowledge about diseases from the human 
genome project. All therapeutic agents would optimally require tailored drug 
delivery systems and targeting mechanisms to deliver them to their specific target 
tissues without reducing their therapeutic efficacy. In this research, it was shown that 
biodegradable particles could be prepared with high encapsulation efficiency for 
estradiol, which is a hydrophobic drug. Particles formulated from PLGA should also 
be investigated for sustained and targeted/localized delivery of other ranges of 
therapeutic agents including cells, plasmid DNA, proteins and peptides. 
 
6.2.2 Cell study for nanoparticles 
Nanoparticles are a potentially useful drug delivery system capable of delivering a 
therapeutic agent by sustained delivery. Also, the nanoparticle size is very important 
for their great efficiency of arterial uptake [Song et al. 1998] and cellular entry 
[Desai et al. 1997] and preventing inflammatory tissue responses usually associated 
with larger size microparticles [Dev et al. 1997]. In this study, PLGA nanoparticles 
Chapter	  6:	  Conclusions	  and	  future	  work	  
	  
162	  
with the size of ~100 nm were produced successfully. The in vitro release study 
showed an efficient drug release profile. However the mechanism of enhanced 
therapeutic efficacy of estradiol loaded nanoparticles at cellular level should be 
addressed. For instance, further research can be conducted on the mechanism of 
intracellular uptake of the nanoparticles, their trafficking and sorting into different 
intracellular compartments. 
 
6.2.3 The effect of shape on various in vivo and in vitro parameters 
Recently, there has been growing recognition that particle properties other than size 
and surface chemistry influence the effectiveness of drug delivery systems, in 
particular, shape. In this thesis, it was shown that carriers of different shapes could 
be obtained through different combinations of processing parameters. However, 
more studies should be carried out to fully understand how to control all EHDA 
processing parameters to obtain both the desired size distribution and shape, e.g. 
aspect ratio in needle-like shape particles. Also, in vivo and in vitro investigations of 
release profile, biocompatibility, clearance, and targeting of these particles are 
required to fully understand the factors determining the effectiveness of these 
particles. For instance, the dependence of phagocytosis by macrophages on shape 
and aspect ratio, the internalisation of needle-like shape particles and the 
biodistribution should be studied. 
 
6.2.4 Micro and nanoparticles in tissue engineering 
Tissue engineering has emerged as a viable alternative to the problem of organ and 
tissue shortage. The use of microspheres as scaffold materials for the growth of cells 
for tissue engineering is an emerging area of application in medical engineering 
[Botchwey et al. 2004]. Further research in this area could open up a new branch of 
applications for the micro and nanoparticles prepared by EHDA processing. 
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6.2.5 Preparation of multilayer particles 
Further structures that can potentially be prepared using EHDA processing are multi-
layered micro- and nano-particles capable of successfully penetrating the body's 
immune system and efficiently carrying therapeutic agents to their intended sites. 
Each layer can be systematically designed for a specific reason, which can meet and 
overcome each physiological barrier encountered as it moves through the body. 
Therefore, this technique is a significant progression which would lead to 
multilayered structures that could then have the potential for multilayer particles, 
multiple loading of drugs, prodrugs or other active agents required at a different 
time. This leads to greater efficiency and reduces the required dosage. 
 
These multilayered structures can be produced via two methods. First, drug loaded 
nano/microparticles could be prepared using single or co-axial EHDA systems and 
subsequently they could be sent through the inner needle of the co-axial EHDA 
while sending an encapsulating polymer through the outer. This technique can be 
classed as a multi-step technique while there is a second method which is a simpler 
single-step technique. In this method, a co-axial tri-needle device can be designed to 
generate a variety of multilayer encapsulated structures using a range of materials. 
This would show major improvement on co-axial work and suggests considerable 
benefits, particularly in the healthcare area with potential applications within 
biomedical and pharmaceutical fields, for the preparation of encapsulated carriers 
and multilayered micro or nanoparticles.  
 
6.2.6 Preparation of nanoparticles with low polydispersivity 
As mentioned, nanoparticles are very much in need for drug delivery, particularly to 
the central nervous system [Blasi et al. 2007]. Since nanoparticles with a size and 
polydispersivity index of 100 nm and 11%, have been prepared with existing 
facilities in the EHDA set-up, it may be possible to prepare nanoparticles with a 
diameter < 100 nm. As various parameters (processing parameters and properties of 
the solution) are involved in the EHDA technique, modifying the processing 
parameters such as varying the collection distance, narrowing the gap between the 
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tip of the outer needle and varying the concentration of the solution may help in 
reducing the size to less than 100 nanometres with lower polydispersivity. 
 
6.2.7 The effect of needle geometry on the EHDA processing  
The geometry of the needle used in EHDA processing, is an important factor for the 
electric field. However, to the best of the author’s knowledge, within the research 
work of EHDA spraying in the past few years, there are few documents to 
systematically demonstrate the influence of needle geometry, a vital factor for 
electric field which actually is the driving force for the liquid to form cone-jet mode 
in EHDA spraying. Almost all the previously discussed studies and investigations 
are based on the capillary with regular geometry. It was only briefly mentioned that 
‘the geometry of the nozzle influences the cone-jet domain drastically’ without 
giving any explanation on the influence phenomena and mechanism [Chen et al. 
1999]. Therefore, further investigations need to be conducted on studying the effects 
of the needle geometry (such as tip angle, tip length and shape) on the stable cone-jet 
domain, in which the cone-jet mode can only be achieved and maintained. 
 
6.2.8 Targeted drug delivery via bioconjugation 
EHDA method can be used to produce bioconjugated polymeric particles for 
targeted drug delivery. One of the most significant applications of targeted drug 
delivery is for cancer therapy. Cancer drug delivery is no longer simply 
encapsulating the drug in formulations for different routes of delivery. Experience, 
skill and knowledge from various technologies such as nanotechnology and 
advanced polymer chemistry need to bring together new ways of developing novel 
drug delivery system. One of the methods that can be applied is using monoclonal 
antibodies (MAbs). These are used both for diagnosis and therapy in cancer. PLGA 
polymeric particles can be used for site-specific drug delivery by incorporation of 
appropriate targeting groups of antitumor monoclonal antibodies. They can deliver 
anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to 
the tumors. Therefore, it prevents damage to the normal surrounding tissues. 
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6.2.9 Microbubbling 
In all the experiments carried out via co-axial EHDA in this research, the 
encapsulated material was a dye or drug solution. However, this solution can be 
replaced with air to produce bubbles. In medical and pharmaceutical applications, 
there is rapidly growing interest in the use of microbubbles as ultrasound contrast 
agent particles, drug delivery systems and in the synthesis of artificial cell structures 
[Bertling et al. 2004, Botchwey et al. 2004]. A prerequisite for using microbubbles 
as contrast agent particles in ultrasound radiography is that they degrade in vivo 
within hours and that the largest particle should not exceed 8 µm diameter, in order 
to avoid capillary blockage [Raisinghani and DeMaria 2002]. In 2009, Farook et al. 
first developed the technique using co-axial EHDA to prepare microbubbles [Farook 
et al. 2009a]. They found EHDA microbubbling as a promising method to prepare 
microbubbles with specific size and size distribution. However, they have used 
polymethylsilsesquioxane biopolymer in their experiments which is not a degradable 
polymer. Therefore, it could be potentially beneficial to fabricate microbubbles from 
biodegradable and bioerodible polymers such as PLGA to improve the degradation 
properties of the microbubbles. 
 
6.2.10 Ultrasound safety 
Ultrasound has a long history of use in biomedical fields. In this study ultrasound 
was used in combination with estradiol drug. It was shown that ultrasound (range of 
applied frequencies were 20 to 22.5 kHz), enhanced the drug release. However, 
understanding the safety of therapeutic ultrasound and the development of 
generalised rules that account for ultrasound safety is an important topic for future 
research activities [Nyborg 2001, Madersbacher et al. 2003]. 
 
The issue of biological response in the use of ultrasound to stimulate drug release 
should be addressed. It is very probable that ultrasound frequencies which optimise 
membrane permeability are different to the frequencies which optimise drug release. 
Thus the response of cells and their membranes to ultrasound must be considered 
and damages to the target or adjacent tissues should be avoided or minimised. 
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Ultrasound frequencies used for medical applications is ranged from 19.5 kHZ to 10 
MHz. Some examples of the applications of low frequency ultrasound are; 
angioplasty (19.5 kHz), ocular drug delivery (20 kHz), lipoplasty (20–50 kHz) and 
transdermal delivery of insulin, low-molecular weight heparin, vaccines (20-100 
kHz) [Mitragotri 2005]. However, the significant clustering of applications is found 
around frequency of 1 to 3 MHz. For instances, the frequencies used for imaging and 
thus readily available to clinicians are 1MHz and above. At these frequencies, 
focusing and therefore targeting of treatments is better. Therefore, it is beneficial to 
look at exposing the particles at higher frequencies and study their release 
characteristics. 
 
6.2.11 Commercial viability 
A full assessment of commercial and clinical viability of the utilised techniques in 
this study is an important issue which should be addressed in future. EHDA 
technique has some clear advantages in terms of simplicity, efficiency, cleanliness 
and ambient operation. However there is the issue of scaling up and associated cost 
to address. It should be noted that EHDA with a single nozzle is a low-volume 
throughput process and it is not suitable or efficient for traditional industrial spraying 
processes. Approaches that address this problem are to use multi-nozzle or slit-
nozzle systems [Snarski et al. 1991, Almekinders and Jones. 1999, Regele et al. 
2002]. Therefore, more investigation can be conducted on scaling up and 
commercialising this technique via two methods: first, scaling up for mass 
production through the use of multiplexed microfabricated sources of spraying, 
second, fabrication of miniaturised portable devices for encapsulation and delivery 
of drugs for patient-specific needs. 
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